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Abstract 
Ribosomally synthesized and posttranslationally modified peptides (RiPPs) are a rapidly growing class of 
natural products. RiPP precursor peptides can undergo extensive enzymatic tailoring to yield structurally 
and functionally diverse products. Cyclodehydratases are a type of RiPP modifying enzyme that catalyze 
phosphorylation of the peptide backbone and subsequent nucleophilic attack by the sidechains of Cys, Ser, 
or Thr to form azoline heterocycless (or azoles upon oxidation). The catalytic unit of the cyclodehydratase 
is a YcaO-family protein which is often accompanied by a partner protein from the E1-like superfamily 
(depending on the of type cyclodehydratase). Although primarily known for azoline formation, recent work 
suggests that YcaO proteins can use different nucleophiles and partner proteins to generate thioamide, 
macroamidine, and possibly other peptide posttranslational modifications. In Chapter 1, I comprehensively 
review the biosynthetic gene clusters (BGCs), natural products, functions, mechanisms, and applications of 
YcaO proteins and outline future directions for this protein superfamily. 
 In Chapter 2, I report my investigations into the substrate recognition of canonical 
cyclodehydratases. Recent work suggested that unrelated RiPP modifying enzymes contain structurally 
similar precursor peptide binding domains. Using profile hidden Markov model comparisons, I discovered 
related and previously unrecognized peptide binding domains in proteins spanning the majority of known 
prokaryotic RiPP classes. This conserved domain was designated the RiPP precursor peptide recognition 
element (RRE). Through binding studies, I verified the RRE's role for three distinct RiPP classes: linear 
azole-containing peptides, thiopeptides, and lasso peptides. Because numerous RiPP biosynthetic enzymes 
act on peptide substrates, these findings have powerful predictive value as to which protein(s) drive 
substrate binding, thereby laying a foundation for further characterization of RiPP biosynthetic pathways 
and the rational engineering of new peptide binding activities. 
In Chapter 3, I use knowledge gained from precursor peptide binding studies to engineer a peptide 
that can be recognized and modified by two biosynthetic enzymes from different pathways. Combining 
enzymes from multiple pathways is an attractive approach for producing molecules with desired structural 
features, but this strategy thus far has been hampered by limited substrate tolerance of enzymes from 
unrelated pathways. Because RiPP biosynthetic enzymes modify their substrates by binding motifs located 
usually in the N-terminal leader region of precursor peptides, RiPP biosynthetic systems are highly 
amenable to the engineering of new compounds. I exploit this by designing chimeric leader peptides that 
can be bound and processed by multiple enzymes from unrelated RiPP pathways. Using this broadly 
applicable strategy, a cyclodehydratase was combined with enzymes from the sactipeptide and lanthipeptide 
RiPP classes to create new-to-nature hybrid RiPPs. These hybrids provide insight into biosynthetic timing 
and enzyme compatibility and establish a general platform for the engineering additional hybrid RiPPs. 
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Chapter 1: YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and 
Function1 
 
1.1 Introduction 
With the advent of high throughput genome sequencing technology, the number of available protein 
sequences has grown at a staggering rate. To organize all of this data, public databases collate protein 
sequences into superfamilies based on amino acid sequence similarity and conserved domains. 
Computationally, these groupings are determined by hidden Markov models (HMMs),1, 2 which use pattern 
recognition algorithms that predict whether one protein sequence matches an established group. Once a 
protein is matched with a superfamily, it is presumed to be functionally similar with other members of that 
superfamily. Alternatively, function can often be understood by analyzing a protein’s constituent 
domain(s).3, 4 This function inference process is essential for automating the annotation of whole genomes, 
and fittingly, has been employed to predict the functions for millions of proteins without them having been 
experimentally validated. 
Unsurprisingly, these homology-based approaches to protein function annotation are not without 
errors or inaccuracies.5, 6 Although useful in certain situations, simply matching a superfamily does not 
necessary imply one specific function because many protein superfamilies consist of multiple different iso-
functional families, which may only share a partial mechanistic step or certain sequence motifs.7-10 
Moreover, there are many proteins, ~20% of all classified protein domains, that consist entirely of domains 
of unknown function (DUFs) and possess no characterized homologs.11, 12 
Thus, much can be learned by investigating proteins that are too divergent to be confidently 
assigned a function by homology or contain DUFs with no assigned function. This is especially true for 
such proteins found in natural product biosynthetic pathways. The enzymes encoded by these pathways 
catalyze the chemical reactions that build complex molecules and exploration of their reactions often 
reveals unexpected or entirely new reaction mechanisms.13-16 The topic of this review, the YcaO 
superfamily, exemplifies many of the challenges, triumphs, and future benefits in studying these 
uncharacterized biosynthetic proteins.  
Originally defined as DUF181, YcaO proteins were studied through genetic and biochemical 
methods for over two decades until sufficient evidence could be gathered to suggest a common function for 
this superfamily in ATP utilization.17, 18 However, what ATP is being used for is unknown for much of the 
superfamily. The term “YcaO” itself alludes to the enigmatic nature of this superfamily as it originates from 
                                                     
1 This chapter has been reproduced with permission from Burkhart, B.J.; Schwalen, C.J.; Mann, G.; Naismith, J.H.; Mitchell, 
D.A. YcaO-dependent posttranslational amide activation: Biosynthesis, structure, and function. Chem. Rev. 2017, 117, 5389-
5456. Copyright 2017 American Chemical Society. B.J.B wrote this work with contributions from C.J.S. for figure generation 
and section 1.7 and from G.M. and J.H.N. for sections 1.4, 1.6, and 1.8. All coauthors reviewed and edited the manuscript. 
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a gene-naming rubric established in Escherichia coli (E. coli). If a gene was of unknown function, it was 
given a provisional, four-letter name beginning with “y” and ending with three letters that indicated its 
genomic location.19 Hence, the ycaO gene of E. coli is located between the 21- and 30-min region of the 
genome, after ycaN but before ycaP. Many of these “y” proteins remain uncharacterized to this day, even 
for the most studied model organism, which underscores the difficulty in defining roles for genes when no 
clear phenotype is evident upon deletion, overexpression, or other functional genomics methods.20-22  
 Despite the mystery that still surrounds many YcaO proteins, the currently available data suggest 
four functions within the YcaO superfamily: (1) azoline formation, (2) macroamidine formation, (3) 
thioamide formation, and (4) potentiation of RimO-dependent methylthiolation. Little rationale has been 
provided for YcaO involvement in methylthiolation beyond the associated effect from gene deletion studies 
(section 1.7.1).23-25  However, the other functions are better understood and come from work on YcaO 
proteins encoded within the biosynthetic gene clusters (BGCs) of ribosomally synthesized and 
posttranslationally modified peptide (RiPPs).26  
RiPPs comprise a structurally and functionally diverse class of natural products and are categorized 
into subclasses based on common features installed by conserved biosynthetic enzymes.26 With rare 
exception, RiPP biosynthesis begins with posttranslational modification of an inactive precursor peptide, 
composed of N-terminal leader and C-terminal core regions (Figure 1.1). Within the leader region are 
specific motifs that are recognized and bound by key biosynthetic proteins. To govern this substrate-binding 
event, several RiPP modifying enzymes rely on a structurally conserved domain, known as the RiPP 
precursor peptide recognition element (RRE),27 whereas other RiPP biosynthetic protein bind their cognate 
leaders peptides in structurally unique ways.28, 29 Once engaged with the substrate, the biosynthetic enzymes 
(e.g. YcaO) then install residue-specific modifications to the core region. After these modifications are 
complete, the leader region is removed while other tailoring enzymes, if present, further modify peptide. 
After enzymatic processing is completed, the mature compound is usually exported by ATP-binding 
cassette (ABC) transporters.26 In some cases, mature RiPPs have been so heavily modified that they no 
longer resemble ribosomal peptides and had been postulated to derive from non-ribosomal pathways.30-32 
Additionally, because of their biosynthetic logic, RiPPs have many alluring biotechnological applications 
in engineering new natural products (further discussed in section 1.8). 
Within the field of RiPP biosynthesis, the first conclusive role of a YcaO protein was elucidated by 
studying the biosynthesis of the antibiotic microcin B17 (MccB17). In 1986, the MccB17 ycaO gene was 
linked to an unknown posttranslational modification,33 which was later identified as peptide backbone azole 
heterocycles.34-36 A decade later in 1996, azole biosynthesis was reconstituted in vitro and demonstrated to 
depend on ATP and a trimeric enzyme complex of the YcaO protein, a dehydrogenase, and a member of 
the E1-ubiquitin activating (E1-like) superfamily.37 At the time, it was clear that the FMN-dependent 
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dehydrogenase (encoded by a gene adjacent to the YcaO) would oxidize azolines to the corresponding 
azoles, but it was unclear what roles ATP, the YcaO, and E1-like protein played in azoline heterocycle 
synthesis. In 2012, it was determined again through in vitro reconstitution that the YcaO and E1-like protein 
functioned together as a cyclodehydratase wherein the YcaO protein performs the ATP-dependent 
cyclodehydration reaction by catalyzing the attack of a β-nucleophilic side chain (Cys, Ser, or Thr) into the 
preceding amide bond to form a presumed hemiorthoamide intermediate (Figure 1.1c).17 This species then 
undergoes an ATP-driven O-phosphorylation, followed by N-deprotonation and elimination of phosphate 
to yield the azoline heterocycle. In the absence of the E1-like protein, the catalytic activity of the YcaO was 
minimal; the E1-like protein potentiates cyclodehydratase activity by nearly three orders and binds the 
precursor peptide through what is now known to be its N-terminal RRE domain.17, 18, 27 This finding resolved 
the historical confusion over the roles of the two components of the cyclodehydratase. In the past, the E1-
like and YcaO proteins have been wrongly referred to as the cyclodehydratase and docking protein, 
respectively. Although these were the originally postulated functions, data now establishes the YcaO as the 
cyclodehydratase while the E1-like protein brings the substrate into proximity of the catalytic center of the 
YcaO. Since most YcaO cyclodehydratases are all but inactive without their cognate E1-like protein, the 
cyclodehydratase is most properly defined as the combination of both proteins. More detail into the 
cyclodehydratase reaction mechanism and substrate processing is covered in section 1.6. 
As YcaO/DUF181 members became functionally linked with azoline heterocycles in RiPPs, 
intriguing counterexamples surfaced which suggested a YcaO-mediated role in other peptide backbone 
modifications, namely amidine and thioamide posttranslational modifications. For example, the BGC for 
the antibiotic natural product bottromycin encodes two YcaO proteins yet only one azoline heterocycle is 
present.38-40 However, bottromycin contains a second amide backbone modification in the form of a 
macroamidine (covered in section 1.7.2). Surprisingly, the two YcaOs within this gene cluster also do not 
have an E1-like partner protein suggesting that fully functional, standalone YcaOs are a possible division 
within the YcaO superfamily. Another case for additional YcaO functional capacity comes from 
thioviridamide biosynthesis, as it is devoid of azol(in)e heterocycles. Instead, it has several thioamides 
(sulfur in place of the oxygen in the peptide backbone) and an uncharacterized protein (TfuA) seems to co-
occur immediately adjacent to the YcaO gene in many divergent YcaO-containing gene clusters, indicating 
that this may be another distinguishable division (section 1.7.3). While the role of the YcaO proteins during 
bottromycin and thioviridamide have yet to be experimentally established, these posttranslational 
modifications could share a mechanism, proceeding through a common phosphorylated amide intermediate, 
with the only variable being the identity of the nucleophile.  
With the varied activities associated with the YcaO superfamily, categories have been introduced 
to help distinguish different types of YcaO (Figure 1.2). The most well-studied are azoline-forming YcaOs 
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that cyclodehydrate Cys, Ser, and Thr through collaboration with a member of the E1-like superfamily. 
These azoline-forming YcaOs are further described in the next section. Related to this type are standalone 
azoline-forming YcaOs, like in bottromycin, that appear to install azoline heterocycles without any partner 
protein. Also found in the bottromycin BGC is an amidine-forming YcaO. Another emerging type are 
YcaOs that co-occur with a TfuA gene. The only investigated example to date is found in the 
thioviridiamide gene cluster and may be a thioamide-forming YcaO (also referred to as TfuA-associated). 
Lastly, because some YcaOs lack the experimental data to be confidently assigned a function, the remaining 
YcaOs are generally referred to as enigmatic YcaOs. These would include members like the YcaO 
associated with RimO-dependent thiomethylation and other YcaOs with no predicted function. This review 
covers the current knowledge for each of these groups, with emphasis on the extensively explored azoline-
forming YcaOs, and outlines future research directions and applications. 
 
1.1.1 Azoline-forming YcaOs 
By far the most explored group of the YcaO superfamily are the azoline-forming YcaOs. These are 
associated with thiazoline and (methyl)oxazoline biosynthesis and have been found exclusively within RiPP 
biosynthetic pathways. Among RiPPs, backbone azole and azoline heterocycles are found within several 
formally defined subclasses, including the linear azol(in)e-containing peptides (LAPs), azol(in)e-
containing cyanobactins, thiopeptides, and bottromycin.26, 41 In each RiPP subclass, the YcaO protein is 
responsible for azoline formation, but additional structural modifications further differentiate them. For 
instance, LAPs are linear peptides with backbone azol(in)e heterocycles. However, azol(in)e-containing 
cyanobactins are formed by N- to C-macrocylization of a LAP intermediate,42, 43 and it is this 
macrocylization that defines the cyanobactins as some lack azol(in)e heterocycles and correspondingly do 
not have a ycaO.26 Similarly, during thiopeptide biosynthesis, a LAP intermediate is formed which later 
undergoes a class-defining [4+2] cycloaddition to give rise to a six-membered, nitrogen-containing 
heterocycle (often pyridine).44, 45 Lastly, the bottromycins bear not only a Cys-derived thiazole, but also a 
macroamidine. To underscore the biosynthetic commonality of these four RiPP subclasses, we will 
generally refer to them as azol(in)e-containing RiPPs.41  Throughout this review, an azoline-forming YcaO 
is defined as any member of the YcaO superfamily that is involved in heterocycle formation with a RiPP 
substrate through the cyclodehydration of Cys, Ser, or Thr. Additionally, we will use RiPP 
cyclodehydratase to refer to the protein complex of an azoline-forming YcaO and any associated partner 
proteins that catalyze heterocycle formation in RiPP pathways.  
The first YcaO to be studied was azoline-forming and involved in the biosynthesis of a LAP named 
microcin B17 (MccB17).37, 46, 47 Owing to their relative chemical simplicity, LAPs have historically 
provided the most significant insights into the function of YcaO proteins. Moreover, because other more 
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structurally complex azol(in)e-containing RiPPs proceed through a LAP-like intermediate, this classic work 
laid a foundation for the more recent comprehension of  RiPP cyclodehydratase function senso lato. 
However, it would require the revolution in genome sequencing before the broad distribution of the 
cyclodehydratase and the diversity of molecular scaffolds that were biosynthesized by azoline-forming 
YcaOs was fully realized. In the mid-2000s, the next group to be biochemically characterized after MccB17 
was the cyanobactins.48-50 The number of BGCs was then greatly expanded as a result of studying the 
genetic distribution of the cytolytic bacterial virulence factor, streptolysin S (SLS).51 As sequencing 
technology continued to advance, the long-known and potent antibacterial thiopeptides were also 
demonstrated to be RiPPs that employed azoline-forming YcaO proteins.52-56 A 2015 survey found a total 
of ~1,500 azoline-forming YcaO gene clusters distributed among numerous bacterial phyla and even some 
archaea.57  
The ability of RiPP biosynthetic pathways to incorporate thiazole(in)e and oxazol(in)e heterocycles 
through a YcaO protein greatly expands their structural variability and bioactive potential. From a structural 
perspective, azol(in)e heterocycles rigidify and enforce specific orientations in peptidic natural products so 
they presumably can interact with their intended targets more efficiently. Consequently, these heterocycles 
are also found in the products of non-ribosomal peptide synthetases (NRPS) or hybrid polyketide synthase 
(PKS)/NRPS pathways.58, 59 Bleomycin, a PKS/NRPS approved anticancer agent, has a crucial 
bisheterocycle that drives DNA intercalation.60 Another anticancer azole-containing PKS/NRPS is 
epothilone and has a synthetic macrolactam analog, ixabepilone, which has also been approved for human 
use (Figure 1.3).61 In addition to their appearance in natural products, thiazoles are a popular heterocycle 
for medicinal chemists and thus they can be found in a number of approved drugs with activities spanning 
many therapeutic categories.62-64 For example, meloxicam, a nonsteroidal anti-inflammatory drug, and 
ritonavir, an HIV protease inhibitor, both possess thiazoles (Figure 1.3). However, no azoline-containing 
RiPP has been approved for use in humans because they tend to have inadequate pharmacological 
properties. Their peptidic nature lowers stability in vivo, and more highly modified azol(in)e-containing 
RiPPs, which are not susceptible to proteases are often limited by poor solubility, absorption, and 
bioavailability. Nonetheless, several are used in animals for various purposes with two examples being 
growth promotion in livestock (nosiheptide) and treatment of skin infections for both companion animals 
and livestock (thiostrepton).65-67 Additionally, azol(in)e-containing RiPPs often represent enticing, but 
challenging, drug leads for treatment of human disease. For instance a semi-synthetic derivative of 
GE2270A named LFF571 has enhanced solubility (12 mg/mL compared to <0.001 mg/mL) and is showing 
promise in clinical trials for treating Clostridium difficile infections (Figure 1.4).68-70 
Based on the bioactivities of azol(in)e-containing RiPPs, there has been much interest in identifying 
gene clusters that have potential to encode structurally and functionally unique compounds. This has 
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generated interest in identifying YcaO-containing BGCs, but as new YcaO sequences are added to public 
databases regularly, there is a need to bioinformatically distinguish which may catalyze azoline formation. 
Fortunately, azoline-forming YcaOs are in many cases readily differentiated from other YcaOs based on 
whether the a partner (E1-like) protein is locally encoded or if one is fused to the YcaO to yield a single 
polypeptide.17, 18, 57 Identifying standalone azoline-forming YcaOs is more difficulty and currently relies on 
homology to proteins encoded by the bottromycin and trifolitoxin BGCs (see sections 1.7.1 and 1.7.2, 
respectively).  
From the known or putative azoline-forming YcaOs, a powerful insight into the diversity of their 
products has been revealed by plotting all proteins on a sequence similarity network (a method of clustering 
homologous sequences in two dimensional space).57 Multiple distinct clusters of related YcaO proteins are 
formed as a result and can be viewed as a “family” given their genetic relatedness. An analogy can be drawn 
to human genealogy: identical twins look more alike than non-identical twins, parents and children also 
tend to more closely resemble each other in appearance as opposed to distant cousins or non-family 
members. Thus, if two YcaO proteins have high sequence similarity, they will be part of the same cluster 
and family, and correspondingly their BGCs and the structure of their mature natural products will generally 
be similar as well. However, more divergent YcaOs will be part of other discrete clusters and are likely to 
make a structurally different product. By comparing and analyzing the distribution of sequence clusters, an 
overview of the different potential molecular scaffolds encoded by azol(in)e-containing RiPPs is revealed, 
and distinct families are identified. Interestingly, many groups emerged from this analysis that fall within 
established subclasses (e.g. LAPs, cyanobactins, thiopeptides) but others had no characterized members, 
which implies new opportunities for the discovery of biologically active  azol(in)e-containing RiPPs.57 
Another very recent bioinformatic survey went further and predicted the products of putative LAP, 
cyanobactin, and thiopeptide BGCs based on the encoded genes/peptides.71 The result of this analysis again 
underscored the great diversity of potential azol(in)e-containing RiPPs. In the next section, we review the 
subset of BGCs found through these bioinformatic surveys that have been experimentally investigated. 
  
1.2 Linear azole-containing peptides (LAPs) 
The LAPs are a heterogeneous subclass of RiPPs, with YcaO proteins being the primary element of their 
BGCs.26 Their unifying feature is azole or azoline heterocycles within a linear ribosomal peptide. 
Accordingly, their BGCs can be as minimal as a precursor peptide and a cyclodehydratase. However, the 
cyclodehydratase is often accompanied by a flavin-dependent dehydrogenase which oxidizes azoline to 
azole heterocycles (Figure 1.5).37, 72 Additional tailoring enzymes, where present, further modify the peptide 
and are responsible for the chemical diversity amongst LAPs. For example, the selective anti-Bacillus 
anthracis compound named plantazolicin (PZN) has a dimethylated N-terminus whereas the secondary 
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metabolism inducer goadsporin undergoes N-terminal acetylation and contains dehydroamino acids (see 
sections 1.2.3 and 1.2.7, respectively). Meanwhile, other notable members of the LAP subclass possess no 
additional modifications (other than leader peptidolysis) such as MccB17 and the cytolytic virulence factor 
SLS.  
With the unification of the subclass,26 LAP biosynthetic genes and their products share a common 
nomenclature with A (precursor peptide), B (dehydrogenase), C (E1-like protein), and D (YcaO) although 
genes in some older BGCs are designated contrary to this convention based on historical precedent (i.e. 
MccB17). Also, the C and D proteins are found as a single fusion protein in roughly half of all known 
pathways.57 The other modifying enzymes are pathway specific and are usually named sequentially starting 
at E (following from D). 
 
1.2.1 Microcin B17 
The secretion of a growth-suppressive metabolite is an effective strategy for bacteria to compete within 
their niche, where nutrients are a precious commodity. In cases where the growth-suppressive metabolite 
is of ribosomal origin, the bioactive species are referred to as bacteriocins. These can vary widely in 
molecular weight, structural modifications, and mode of action, which has convoluted their classification.73-
77 The lower molecular weight bacteriocins are commonly referred to as microcins78 to distinguish them 
from the higher molecular weight protein toxins, which will not be discussed further in this review. It is 
important to note, despite the incorrect terminology propagated, “microcins” need not come from 
Enterobacteriaceae. Indeed, the first description of microcins include examples from Pseudomonas, which 
are taxonomically distinct and non-enteric.78 
A well-studied microcin is microcin B17 (MccB17), a narrow-spectrum bactericidal peptide that 
targets DNA gyrase.79-81 MccB17 was isolated from strain 17 during a screen of antibacterial compounds 
produced by intestinal bacteria of infants.78 Soon the name MccB17 was established, based on the 
observation that it targeted DNA replication (class B).74 Interest into MccB17 biosynthesis grew as the 
plasmid encoding the genes necessary for its production was isolated from E. coli.82, 83 Early experiments 
with this plasmid indicated that transcription of the MccB17 BGC was under the control of the extensively 
studied outer membrane protein regulator (OmpR) and increased greatly as cultures approached the 
stationary phase.84-86 After further genetic studies, the entire BGC was sequenced to reveal seven genes: 
mcbABCDEFG (Figure 1.5).87, 88  
While most of the MccB17 biosynthetic genes would be functionally analyzed by in vitro 
reconstitution or genetic deletion, the nucleotide sequence of mcbA immediately indicated that it encoded 
a precursor peptide as it matched the structure of MccB17, which was obtained from Edman degradation.33 
From these initial structural data, it was evident that a number of residues were posttranslationally modified, 
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including all four Cys and four of the six Ser.46, 47 Structural characterization by NMR showed these 
modifications to be azole heterocycles,34, 35 and they are formed by the action of a trimeric synthetase 
comprised of McbB, McbC, and McbD (E1-like, dehydrogenase, and YcaO proteins, respectively).36, 37 
After azole formation on the core region of McbA, the leader region is removed by a protease (tldD/tldE) 
encoded on the chromosome of E. coli.89, 90 After complete processing, a two-component ABC transporter 
(McbE/McbF) presumably exports mature MccB17 while at the same time providing a level of self-
protection. Previous reports have also designated McbG as an imunity protein, although it has no 
experimentally verified immunity mechanism.91 McbG is however homologous to pentapeptide repeat 
proteins which are known to structurally mimic DNA, interact with DNA gyrases, and protect against the 
quinolone antibiotics which represent another class of gyrase inhibitors,.92 
Like most classically-defined microcins, MccB17 has a narrow spectrum of activity affecting only 
other Enterobacteriaceae and some Pseudomonas species. The narrow spectrum activity is largely due to 
the cellular uptake machinery that mediates the entrance of MccB17 into cells. For example, deletion or 
alteration of the C-terminal residues of McbA results in MccB17 analogs that retain inhibitory activity 
against DNA gyrase in vitro but are significantly less active towards live bacteria.93, 94 Similarly, MccB17 
variants from Pseudomonas syringae inhibited both Pseudomonas sp. and E. coli, but their effectiveness 
varied depending on the precursor peptide sequence despite having similar gyrase inhibitory activity in 
vitro. Interestingly, when a Gly3 sequence from the P. syringae MccB17 variant was substituted into E. coli 
McbA, this chimeric structure exhibited a broader spectrum of activity that included additional 
Pseudomonas strains. Together, these data demonstrate that multiple segments of MccB17 contribute to its 
uptake and bioactivity and that sequence modification is a viable option for controlling the activity spectrum 
of microcins.95 
Two proteins, OmpF and SmbA, are largely responsible for governing the entry of MccB17 into 
cells, and thus define its spectrum of activity. The outer membrane porin OmpF (and partially OmpC) first 
allows entry into the periplasm.96 Subsequently, SmbA, an inner membrane protein involved in the uptake 
of many different peptide antibiotics, enables entrance to the cytoplasm.96-99 Once inside, MccB17 inhibits 
DNA gyrase and triggers double strand breaks in DNA. The initial DNA damage occurs through 
exploitation of the enzymatic mechanism.79, 81 DNA gyrase introduces negative supercoils, which are 
required for DNA replication, by wrapping DNA around itself, cleaving the two strands of the DNA, 
passing bound DNA through this newly formed gap, and finally re-ligating the DNA.100, 101 The active 
enzyme is a heterotetramer, A2B2, where the A subunit (GyrA) is responsible for DNA wrapping, cleavage, 
and re-ligation while the B subunit (GyrB) has an N-terminal ATPase domain and interacts with DNA and 
GyrA through its C-terminus. Although the exact binding site is unknown, a resistance mutant (W751R) 
suggests that MccB17 interacts directly with the C-terminal domain of GyrB.79, 102 MccB17 has little effect 
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on the rate of supercoiling by DNA gyrase in vitro (~2-fold reduction), but it does appear to stabilize a 
transient enzyme intermediate during DNA strand passage that results in release of bound DNA from the 
enzyme before it can be re-ligated (known as the cleavage complex).103-107 Since the damaged DNA cannot 
be replicated, inhibited cells undergo rapid DNA degradation that is prevented by resistance genes encoded 
in the MccB17 BGC.80, 108 In addition to McbEFG, the proteinaceous DNA gyrase inhibitor GyrI also 
protects against MccB17 because it blocks the enzyme’s interaction with DNA, thereby preventing DNA 
cleavage, and ultimately allows cell growth despite its inhibition of DNA gyrase.109-111  
It has been reported that MccB17 isolated from natural sources actually replaces a backbone amide 
with one ester linkage resulting from an N → O acyl shift at residue 52.112 This does not affect activity, as 
both the amide and ester forms exhibit activity against E. coli (minimum inhibitory concentration, MIC, of 
60 nM).94 The thiazole and oxazole heterocycles are critically important and cannot be substituted for each 
other without loss of activity, and the antibacterial potency correlates with the total number of heterocycles 
present in the peptide.107, 113 Of the these azoles, the second bisheterocycle (B-site) is the most important 
for antibiotic activity and may intercalate DNA, like the bisthiazole of bleomycin (Figure 1.3), although 
this has yet to be proven.60 Notably, MccB17 does not directly bind naked DNA but likely interacts with 
DNA once bound to gyrase.105 Conceivably, many new MccB17 derivatives could be explored through 
solid phase peptide synthesis, but in practice, the Gly-rich region is synthetically troublesome and limits 
the usefulness of this approach.114, 115 Overall, MccB17 has a complex structure-activity relationship that 
remains poorly understood, since changes can affect export, import as well as inhibition.  However, it is the 
study of MccB17 that has laid much of the foundation for our current understanding of RiPP 
cyclodehydratases.116 Later in this review, we will return to the topic of MccB17 biosynthesis for its insights 
into cyclodehydratase function (section 1.6). 
 
1.2.2 Cytolysins 
Certain human and animal pathogens employ cytolytic toxins that disrupt host cell membranes to enhance 
virulence during infection.117-120 Streptococcus pyogenes, a bacterial cause of pharyngitis and more severe 
infections such as necrotizing fasciitis,121 produces a cytolytic LAP named SLS.122 Though its identity and 
nature were unknown at the time, the cytolytic activity of SLS was first reported in 1895 when certain 
Streptococci were observed to produce a hemolytic phenotype when grown on blood agar media.123 
Variations of this phenotype include the γ-, α- β-, and hemolytic phenotypes and describe no hemolysis, 
partial hemolysis, or complete lysis of erythrocytes, respectively. SLS causes β-hemolysis and results in 
complete clearing of blood agar around producing bacteria.124 Early efforts to isolate and characterize SLS 
were limited by its poor physiochemical properties, and its need for stabilizing carrier molecules (e.g. RNA, 
serum, detergents) to retain activity.125, 126 Despite these challenges, analysis of crude preparations indicated 
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that the active component of SLS was a peptide.127-130 However, it was not until the year 2000 that 
transposon mutagenesis and DNA sequencing studies131, 132 revealed that SLS was a RiPP.133, 134 These 
genomic studies demonstrated that nine genes, sagABCDEFGHI, comprised the SLS operon (Figure 1.6).135  
As is standard for LAP BGCs, a precursor peptide (SagA) and azole synthesizing machinery are 
present (SagB, SagC, and SagD).51, 136 SagE is presumably the leader peptidase,137, 138 as it is the only gene 
within the operon with homology to a protease, in this case, the type II CaaX proteases139-141 and some 
homologs are also involved in bacteriocin maturation pathways.142 SagGHI comprise a multi-component 
ABC transporter and thus are presumed to export mature SLS. Another predicted membrane protein, SagF, 
currently has an unknown function despite being conserved in multiple SLS-like gene clusters.51, 135, 137   
Although the gene cluster for SLS is known and should aid in determining its structure, the mature 
structure of SLS remains elusive due to difficulties in working with the molecule. From bioinformatics and 
gel filtration experiments,130, 143 the SLS core is predicted to begin just before the Cys-rich region at the C-
terminus of SagA. Most Cys and Ser residues are expected to be heterocyclized based on the ability of 
heterologously expressed and purified SagBCD to accept McbA (the MccB17 precursor) as a substrate.51, 
136  Partial MS support for conversion of the final two Ser in SagA to oxazoles has also been obtained.144 
The only other inference into which SagA residues are modified has come through mutagenesis of 
heterocyclizible residues (Cys, Ser, or Thr) to Ala or Val.136 Assuming that a residue is normally 
heterocyclized into an azole, then the introduction of a free side chain at such a position should be 
detrimental to the resulting mutant’s lytic activity. By assessing SLS mutants in this way, many of the 
residues in the N-terminal poly-heterocyclizable (NPH) region of the core, CCCCCTTCCFS, were 
identified as important for blood cell lysis while only three of the remaining Ser outside of the NPH 
contribute to its effect.136 Interestingly, some SLS-like gene clusters from Borrelia were predicted to encode 
a short cytotoxin, possessing only this short NPH, and indeed the minimal cytolytic unit of SLS is the NPH 
region (the first 11 residues of SLS).145 This indicates that the extended and variable C-terminal region of 
SLS could play a role in governing cellular specificity.  
Various types of membrane bound compartments are sensitive to SLS including leukocytes, 
platelets, subcellular organelles, and even some bacteria lacking a cell wall.146-150 SLS appears to interact 
with membranes and causes temperature dependent osmotic lysis by forming pores in the membrane.151, 152 
Recently, more mechanistic insights were gained when SLS was shown to trigger influx of Cl– by 
interacting with anion exchanger 1 (band 3), resulting in lysis, but the precise binding site and mechanism 
of ion dysregulation are not known.153 Given the broad range of membranes affected by SLS, homologous 
anion transporters are likely also targeted in other eukaryotic cell types; however, sub-lethal amounts of 
SLS activate programmed cell death and inflammation in epithelial cells so SLS seems capable of affecting 
cells in multiple ways.154 
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 Because of the enhanced virulence of SLS-producing streptococci,137, 155 it is not surprising that 
other pathogens similarly employ SLS-like toxins. Other Streptococcus species that have been found to 
produce SLS-like cytotoxins include the following Streptococcus species: S. dysglactiae subsp. 
equisimilis,156 S. iniae,157 S. equi,158 and S. anginosus.159 Additional Firmicutes encode SLS-like BGCs, 
including select strains of Clostridium, Listeria, Staphylococcus, and even certain Spirochete species from 
Borrelia and Brachyspira. These putative toxins have correspondingly been named clostridiolysin S 
(CLS),144 lysteriolysin S (LLS),160-162 stapholysin S,51 and borreliolysin S.145 While only CLS and LLS have 
been isolated from their native organisms,144, 160 fusing the core sequence for any one of these toxins to the 
SagA leader peptide followed by treatment with SagBCD resulted in the production of a cytolytic agent 
(presumably upon the installation of the heterocycles).136, 145 The BGC for clostridiolysin S has the same 
architecture as SLS, exemplified by C. botulinum, and its cyclodehydratase (ClosCD) has been 
reconstituted in vitro with SagB as its dehydrogenase (the cognate ClosB was inactive).144 In addition to 
these, other putative SLS-like gene clusters have also been bioinformatically identified among Firmicutes 
and Actinobacteria but require additional work to demonstrate their predicted activity.57, 137, 145, 163  
 
1.2.3 Plantazolicins 
Plantazolicin (PZN) is a highly specific, bactericidal antibiotic that targets Bacillus anthracis, the causative 
agent of anthrax (Figure 1.7). 164 PZN is part of a growing trend where new molecules are first identified 
through genomics rather than traditional bioactivity-guided screening as a consequence of the increased 
availability of organism genomes.165 The BGC of PZN was discovered in 2008 in the genome of Bacillus 
velezensis FZB42 (formerly Bacillus amyloliquefaciens) through its similarity to the SLS gene cluster.51 
Three years later when PZN was isolated from its native host and structurally characterized, much of its 
structure had been correctly predicted based on its gene cluster and the biosynthetic logic of azoline-forming 
YcaOs. Indeed, with the movement toward genome-guided natural product discovery, genome-guided 
structure elucidation has become increasingly powerful.166 Based on the PZN precursor peptide (BamA), 
and presumed similarity to SLS, all Cys, Ser, and Thr residues were predicted to be converted to azol(in)es 
by the cyclodehydratase/dehydrogenase (BamBCD). By homology to SagE, the previously described type 
II CaaX-like protease, BamE was hypothesized to remove the leader.138 Additionally, methylation was 
anticipated based on the presence of a S-adenosylmethionine (SAM)-dependent methyltransferase (BamL). 
This methyltransferase was later shown to selectively dimethylate the newly formed N-terminus of PZN 
through a narrow substrate tunnel which limited access to the active site.167-170 Although the exact position 
and selectivity of these modifying enzymes could not be predicted a priori, the high resolution mass of 
purified PZN was consistent with 10 cyclodehydrations, 9 dehydrogenations, 2 methylations, and leader 
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peptidolysis between Ala-Arg (Figure 1.7). With this information, NMR was used primarily to confirm the 
structure rather than elucidate it outright.164, 171, 172 
Mature PZN is presumably exported by an ABC transporter comprised of BamG and BamH. Of 
the remaining proteins encoded in the BGC, BamK is a predicted transcriptional regulator, but BamF, BamJ, 
and BamI have unclear functions. Deletion studies showed BamF and BamI were dispensable for PZN 
production whereas deletion of BamJ abolished PZN production.171 Notably, BamJ is present in every PZN-
like gene cluster,164, 173 but it is clearly not required for the in vitro formation of PZN, given that the 
biosynthetic pathway has been reconstituted for two PZN family members and neither required the addition 
of BamJ.173  
Since the identification of the first PZN gene cluster, 14 additional PZN-like BGCs have been 
identified through conservation of the genes bamJBCDE and similarity of motifs in the precursor peptides 
(two discrete regions of 4 to 6 heterocyclizable). The product from Bacillus pumilus (Bpum) has been 
confirmed to be identical to PZN as indicated by its core peptide,164 and one other close PZN variant from 
Bacillus badius (Bbad) named “badiazolicin” (BZN) has also been isolated and shown to be similarly active 
against B. anthracis.173 Importantly, work with proteins from the Bpum BGC allowed reconstitution of a 
PZN azole-synthetase by combing BpumC with BamB and BamD (the cognate BamC expressed poorly 
and was unstable). With an active azole-forming synthetase (BamB/BpumC/BamD) in vitro, numerous 
precursor peptides could be tested as substrates and partially processed intermediates could be analyzed to 
determine the rules governing substrate processing (further discussed in section 1.6.3). Encouraged by this 
success, the azole synthetase (CurBCD) from Corynebacterium urealyticum was also reconstituted and 
demonstrated to install ten azoles on CurA. Then, taking this decazole intermediate forward, its leader 
peptide was removed, and it was subjected to chemical N-terminal dimethylation to yield the putative 
natural product “coryneazolicin” (CZN).173  
PZN is only known to target B. anthracis, with the exception of one B. anthracis strain that is non-
susceptible and one B. cereus strain that is susceptible.164, 174 Given this ultra-narrow spectrum of activity, 
there has been much investigation into the mode of action of PZN.174 Nonetheless, it is still not clear what 
mediates PZN susceptibility or selectivity. PZN resistance mutants, which could indicate the target, 
upregulated multidrug resistance efflux pumps or had missense mutations in two-component regulatory 
gene directly upstream of a cardiolipin synthase.174 As efflux pumps provide general resistance, this result 
suggested that cardiolipin may be involved in the PZN mode of action, and in support of this, fluorescently-
labeled PZN co-localized with dye that approximates the location of cardiolipin in B. anthracis membranes. 
Cardiolipin, a diphosphatidylglycerol lipid associated with regions of membrane curvature,175-177 has an 
unusual localization in B. anthracis relative to other bacteria.174 Accordingly, it was hypothesized that PZN 
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interacts with these unique regions of cardiolipin to destabilize and lyse the cell membrane of only B. 
anthracis, but the molecular details of this process remain to be elucidated. 
Given the narrow spectrum of PZN, there has been interest in obtaining new variants to explore 
structure-activity relationships and identify the key features for bioactivity. Deletion of the 
methyltransferase from B. velezensis, produces PZN with an unmodified N-terminus (desmethyl-PZN), but 
this variant had dramatically reduced potency.164 Full heterocyclization was also important as acid 
hydrolysis of the methyloxazoline in PZN showed a 10-fold loss of activity (Figure 1.7) 164 In another 
experiment designed to generate and test novel PZN derivatives, the PZN gene cluster was heterologously 
expressed in E. coli with different precursor peptides.178 However, the heterologous biosynthetic pathway 
was essentially intolerant to substitution at positions normally converted to azoles. Ten variants at other 
accepted positions were purified from E. coli but were found to be less active.178 Overall the data suggest 
that few PZN structural features can be changed without reducing activity against B. anthracis. 
Additional information about the structure-activity relationships of PZN comes from chemically 
synthesized analogs. PZN has been the subject of several total syntheses179-181 and the N-terminal half of 
PZN (Me2-Arg-Az5) has also been prepared synthetically as a methylester (Figure 1.8). Unexpectedly, this 
truncated pentazole analog retained nearly all of its antibiotic potency towards B. anthracis but additionally 
killed S. aureus and other Gram-positive bacteria unaffected by PZN.167, 169 In accord with a broader 
spectrum of activity, the mode of action for Me2-Arg-Az5 appears distinct from PZN based on the 
observation that PZN resistance mutants are sensitive to Me2-Arg-Az5, sub-lethal treatments induce 
different expression signatures captured by RNA-seq, and that Me2-Arg-Az5 kills B. anthracis without cell 
lysis.174 The molecular target of Me2-Arg-Az5 is unknown, but these results suggest that the N-terminal half 
of PZN is the bioactive portion while the C-terminal region could control targeting or selectivity. These 
data are reminiscent of what was observed for SLS, with the NPH being the minimal portion required for 
activity.145  
 
1.2.4 Hakacins 
The hakacins represent an example of a RiPP BGC found in Bacillus sp. Al Hakam (Balh) for which no 
known compound has been isolated but is presumed to be a LAP based on the genes present.182 The Balh 
gene cluster was first identified in 2008 and contains two precursor peptides (BalhA1 and BalhA2), a 
cyclodehydratase (BalhC and BalhD), a dehydrogenase (BalhB), and a nearby transporter; no specific 
protease appears linked with the gene cluster (Figure 1.9). 51, 182 Other nearby genes have unknown function 
but also could play a role in modifying the peptide. Highly related BGCs can also be found in closely related 
Bacillus species.57, 182 Even though the hakacin natural product has not been identified, the likely location 
of heterocycles in BalhA1/A2 has been determined from in vitro reconstitution reactions.182, 183 
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Unfortunately, BalhB did not co-purify with its flavin co-factor so it was substituted with a dehydrogenase 
(BcerB) from one of its homologous BGCs in B. cereus, as has been done for other previously discussed 
cyclodehydratases.144, 173 Because the active azole synthetase complex could be formed in this way, the Balh 
cyclodehydratase has proved valuable for probing YcaO-dependent heterocycle formation (section 1.6). 
 
1.2.5 Hetercycloanthracins 
The heterocycloanthracins (HCAs) represent another predicted group of LAP BGCs found through from 
genomic analysis that identifies characteristic features such as a YcaO protein and Cys-rich regions at the 
C-terminus of their precursor peptides. The HCAs are primarily found in B. anthracis and B. cereus and 
possess numerous repeats of Cys-Xxx-Xxx within their precursor peptides, which often are distally encoded 
relative to the biosynthetic enzymes.184 Generally, the only other genes that compose an HCA gene cluster 
are a cyclodehydratase, a partner protein required for cyclodehydratase activity (“ocin-ThiF”), and often a 
dehydrogenase (Figure 1.10). Other potential tailoring enzymes are often present, such as 
methyltransferases, succinyltransferases, and 2-oxoglutarate dehydrogenases, but no transporters, 
immunity proteins, or proteases appear in the local genomic region. Additionally, because most HCA 
clusters have high sequence identity, it can be more difficult to predict BGC boundaries by conservation 
analysis. 
Insight into HCA biosynthesis has come from studying the cyclodehydratase from B. Al Hakam. 
These studies revealed that the “ocin-ThiF-like” protein, named HcaF, encoded immediately adjacent to 
the cyclodehydratase HcaD, was required to reconstitute azoline biosynthesis.185 HcaF is homologous to 
ThiF, a member of the E1-like superfamily but has a distinct role in the biosynthesis of the thiazole moiety 
of thiamine.186-188 Consequently, HcaF is referred to as a cyclodehydratase partner protein and is referred 
to as the F protein. Ocin-ThiF-like partner proteins are also commonly found in thiopeptide BGCs (section 
1.3). Interestingly, azol(in)e-containing RiPP BGCs that encode ocin-ThiF-like proteins (e.g. HCA) lack a 
canonical E1-like “C” protein, which is found in more standard examples (e.g. hakacin), but part of the  
canonical LAP C protein appears fused to the YcaO protein. To distinguish these pathways, the term F-
protein dependent cyclodehydratase was introduced.185  
Of all the identified HCA BGCs, only one product has been purportedly isolated from Bacillus 
sonorensis MT93. Named sonorensin, it was demonstrated to have potent antibacterial activity against 
Listeria monocytogenes and hence, may be useful as a food preservative.189-191 However, the structure and 
the biosynthetic origin remain unverified, and the reported low-resolution mass of the isolated antibacterial 
compound does not match the putative core peptide. Further, the proposed sonorensin leader peptide 
cleavage site is unlikely given that multiple Cys residues appear before it, and for most other azol(in)e-
containing RiPPs, the first Cys is indicative of the beginning of the core. This proposed cleavage site, if 
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correct, would be highly unusual.189 Recombinant expression of only the proposed sonorensin core peptide, 
in the absence of any modifying enzymes, resulted in a peptide with anti-Listeria activity, an observation 
that led to the conclusion there is no modification of the natural product.189 However, until further studies 
including high-resolution mass spectrometry, NMR, and biochemical testing, the actual structure of 
sonorensin and whether it belongs among azol(in)e-containing RiPPs remains uncertain.  
 
1.2.6 Azolemycins 
One of the primary differences between LAPs is the variable functional groups installed by the ancillary 
tailoring enzymes. In this regard, the azolemycins are highly unique LAPs because they feature a rare oxime 
moiety. A few other natural products possess an oxime moiety, for example caerulomycin A,192 
althiomycin,193 collismycin A,194 and nocardicins A and B,195 but no RiPP was previously known to display 
this group. Azolemycin was found in extracts of Streptomyces sp. FXJ1.264 based on its mass and predicted 
molecular formula, which did not match any known compound.196 Further NMR characterization revealed 
four derivatives that vary based on the configuration of the oxime and its methylation pattern. The structure 
was also independently confirmed by total synthesis (Figure 1.11).197 No definitive bioactivity has been 
found for the azolemycins with only modest anti-proliferative activity being observed.197 
Based solely on the structure, it was difficult to predict the genetic origin of the azolemycins so the 
producer, Streptomyces sp. FXJ1.264, was sequenced.196 This revealed a BGC with a precursor peptide 
(AzmA) containing the sequence VVSTCTI that could give rise to the azolemycins. A fused 
cyclodehydratase (AzmC/D) and discrete dehydrogenase (AzmB) form the four azoles. The protein 
responsible for oxime formation (AzmF) has homology to flavin-dependent monooxygenases. Deletion of 
azmF gave products with no oxime and primarily yielded a truncation product lacking the N-terminal Val 
residue, indicating that the oxime protects against proteolysis. AzmE is an SAM-dependent 
methyltransferase that installs two methyl groups. Similar to PZN, desmethyl derivatives can be isolated 
from the  azmE strain.196 Notably, there are no locally encoded proteases encoded in the BGC, yet AzmA 
has both N- and C-terminal regions flanking the core peptide sequence which must be removed during the 
maturation process. Overall, these investigations confirmed the ribosomal origin of the azolemycins and 
demonstrated how oxime functional groups can be introduced in RiPPs. 
 
1.2.7 Goadsporin 
Since sequencing the genome of Streptomyces coelicolor A3(2),198 it has been evident that many BGCs are 
cyptic in that they do not produce detectable amounts of product. This is true even for organisms that are 
known to produce many different secondary metabolites. While these cryptic BGCs can be activated by 
various genetic methods or in heterologous hosts, altering growth conditions or media is often a fruitful 
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approach.199, 200 In their native environments, bacteria live in complex multi-species communities and 
communicate with each other through various physical and chemical cues. Mimicking this environment by 
supplementing growth media with extracts from different bacteria can cause the activation of pathways that 
are silent under normal laboratory culturing conditions. Goadsporin was initially discovered by screening 
several hundred actinomycete broths for the ability to stimulate production of a red pigment, actinorhodin, 
by Streptomyces lividans TK23.201 Goadsporin was isolated from extracts of Streptomyces sp. TP-A0584 
and further characterization indicated that it induced secondary metabolism and sporulation in various 
streptomycetes. Its bioactivity spectrum was broad among Streptomyces, affecting 36 of 42 tested strains at 
a concentration of 1 μM. Above this concentration, goadsporin displays growth inhibitory activity. 
The structure of goadsporin is unusual for a LAP because in addition to its azole heterocycles it 
contains two dehydrated amino acids (Figure 1.12).202, 203 Genetic deletion studies support a biosynthetic 
pathway in which the azoles are formed first by a fused cyclodehydratase (GodD) and a dehydrogenase 
(GodE).204 In the next likely step, dehydroamino acids are formed by what is now termed a split LanB 
dehydratase that catalyzes the glutamylation of select Ser and Thr (GodG) and subsequent elimination 
(GodF) to yield the corresponding dehydroalanine and dehydrobutyrine moieties.204, 205 Putative membrane-
associated proteases (GodB and GodC) cleave the modified precursor peptide (GodA), and an N-
acetyltransferase (GodH) modifies the newly formed N-terminus.206, 207 Transcription of the goadsporin 
BGC is controlled by GodR, an activator,208 whose overexpression results in increased production of 
goadsporin, although the best titers were achieved through heterologous expression in S. lividans and co-
culturing with Tsukamurella pulmonis.208, 209 In order to prevent inhibition of its own growth, the BGC 
encodes the immunity protein GodI (see below).  
The dehydrated residues of goadsporin are noteworthy because the split LanB dehydratase that 
forms them is so named owing to homologous proteins being involved in lanthipeptide biosynthesis. 
Lanthipeptides comprise their own RiPP class and are beyond the scope of this review; however, they have 
been extensively reviewed elsewhere210, 211 and unique aspects of their unusual enzymology are found in an 
accompanying review from van der Donk, Nair, and co-workers.212 Genes encoding a split LanB 
dehydratase are also found nearby cyclodehydratase genes in the thiopeptide class of RiPPs (section 1.3). 
Thus, a LanB dehydratase can be found in multiple RiPP classes and can provide increased 
chemical/structural diversity to a natural product pathway. Indeed, the dehydroamino acids of goadsporin 
are required for bioactivity.204 Other structural features that have been investigated show flexibility in 
swapping oxazole and methyloxazole heterocycles,213 but alteration of the C-terminus or to Gly10 
compromise its activity. 
Insight into the mode of action of goadsporin has come from studying its immunity protein. 
Because GodI has homology to the 54 kDa “Ffh” subunit of the signal recognition particle (SRP), 
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goadsporin is believed to bind and inhibit native Ffh. This would interfere with the normal function of the 
SRP, which transports specific proteins to the plasma membrane. However, GodI is insensitive to 
goadsporin and presumably replaces the inhibited subunit, allowing normal SRP function.207 The 
observations that goadsporin induces secondary metabolism but at higher concentrations is growth 
inhibitory raises questions about what its “true” function may be in vivo. Goadsporin serves as a reminder 
that not all natural compounds that inhibit the growth of various microorganisms were necessary intended 
for niche competition.214, 215 
 
1.3 Thiopeptides 
The thiopeptides (originally thiazolyl peptides216) are an extensively studied group of azol(in)e-containing 
RiPPs known for their inhibition of protein synthesis and potency towards various Gram-positive bacteria, 
especially multi-drug resistant strains, e.g. methicillin-resistant Staphylococcus aureus (MRSA), penicillin-
resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci.32, 217, 218 Since the first 
thiopeptide micrococcin was discovered in 1948,219 over 100 variants have been isolated. In addition to 
their antibiotic activity, other reported bioactivities include anticancer, antimalarial, antifungal, and 
immunosuppressive activities, as well as inhibition of renin and RNA polymerase (see section 1.3.3).65 
Beyond these diverse activities, thiopeptides have received attention for their architectural complexity 
(Figure 1.13). The defining feature of a thiopeptide is six-membered, nitrogenous heterocycle within a 
macrocyclic framework also decorated with multiple azole heterocycles and dehydroamino acids.26, 32, 65 
Thiopeptides frequently feature additional tailoring, including methylations, hydroxylations, and in some 
cases, a second, ester-linked macrocycle derived from Trp or a thioether macrocycle derived from Cys. Due 
to the molecular complexity, early structure determinations required much effort and relied heavily on 
chemical degradation. Eventually, mass spectrometry, NMR, X-ray crystallography, and total synthesis 
became standard methods for structural elucidation and confirmation. These studies and advances in 
thiopeptide total synthesis have been reviewed elsewhere.32, 65, 220-224 Based on their structural complexity, 
many believed thiopeptides would be produced by non-ribosomal peptide synthetases (NRPSs).32, 225 
However in 2009 their ribosomal origin was firmly established by multiple independent research groups, 
and ycaO genes were found in all cases, providing a rationale for the azol(in)e heterocycles found in all 
members of this class.52-56, 226, 227 Since this time, much has been learned about the role of individual 
biosynthetic proteins,65, 224, 228, 229 and taking advantage of their biosynthetic logic, many new thiopeptide 
derivatives have been made easily using different biosynthetic approaches.45, 224, 229, 230 We focus on the 
thiopeptides from a biosynthetic perspective with an emphasis on how their observed structures and 
activities are encoded by their BGCs. 
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1.3.1 Common biosynthetic features 
Despite the large number of known thiopeptides and their congeners, these compounds share many overall 
similarities in their structures, biosynthesis, and biological effects. As mentioned above, the six-membered 
nitrogenous heterocycle is a class-defining feature of the thiopeptides, but it appears in different oxidation 
states and substitution patterns which has led to the classification of five different thiopeptide series termed 
a through e (Figure 1.13).32 The a series possess a fully reduced piperidine, as exemplified by some 
thiopeptins, whereas the b series has a 1,2-dehydropiperidine ring with thiostrepton being the archetype 
member. The c series currently has only one member, Sch 40832, which displays a bicyclic piperidine fused 
to an imidazoline. The d series is most populous and harbors a tri-substituted pyridine ring as in micrococcin 
P1. Lastly, the e series exhibit hydroxylated pyridines as illustrated by nosiheptide. In addition to the 
macrocycle that is formed by the central pyridine/piperidine heterocycle, members of the a-c series contain 
a second macrocycle made from a connection at this central heterocycle to a side chain of the macrocycle 
through a quinaldic acid moiety. The e series also harbor a second macrocycle, but it is smaller and attached 
to two side chains of the primary macrocycle through an indolic acid moiety. 
 Early insights into the biosynthesis of thiopeptides came through feeding studies using isotopically 
labeled amino acids (thoroughly reviewed elsewhere32), among other metabolic precursors, to trace the 
chemical origins for various parts of the structure.225, 231-241 These studies revealed that all structural 
components of thiopeptides were derived from amino acids, as implied by their structures and degradation 
products. The azol(in)e heterocycles came from the cyclodehydration of Cys, Ser, and Thr while the 
dehydroamino acids derived from dehydration of Ser and Thr. The nitrogenous six-membered heterocycle 
originated from Ser residues and was first proposed to form through a cycloaddition reaction in 1977 (Figure 
1.13).242 The quinaldic acid moiety in the secondary macrocycle of the a-c series thiopeptides originated 
from tryptophan and required a ring expansion transformation, and similarly the indolic acid linked 
secondary ring of the e-series also derived from tryptophan through a unique rearrangement reaction.  
The next major advance in understanding thiopeptide biosynthesis required discovery of their 
BGCs. Because of their peptidic nature, thiopeptide could be made ribosomally  (i.e. RiPPs) or by NRPSs.226 
Attempts to identify DNA sequences within producing organisms that might encode a precursor peptide 
matching the deduced precursor sequence of known compounds were initially fruitless, and 
chloramphenicol, an antibiotic that inhibits protein translation, did not seem to block production of 
nosiheptide, which suggested that the ribosome is not needed in thiopeptide biosynthesis.243, 244 Other 
evidence showed that the quinaldic acid and indolic acid moieties found in some thiopeptides had their 
carboxylic acid groups activated with ATP, consistent with NRPS coupling mechanisms.245 Moreover, a 
NRPS putatively involved in micrococcin biosynthesis was identified,246 and other heterocycle containing 
and macrocyclic compounds (e.g. bacitracin) were known to be made by modular NRPSs.247, 248 However, 
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as more RiPPs were studied and discovered in the 2000s, the potential of a ribosomal origin for thiopeptides 
gained more traction.226 Dehydratases from the lanthipeptide subclass of RiPPs were known to transform 
Ser and Thr residues into dehydroamino acids,210 and heterocycles derived from the peptide backbone in 
the azol(in)e-containing RiPPs were also recognized as being much more prevalent.49-51 Consequently in 
2009, a RiPP biosynthetic origin for thiopeptides was proven nearly simultaneously by several independent 
research groups.52-56 
 At present, BGCs for 14 thiopeptides have been verified using genetic manipulations and/or 
heterologous expression. Currently, these include thiocillin,52, 54, 249, 250 thiostrepton,54, 56, 251 siomycin,54 
nosiheptide,53, 252, 253 GE2270,55, 254, 255 thiomuracin,45, 55 nocathiacin,256, 257 cyclothiazomycin,258, 259 TP-
1161,260  GE37468,261 berninamycin,262 lactocillin,263 nocardithiocin,264 and lactazole.265 Many natural 
congeners of these compounds are known to be produced by the same BGC. Based on these studies, all 
necessary biosynthetic genes were found to cluster near a precursor peptide (designated the “A” 
gene/protein) of typically 50-60 amino acids. Additionally, a primary set of six essential proteins emerged 
for building the core thiopeptide scaffold and included a split LanB dehydratase (B and C), [4+2] 
cycloaddition enzyme (D), dehydrogenase (E), cyclodehydratase partner protein (F), and cyclodehydratase 
(G). Despite the institution of a “standard” nomenclature,26 the labeling of these genes tends varies between 
BGCs, and this nomenclature is quite different compared to other subclasses. Usually, thiopeptide genes 
are clustered, but one counter example, cyclothiazomycin C, has a fragmented BGC with the [4+2] enzyme 
being distally encoded.266 In the remainder of this section, the biosynthesis of the core thiopeptide scaffold, 
the formation of the two tryptophan derived secondary rings, and C-terminal amidation are described. These 
steps have been expertly reviewed,65, 228, 229 but here we again cover this material with additional recent 
findings. 
The roles of the aforementioned core biosynthetic enzymes were first assigned through 
bioinformatic analysis and characterization of partially processed intermediates in genetically manipulated 
strains.44, 204, 255, 262, 267 Although not conclusive, these studies suggested the biosynthetic order of events 
began with azol(in)e formation, then Ser/Thr dehydration, followed by macrocyclization through a putative 
[4+2] cycloaddition. The cyclodehydratase (G) was readily identified based on its obvious homology to 
azoline-forming YcaO proteins,17, 18 and similarly, the role of the dehydrogenase (E) in azoline oxidation 
to their corresponding azole heterocycles was easily recognized via homology with other flavin-dependent 
dehydrogenases known to dehydrogenate azoline heterocycles in RiPP pathways (Figure 1.5).72 However, 
the role of the cyclodehydratase partner protein (F) was not realized because its genetic deletion abolished 
thiopeptide production without providing any intermediates.53, 258, 265 The F-protein has low similarity to the 
cyclodehydratase protein (G) but is most clearly homologous to ThiF, an adenylating protein involved in 
thiamine biosynthesis and part of the E1-like superfamily.188, 268 In public genome databases, this protein is 
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most often annotated as “Ocin-ThiF-like.” Importantly, this ThiF-like partner protein contains the RRE, 
which binds the precursor peptide, and potentiates YcaO catalyzed cyclodehydration.27, 45, 185 Accordingly, 
the thiopeptide cyclodehydratase is most accurately described by the combined activities of the partner 
protein and YcaO because both are necessary for azoline biosynthesis.45 Notwithstanding these 
observations, there are rare examples of thiopeptide producers that do not locally encode a ThiF-like protein 
homolog (e.g. Streptomyces bernensis, the producer of berninamycin262). The next step, dehydration of 
Ser/Thr residues is performed by a dehydratase composed of two proteins (B and C) that are homologous 
to the N- and C-terminal domains of class I lanthipeptide dehydratases respectively (referred to as a split 
LanB). These proteins catalyze dehydration through glutamylation of the hydroxyl group (B protein) using 
glutamyl-tRNAGlu with subsequent elimination (C protein).45, 205, 269 A formal [4+2] cycloaddition of two 
dehydroalanines forms the six-membered nitrogenous heterocycle (Figure 1.13).45, 270 The identity of the 
[4+2] cycloaddition enzyme was inferred by its absence in goadsporin (section 1.2.7),204, 213 which 
structurally resembles a presumed intermediate during thiopeptide biosynthesis. Deleting this gene in 
thiopeptide BGCs resulted in the isolation of linear intermediates lacking this 6-membered heterocycle.44, 
265, 271 Unexpectedly, the [4+2] enzyme has high similarity to the elimination domain of LanB dehydratases 
and possibly evolved through a duplication event. Whether or not the cycloaddition is concerted (Diels-
Alder) or stepwise has yet to be evaluated, but these studies support a cycloaddition product as common 
biosynthetic intermediate from which subsequent reductions lead to the (dehydro)piperidine in the b and a 
series (Figure 1.13c). Also from this intermediate, dehydration and -elimination of the leader peptide gives 
rise to the pyridine of the d series; for the e-series a cytochrome P450 monooxygenase must further 
hydroxylate this to form the hydroxypyridine.252 Ultimately, the biosynthetic order of events leading to the 
primary macrocycle were verified by in vitro reconstitution.45 More detail into the rules governing the 
heterocycle formation by the YcaO and how this azol(in)e formation interfaces with modification by other 
enzymes is further discussed in section 1.6.3. 
 After formation of the distinctive (primary) macrocyclic structure of thiopeptides, another common 
modification common is a secondary macrocycle connected through a quinaldic or indolic acid moiety 
(Figure 1.14).229 As shown in Figure 1.15a, the quinaldic acid derivative found in thiostrepton (Tsr) and 
other a-c series thiopeptides begins with C-2 methylation of tryptophan with overall retention of 
stereochemistry of the methyl group via a radical S-adenosylmethionine (rSAM) methyltransferase (TsrM, 
also known as TsrT),234, 272-274 and then an aminotransferase catalyzes deamination (TsrV, also called TsrA, 
note: naming conventions varies between research groups).56 Next a putative oxidase (TsrQ) forms an 
intermediate that presumably undergoes ring opening and recyclization that may be enhanced by the action 
of polyketide-like cyclase (TsrS, also called TsrD).275 After formation of the quinaldic acid moiety, the 
ketone is reduced stereospecifically to an alcohol (TsrN, also called TsrU),275 and a probable next step is 
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attachment to a side chain of the primary macrocycle, which has been suggested to be catalyzed by an 
adenylate forming enzyme (TsrJ).239, 245 A putative cytochrome P450 oxygenase (TsrI) forms an epoxide 
likely after initial attachment to a side chain of the main scaffold.276 Lastly, the leader peptide is removed 
by an α/β-hydrolase fold protein (TsrB, also called TsrI),56, 277, 278 and the newly formed N-terminus attacks 
the epoxide stereospecifically to complete the macrocycle with the aid of the hydrolase.278. Formation of 
the quinaldic acid macrocycle seems required for in vivo production as no intermediates are isolated when 
these genes are inactivated.275 In contrast, the indolic acid moiety found in e series thiopeptides (e.g. 
nosiheptide, Nos) begins with a radical-mediated rearrangement to form 3-methylindolic acid (Figure 
1.15b).53, 228 This step is performed by a rSAM enzyme (NosL) that has been extensively investigated in 
vitro and begins by abstracting hydrogen from the amino group.279-284 After fragmentation-recombination, 
the order of biosynthetic steps is not clear, but the 2-methylindole appears to be linked through its 
carboxylate to the main macrocycle by an ATP-dependent ligase (NosI?), based on a previously observed 
adenylated intermediate.53, 245, 256 The side ring can be further processed while attached to the peptide with 
methylation by a rSAM methyltransferase (NosN) and subsequent hydroxylation by an unidentified 
protein.53 Lastly, the side ring is then likely closed by an acyltransferase (NosK?) to complete its maturation. 
This final condensation which completes the side ring appears to take place prior to macrocyclization.53, 256, 
271 Thus, thiopeptide secondary rings have many commonalities in their biosynthesis and assembly,228, 229, 
245 and attachment of the indole/quinaldic acid is somewhat malleable, exemplified by the observation that  
exogenously supplied fluorinated indole/quinaldic acids can be incorporated into the mature product 
without loss of activity.275, 282 The only exception to this related biosynthetic pathway for side ring formation 
is cyclothiazamycin which forms its secondary ring through a thioether linkage between the main 
macrocycle to its tail via an unknown mechanism (Figure 1.14c). 
 The last prevalent modification during thiopeptide biosynthesis is amidation of the C-terminal 
residue in the tail and is accomplished through two distinct strategies (Figure 1.16).228, 229 The first pathway, 
as exemplified during nosiheptide biosynthesis, utilizes an “amidase” (NosA) to catalyze acrylic acid 
dealkylation of a C-terminal dehydroalanine residue (Figure 1.16a). Notably, the precursor peptide contains 
an extra Ser that is absent in the mature product.53, 253, 285, 286 This mechanism is unlike other peptide 
amidations, which usually occur through oxidative cleavage of a C-terminal Gly residue.287, 288 A second 
route to C-terminal amide formation is seen in thiostrepton-like pathways and necessarily follows a 
different mechanism as there is no extra Ser residue in the core peptide (Figure 1.16b). Accordingly, 
amidation was proposed through transamidation performed by an asparagine synthetase-like protein (TsrT, 
also called TsrC) and requires a de-esterification process.54, 56 The C-terminus is normally in the form of a 
methylester installed by a methyltransferase (TsrP, also called TsrF), but a carboxylesterase (TsrU, also 
called TsrB) reforms the C-terminal carboxylate which undergoes subsequent amidation.251 The free 
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carboxylic acid has some reduced potency relative to the amide but the methylester is the most potent 
derivative, indicating that the C-terminus has an important influence on bioactivity.251 C-terminal amidation 
also enhances potency of other biologically active peptides, particularly hormone/signaling peptides,289 but 
its effect on activity varies among thiopeptides as it does not markedly affect nosiheptide or thiomuracin 
potency.45, 253 Overall C-terminal amidation appears to be a commonly occurring step in thiopeptide 
biosynthesis as very few thiopeptides have a free C-terminus. Other unique modifications (hydroxylation, 
methylation, glycosylation) more specific to individual thiopeptides are discussed later in individual 
sections. 
 
1.3.2 Thiopeptide BGCs 
Although thiopeptides contain common features and biosynthetic steps as described above, each compound 
is made unique by variable ancillary tailoring steps. Thiopeptide BGCs often possess methyltranferases, 
cytochrome P450 oxidases, or other enzymes that have been linked to specific modifications, and although 
the precise timing for many of these modification is not known, they are not required for the formation of 
the thiopeptide core structure.45, 251, 252, 255 Nonetheless, most thiopeptide BGCs produce multiple congeners 
through these enzymes, so even though there are over 100 known thiopeptides, the number of encoding 
BGCs is much less. Analysis of the known thiopeptide parent compounds indicate that ~40 precursor 
peptides are necessary to account for all compounds, as inferred from their structures. The peptides also 
tend to share a common pattern in the position of their azol(in)es, especially among thiopeptides with the 
same ring size (Figure 1.17). Accordingly, there is much that can be learned about how thiopeptide scaffolds 
are formed by comparing their different structures, even if the BGC remains unknown. Here, these 
distinctive thiopeptide subfamilies are reviewed with a focus on their unique biosynthetic steps and 
chemical properties. 
 
1.3.2.1 Thiostrepton-like 
Since its isolation in 1955, thiostrepton290-293  (also known as bryamycin294-297) has been one of the most 
studied thiopeptides. Several highly related, 26-membered macrocycle compounds have been reported, 
including siomycin,298, 299 Sch 18640,300 thiopeptin,301, 302 and Sch 40832.303 With the discovery of the 
thiostrepton and siomycin BGCs in 2009 (Figure 1.18),54, 56 the biosynthesis of their primary scaffold, 
secondary macrocycle, and C-terminal amide is known to be performed by the enzymes discussed in section 
1.3.1. However, thiostrepton/siomycin are unusual in that they encode an extra dehydratase glutamylaton 
protein (glutamylation domain) and possess a doubly hydroxylated Ile, which is likely installed by a 
cytochrome P450 hydroxylase (TsrR). Thiostrepton also possesses inverted stereochemistry at the 
thiazoline in position 9, which could originate from D-Cys, but this inversion seems likely to occur 
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spontaneously after posttranslational modification.304 Additionally, it is not clear which protein is 
responsible for reducing the presumed dihydropyridine intermediate post-cycloaddition to the final 
dehydropiperidine. 
Reprogramming of the thiostrepton precursor peptide has shown that the presence of only one 
dehydrated residue in the secondary macrocycle of the mature product is not due to a limitation of the 
enzymes, as substitution with Ser or Thr at Ala2 or Ala4 also results in modification like in the other 
members.271, 277, 305 Other studies have also sought  to increase the water solubility of thiostrepton without 
reducing target potency by introducing polar residues at positions 2 and 4. These positions were chosen 
because they point toward bulk solvent in the co-crystal structure of thiostrepton bound to the 50S ribosome 
and are less likely to affect binding potency. Unfortunately, charged residues at these positions were 
rejected by the biosynthetic pathway. The biosynthetic machinery were more tolerant to variations at 
position 4 than position 2, but of the accepted residues, generally hydrophobic residues were the only 
substitutions that retained activity.277, 305 Interestingly, the introduction of dehydrobutyrines in this region 
by genetic manipulation resulted in decreased activity, and none of the native sequences utilize Thr, perhaps 
suggesting that nature has already selected against less potent derivatives. Despite these lower potencies 
against live bacteria, in vitro translation inhibition was approximately identical for most of the substitutions, 
indicating the lowering in whole cell activity comes from other sources such as uptake, export, or 
stability.277, 305  
Other changes to the tryptophan-derived macrocycle have also been investigated. Exogenously 
supplied fluorinated or methylated quinaldic acid can be incorporated into thiostrepton by the native 
biosynthetic pathway and results in a slightly more potent derivative.277, 306 The quinaldic acid ring can also 
be contracted if Val or Ile are substituted at position 2 because the  leader protease appears to cleave the 
peptide just before Val/Ile so the traditional position 1 will be removed when position 2 is Val/Ile.277 
Additionally, a fourth ring has been formed by introducing a Cys into the side ring that can then 
adventitiously react with a dehydroalanine in the tail region.305 However, both of these modifications likely 
disrupt the structure of the quinaldic acid ring, preventing it from interacting with the 23S ribosomal subunit 
properly, and result in dramatic loss of antibacterial activity. By similar logic, mutation of Thr7 also 
decreases potency as this conserved residue also interacts with RNA when bound.276, 307 Unexpectedly, a 
C-terminal carboxylate is also detrimental to thiostrepton potency,251 but it is not clear why from a structural 
view and could be due to uptake or other steps outside of target binding. Overall, these data indicate that 
bioengineering of thiostrepton’s side ring tended to abrogate antibacterial activity, but it should also be 
noted that most of the tested mutants did not significantly change thiostrepton ability to inhibit the 
proteasome so this latter effect could more promiscuous.277, 308  
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1.3.2.2 Nosiheptide-like 
Closely related to the thiostrepton-like family, the e series thiopeptides like nosiheptide have a different 
secondary ring but identical core macrocycle size (26-membered). Nosiheptide (also known as 
multhiomycin309-311), was first isolated in 1970312 and is the most studied member of this group (Figure 
1.19). The discovery of the nosiheptide BGC (nos) has provided many insights.53, 228, 257 The BGC includes 
a transcriptional regulator (NosP) and the standard complement of core biosynthetic proteins, indole-
derived macrocycle-forming enzymes, and C-terminal amide-forming enzyme (NosA) under the control of 
a bidirectional promoter.313 The C-terminal amide appears to be installed only after pyridine hydroxylation 
by a P450 (NosC).252 In addition to these standard enzymes, a cytochrome P450 (NosB) is present that 
carries out the γ-hydroxylation of Glu.228, 252 This hydroxyl is the site of glycosylation in many other e series 
thiopeptides, such as glycothiohexide,314-316 philipimycin,317 nocathiacin318, 319 MJ347-81320, thiazomycin,321 
and S-54832;322 however, nosiheptide is naturally an aglycone. Because the primary structural difference 
between e series thiopeptides is the identity of their sugar (their core peptides vary only by Cys to Ser 
substitution), nosiheptide is representative of a likely common intermediate that would form during the 
biosynthesis of these other thiopeptides. Indeed, when the nocathiacin BGC (noc) was discovered,256 
comparison with the nosiheptide BGC provided significant insight. The nocathiacin BGC is organized 
nearly identically to nosiheptide’s but has additional modifying enzymes. Five total P450s (NocB, NocT, 
NocU, NocR, NocV) which corresponds to three additional enzymes presumed to be responsible for 
producing the most oxidized congener of nocathiacin. Additional oxygens appear at the dehydrobutyrine, 
indolic nitrogen, and -carbon of Glu that is crosslinked to a methyl indole carbon resulting in a cyclic ether 
(Figure 1.19). After these oxidations, the hydroxybutyrine is likely O-methylated by NocQ, and a 
glycosyltransferase (NocS1) appends the N-dimethylated aminodeoxysugar (NosS2-5) to complete the 
biosynthetic pathways.256  
Attachment of the sugar moiety to nocathiacin does not appear to enhance potency as the naturally 
isolated aglycone (nocathiacin III) was just as active as the more modified nocathiacins.319 Despite the sugar 
moiety, nocathiacin exhibits the characteristically low solubility of other thiopeptides but more soluble 
variants of nocathiacin have been extensively studied through semi-synthetic modification.323-330 However, 
not as much is known about the importance of the structural features of nosiheptide aside from the 
previously mentioned minimal effects of converting the C-terminus to a carboxylate or incorporating 
fluorinated indolic acid moiety. One mutagenesis study has shown that substitution of Ser13 does not 
particularly affect the biosynthetic pathway except for preventing de-acylation to the C-terminal amide by 
NosA.331 There has been more interest in optimizing nosiheptide production332-335 due to its use as a 
livestock growth promoter.66, 67  
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1.3.2.3 Thiocillin-like 
Another family of thiopeptides with 26 (atom) membered macrocycles lacks the secondary macrocycle 
while retaining the same pattern of azol(in)e heterocycles (Figure 1.17). Although micrococcin219, 336 was 
the first discovered member of this group (1948), thiocillin337, 338 was the first to have its BGC reported 
(Figure 1.20).52 The thiocillin BGC produces multiple congeners including micrococcin219, 336 and YM-
266183339, 340 (also known as QN3223341). Given that these variants escape modification by some of the 
ancillary tailoring enzymes, they are now generally referred to as thiocillins. More recently, an authentic 
micrococcin BGC has been identified and heterologously reconstituted in Bacillus subtilis, which has 
provided further insight in the biosynthesis of the thiocillin family.249, 250 Aside from the core biosynthetic 
enzymes, thiocillin BGCs contain two NAD(P)-dependent short chain dehydrogenases which convert a C-
terminal Thr to an aminoacetone (TclP) or further to an aminoisopropanol (TclS). Although TP-1161 
(section 1.3.2.7) also bears an aminoacetone moiety, it derives from a C-terminal Ser and the responsible 
enzyme (TpaJ) is an Fe-dependent dehydrogenase. In micrococcin, aminoacetone formation is required for 
antibacterial activity,249 whereas TP-1161 required the modification for production in vivo. The optional 
methylation of Thr8 in thiocillin is likely performed by a methyltransferase (TclO), and the Val6 
hydroxylation appears to installed by an Fe(II) oxygenase unlike other thiopeptides that usually employ a 
cytochrome P450 for hydroxylations. Although not involved in maturation, a putative N-acyltransferase 
may play a role in detoxifying stalled thiopeptide maturation by succinylating Lys residues on linear 
intermediates.342 
 Nocardithiocin343 and lactocillin are two other thiocillin-like molecules for which BGCs are known. 
The nocardithiocin pathways follows biosynthetic steps seen in other thiopeptides and contains a putative 
regulator (NotD). It has an Ile with two hydroxyl groups reminiscent of modifications seen in thiostrepton 
and thiomuracin that are likely installed by a P450. A second P450 likely hydroxylates a dehydroalanine 
(Dha4), with a modification also observed in some berninamycin-like thiopeptides. Two methyltransferases 
(NotC and NotE) are also present and could catalyze methylation of the hydroxydehydroalanine and of the 
C-terminus. In contrast, lactocillin is a more enigmatic and structurally divergent thiocillin-like molecule. 
Outside of the core biosynthetic enzymes, its unique modification is the indolyl-S-Cys residue at position 
8. This moiety bears strong resemblance to nosiheptide’s indole side ring, but the proteins that are likely 
involved in the thioether linkage, an adenyltransferase (LclJ), hydrolase (LclK), and thiolation domain 
(LclI), are only convergently related to the nosiheptide side ring forming enzymes.263 Additionally, it is 
very unusual for thiopeptides to have an unmodified C-terminus, but lactocillin still possess antibacterial 
activity. 
 Based on their macrocycle size, promothiocin and JBIR-83 are also included in the thiocillin-like 
group, but they bear a clear sequence resemblance to berninamycin-like thiopeptides which have a 35-
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member macrocycle (i.e. radamycin). This is unexpected as thiopeptides within a given macrocycle size 
usually are more similar to each other than those of a different size. Currently, it is not known if the 
conformation of substrate or the cycloaddition enzyme has a stronger effect on controlling macrocycle size 
so the similarity between these thiopeptides with 26- and 35-member macrocycles may indicate the 
importance of the cycloaddition enzyme. Indeed, experiments with the thiocillin biosynthetic pathway 
demonstrate that insertion of Gly residues between Thr3 and Thr4 or deletion of Thr3 allows for the creation 
of 35 to 23 membered macrocycles, indicating that the enzyme recognizes the residues around the 
macrocyclization site (Ser1 and Ser10) regardless of the ring size.344 Additionally, thiocillins with residue 
substitutions that convert one heterocycle to an unmodified residue or vice versa inside the macrocycle can 
also be macrocyclized in select instances so multiple peptide conformations can be recognized by the [4+2] 
cycloaddition enzyme.267, 342 Introducing additional dehydroalanines (via Ser substitution) adjacent to the 
default macrocyclization site indicated that the default site is favored (Ser1) as the dienophile, but there is 
some flexibility with the diene site (Ser11) provided that there are two thiazoles C-terminal to the 
position,344 which may explain differences in cyclization between the 26- and 35-member macrocycles. 
However, it should be noted that all engineered thiopeptides with altered ring sizes appeared to be devoid 
of any antibiotic activity.344 Lastly, promothiocin/JBIR-83 are different from the other thiocillin-like 
compounds because they do not have antibiotic activity, but this is likely due to mutation of Thr3/4, which 
are essential for activity in thiocillin.342 Indeed, promothiocin barely interacts with the 23S/L11 complex 
(Kd >10 μM).345 However, these thiopeptides do still activate TipA demonstrating that TipA stimulation is 
not equivalent to antibiotic activity.346 
 Many thiocillin variants have been tested as substrates for the pathway to gain insight into rules 
governing processing (further discussed in section 1.6.3) and to decipher structure activity relationships. 
Based on the structure of micrococcin bound to the ribosome, the heterocycles are important for enforcing 
the geometry necessary for interacting with the ribosome.347 Replacement of an azole with a noncyclized 
residue significantly alters the structure of thiocillin,267 and accordingly no heterocycle positions within the 
macrocycle can be substituted without loss of activity. Similarly, the Ser residues that form the pyridine 
cannot be mutated, but generally the tail region is more accommodating to substitution. Mutation at other 
positions indicated that solubilizing, charged residues are not accepted or are inactive. Thr3 and Dha4 are 
both important for activity with Thr3 possibly involved in a hydrogen bond.267 Additionally, the non-
canonical amino acids N-(tert-butoxycarbonyl)-L-lysine (BocK), N-allyloxycarbonyl-L-lysine, (AlocK) 
and N-prop-2-ynyloxycarbonyl-L-lysine (ProcK) have been incorporated into thiocillin with only partial 
loss of activity at Thr3 and Val8.230 Notably, using a Thr3ProcK variant, an azirine for crosslinking and 
biotin purification handle were attached and used to pulldown ribosomal protein L11, the target of 
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thiocillin.230 Overall, these analogs again suggest that the highly modified nature of thiopeptides are already 
optimized for binding to the ribosome as nearly all alterations reduce activity. 
 
1.3.2.4 GE2270-like 
A related group of thiopeptides with an expanded macrocycle size of 29-atoms is represented by GE2270348-
350 but also includes amythiamicin,351-354 thiomuracin,55 GE37468,355, 356 and baringolin357 (also known as 
kocurin358, 359) (Figure 1.17). Comparison of the BGCs for GE2270,55, 255 GE37468,261 and thiomuracin55 
has given insight into the differences in the ancillary tailoring of these thiopeptides (Figure 1.21). The 
GE2270 BGC is normally activated during exponential growth and has been heterologously expressed in 
multiple organisms to better understand its biosynthesis.55, 254, 255, 360 Gene deletion studies indicate that Phe 
-hydroxylation, Asn N-methylation, and C-methylation of thiazole 4 are performed by a cytochrome P450 
oxidase (TpdQ), N-methyltransferase (TpdT), and radical SAM methyltransferase (TpdU), respectively.55, 
255 An additional rSAM methyltransferase (TpdL) C-methylates the thiazole in the sixth position, which 
then undergoes hydroxylation by an unidentified protein and O-methylation (TpdM) to yield the 
methoxymethyl-thiazole (Figure 1.21). The C-terminal amide is probably formed as in other thiopeptides 
through cleavage of a C-terminal dehydroalanine (TpdK). In addition to these distinguishing ancillary 
tailoring steps, the GE2270 BGC has an unexpected duplication of the YcaO cyclodehydratase (TpdO) and 
the glutamylation domain of the split LanB dehydratase (TpdP). The reason for this is not fully understood, 
but the extra YcaO is associated with formation of the sole oxazoline. Other members of the GE2270 group 
convert this Ser to dehydroalanine.255 Given the similarity to GE2270, amythiamycin probably undergoes 
the same steps except at the site of Phe to Val substitution. 
Thiomuracin biosynthesis is highly analogous to GE2270, however, there is only one rSAM 
methyltransferase (TpdI) for thiazole C-methylation. Further, there are two cytochrome P450 enzymes 
(TpdJ1 and TpdJ2) with one catalyzing Phe -hydroxylation as in GE2270 biosynthesis and the other 
tailoring the side chain of Ile to various oxidation states (Figure 1.21).55 Although the C-terminal Ala 
present in the precursor peptide is not detrimental to antibiotic activity,45 it is presumably removed by a 
putative carboxypeptidase (TpdH) in the mature product. As previously stated, it is uncommon for 
thiopeptides to have free C-termini. On the other hand, the GE37468 BGC has a putative carboxypeptidase 
(GetM) for removal of the C-terminal Asn but lacks the methyltransferase responsible for ester formation. 
GE3748 thus is an exception, as it bears a C-terminal carboxylate. Another notable feature of GE3748 is 
the cytochrome P450-dependent (GetJ) formation of methylhydroxyproline, which derives from oxidation 
and cyclization of Ile8 and is likely installed prior to macrocyclization.261, 361 Interestingly, baringolin 
appears to natively encode a Pro at this position; however, replacement of the methylhydroxyproline 
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modification with unmodified Ile (via GetJ deletion) or Ala (via core sequence substitution) in GE37468 
has little effect on bioactivity.261 
Using precursor peptide replacement, many potential GE37468 variants have been assessed for 
their ability to be produced and their antibiotic activity.361 Despite the overall similarity in the core 
sequences of GE2270 and GE37468, precursor replacement of the GE37468 core peptide with a quadruple 
amino acid substituted variant (Thr2Cys, Phe5Val, Tyr7Gly, Ile8Phe) to make it more GE2270-like resulted 
in no product from the GE37468 biosynthetic pathway. To further investigate tolerance and processing 
rules of the GE37468 biosynthetic machinery, over 100 additional substitutions were assessed for their 
ability to be produced and their antibiotic activity.361 In total, 29 mutants were tolerated by the GE37468 
biosynthetic pathway, of which 12 had detectable bioactivity. Thr2 could only be replaced by other 
cyclizible residues Ser or Cys, which were converted to azoles, and retained bioactivity. Asn3 accepted 
mostly smaller residues, but none were bioactive as the native Asn donates a transannular hydrogen bond 
stabilizing the macrocycle conformation and accepts a hydrogen bond to aid binding of EF-Tu. Cys4 cannot 
be mutated and is crucial for production. Positions 5, 7, and 8 were the most tolerant in terms of 
biosynthesis, but the only substitutions which remained bioactive, albeit moderately reduced, were Phe5Tyr 
and Tyr7Phe. Interestingly, Phe/Tyr are both required at positions 5 and 7 for Ile8 oxidation and cyclization 
and are likely key recognition determinants for the P450 tailoring enzyme.361 Lastly, mutation of Ser13 in 
the tail tended to produce linear or inactive intermediates, demonstrating that alteration of this position can 
affect downstream dehydration necessary for cycloaddition. Of all these GE37468 analogs, only a Thr2Cys 
variant had slightly improved activity over the native GE37468 indicating that evolution may have reached 
an optimal structure for bioactivity.361 
The promiscuity of thiomuracin and GE2270 biosynthesis have not yet been tested through 
precursor peptide replacement, but with the reconstitution of the core thiomuracin biosynthetic pathway 
from Thermobispora bispora,45  there is an opportunity to investigate tolerance and create new derivatives 
in vitro.  Semi-synthetic derivatives have been investigated as an alternative to improve solubility of these 
compounds,362-367 with GE2270 optimization eventually leading to LFF571,368-373 a compound that has 
undergone clinical trials for treatment of C. difficile.68-70 Baringolin has also been investigated through 
alteration of its tail.374 Overall, these studies have shown that semi-synthetic tailoring of the tail region of 
thiopeptides holds promise for enhancing solubility and potency against gram-positive organisms, but the 
advantage of the in vivo engineering is the ability to rapidly examine the importance of different positions 
within the macrocycle which are more difficult to test synthetically.224 
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1.3.2.5 Cyclothiazomycins 
The cyclothizomycins d series thiopeptides have also 29-membered macrocycles (Figure 1.22). Their 
distinguishing feature is an unusual secondary macrocycle that links the Cα of a Ser residue with the thiol 
group of the C-terminal Cys in the form of a thioether.266, 375-378 Cyclothiazomycins also have three 
thiazolines while most other thiopeptides contain oxidized heterocycles. The BGC for cyclothiazomycin A 
contains the core thiopeptide genes (cyclodehydratase, dehydrogenase, dehydratase, cycloaddition) under 
the control of a LuxR-type regulatory gene (cltH).258, 259 Recent genome mining studies have led to the 
isolation of cyclothiazomycin B and C.266 However, the genes flanking the core biosynthetic proteins are 
variable, so it is not clear which genes are responsible for forming the thioether-linked secondary 
macrocycle. Heterologous expression of cyclothiazomycin A required cltMN, but these are absent from the 
genomes of the other producers and their putative annotations (ether degradation and unknown, 
respectively) do not suggest a clear role in thioether formation. Thus, the enigmatic nature of the thioether 
modification combined with the nontraditional bioactivities (RNA polymerase and renin inhibition) 
reported highlight the distinctiveness of this group.377-379 
 
1.3.2.6 Lactazoles 
The lactazoles are an unprecedented group of thiopeptides first reported in 2014. They are the only 
thiopeptide family with a 32-membered macrocycle, and they exhibit an unusual amino acid composition 
in the core region of the precursor peptide (Figure 1.23).265 The lactazole BGC is by far the most compact 
(9.8 kb) and contains only the core modifying enzymes (Figure 1.23). Also, this BGC fuses the elimination 
domain of the split LanB dehydratase to the azoline dehydrogenase.265 In stark contrast to all other 
thiopeptides, the lactazoles have no known antibiotic activity. It is worth mentioning that thiopeptides have 
historically been discovered through bioassay-guided isolation; however, the lactazoles were identified 
through genome mining so having an associated bioactivity was not a prerequisite for discovery. The 
lactazole biosynthetic pathway was found to tolerate various amino acid substitutions in the core, such as 
W2S and S11C. The latter substitutes a thiazole for an oxazole in the mature structure. Future genome-
guided discoveries may reveal more lactazole-like thiopeptides, but currently this is a rather unusual group. 
 
1.3.2.7 Berninamycin-like 
The largest known macrocycles for thiopeptides are 35-membered, and members of this family are closely 
related in the sequence of their core peptides (Figure 1.17). Being first isolated in 1969, berninamycin and 
sulfomycin are the oldest members of this group,380-382 but with the confirmation of the berninamycin BGC 
through heterologous expression,262 it is the most suitable representative for understanding this group 
(Figure 1.24). Berninamycin is not heavily modified outside of the core thiopeptide scaffold, but the BGC 
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does contain one cytochrome P450 oxidase (BerH) and a hypothetical monooxygenase (BerI) that are 
putatively responsible for hydroxylvaline formation, which appears to occur after macrocyclization. Its C-
terminal amide is installed as in other thiopeptides though removal of the C-terminal dehydroalanine (BerJ). 
Geninthiocin differs from berninamycin by a single methyl group,383 due to a Thr to Ser substitution, and 
likely is biosynthesized in the same way. The only other 35-membered thiopeptide with a known BGC is 
TP-1161,260 which was verified through heterologous expression. Akin to berninamycin, TP-1161 has only 
one ancillary modification, a C-terminal aminoacetone reminiscent of thiocillin (section 1.3.2.3). As 
mentioned above, this group is believed to be installed by an Fe-dependent dehydrogenase (TpaJ) followed 
by decarboxylation and appears to be required for maturation.260 However, the unique feature of these two 
BGCs is that their cyclodehydratase and dehydrogenase, responsible for azole formation, are split in 
nontraditional ways. The berninamycin YcaO “G” protein is split into BerG1/2. There is no “F” protein, 
but there is an E1-like homolog that is fused to part of a dehydrogenase (BerE2) near another dehydrogenase 
component (BerE1). Given this genetic structure, it is hard to predict how the active azole forming proteins 
work with each other. Perhaps not coincidentally, the TP-1161 BGC also has an unusual array of proteins 
with cyclodehydratase homology. TpaGH appear to be a standard cyclodehydratase (partner protein and 
YcaO, respectively), but there is a second YcaO (TpaC) next to a truncated E1-like protein (TpaD). As in 
berninamycin, there appears to be a canonical E1-like protein fused to a dehydrogenase (TpaE) and another 
smaller dehydrogenase domain (TpaF) nearby. These atypical azole forming proteins may influence the 
processing of the peptide in such a way that leads to the larger 35-member macrocycle being formed. The 
spacing of azol(in)e heteorcycles in the macrocycle region of the berninamycin-like thiopeptides is nearly 
identical to the thiocillin-like thiopeptides which have 26-member macrocycles. In particular, 
promothiocin384 and JBIR-83385 are nearly identical to radamycin386, 387 with regard to the sequence around 
the macrocycle, but a dehydroalanine becomes an oxazole in radamycin and the larger macrocycle results.  
Although speculative, future discovery of BGCs for other 35-membered thiopeptides may shed 
light on the rules that govern macrocycle size and downstream tailoring. It is likely that these BGCs would 
possess additional cytochrome P450 and methyltransferase genes to install the additional hydroxylations 
and methylations seen in (methyl)sulfomycin,382, 388 promoinducin,389 thiotipin,390 and A10255.391, 392 
Additionally, it is curious that the cyclodehydratases for thioxamycin393 and thioactin394 apparently skip 
over Cys4, which becomes an S-methylcysteine in the mature compounds. These unexplored areas may 
reveal new enzyme chemistry and rationalize the unusual features of this thiopeptide family. Another future 
avenue for research is to further explore structure-activity relationships through precursor peptide 
replacement. Berninamycin has had only three altered precursor peptides tested in vivo. Thr3Ala was 
tolerated but inactive while Thr4Ala and Thr5Ala did not give any macrocyclic products.262 Further 
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bioengineering of berninamycin may also reveal the unique characteristics of the enzymes in these 
pathways. 
 
1.3.3 Bioactivities 
Because of the structural similarity of thiopeptides, they also share biological activities. In particular, 
thiopeptides are renowned for their potent antibiotic activity towards Gram-positive bacteria through 
inhibition of protein translation.32 Ribosomes are composed of two RNA-protein complexes known as the 
small (30S) and large (50S) subunit that can assemble into a full (70S) ribosome.395, 396 Translation begins 
when the 30S subunit binds an mRNA and associates with an initiator tRNA (fMet-tRNAfMet) and a free 
50S subunit through the help of initiation factors. This complex places the initiator tRNA in the peptidyl 
site (P site), and its acceptor site (A site) is empty for incoming aminoacyl-tRNAs. Aminoacyl-tRNAs are 
delivered by GTP-bound, elongation factor Tu (EF-Tu). After GTP hydrolysis and dissociation of EF-
Tu·GDP, a new amide bond is formed between the P site and the A site tRNA, which transfers the growing 
peptide and extends it by one amino acid. Next, GTP-bound elongation factor G (EF-G) binds the ribosome 
and triggers translocation, promoted by GTP hydrolysis, that shifts all associated tRNAs downstream one 
site (bringing the base paired mRNA with it).397 This movement opens the A site for the next aminoacyl-
tRNA, and the cycle can repeat after release of EF-G·GDP.  
Thiopeptides interfere with the protein translation process in two distinct ways, and the size of the 
main macrocycle largely determines how inhibition will occur. Those with 29-membered macrocycles 
including GE2270, GE37468, amythiamicin, and their congeners bind to and inhibit elongation factor Tu 
(EF-Tu) at nM concentrations.55, 351, 355, 365, 369, 398-400 Binding sterically blocks tRNA binding to EF-Tu and 
stabilizes a protein conformation that disrupts its interaction with ribosomes.348, 401-403 Multiple analogs have 
also been co-crystallized with the target further verifying the binding site of these molecules.362, 363, 365, 369 
Consistent with this data, resistance to thiopeptides is mediated through EF-Tu variants or mutation,254, 351, 
399, 404, 405 but the overall mechanism and binding site is unique compared to other antibiotics that target EF-
Tu.405-407  
In contrast, thiopeptides with 26-membered macrocycles (e.g. thiostrepton, siomycin, nosiheptide, 
berninamycin, and thiocillin/micrococcin) target the 50S subunit of by interacting with the 23S rRNA and 
ribosomal protein L11.65, 345, 408-410 Binding is mediated primarily by interaction with 23S rRNA and is 
cooperative with L11.411-414 Resistance to thiopeptides of this variety occurs through mutation of either 23S 
rRNA or L11.345, 415-421 Alternatively, methylation of the 23S rRNA also confers resistance.422-433 Improving 
initial models,434, 435 more recent structural studies based on NMR, X-ray crystallography, and molecular 
modeling showed that these 26-membered thiopeptides bind to a cleft between the 23S rRNA and L11,347, 
436-442 but covalent capture data suggest binding may be more on the surface of the rRNA and not between 
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23S/L11.443 The interface of the 23S rRNA and L11 is called the “GTPase-associated center” and is crucial 
for ribosome function given its interaction with many translation factors.444-450 Consequently, the binding 
of thiopeptides with a 26-member macrocycle in this area can affect all phases of translation,451-458 but the 
most studied effects are on EF-Tu and EF-G during elongation.458-474 Inhibition of EF-Tu and tRNA delivery 
presumably occurs because thiopeptides partially conflict with the ternary (EF-Tu, GTP, and aminoacyl-
tRNA) complex’s binding site near the 23S rRNA/L11.447, 448, 473 In contrast, the mechanism of action 
against EF-G varies depending on the thiopeptide. Specifically, thiopeptides with a secondary 
quinaldic/indolic ring (i.e. thiostrepton/nosiheptide) interact differently with EF-G than those that have just 
one macrocycle (i.e. micrococcin) because they bind in slightly different orientations at the 23S rRNA/L11 
interface.347, 440, 474, 475 Thiostrepton disrupts binding of EF-G to the ribosome, thereby inhibiting GTP 
hydrolysis,458, 463-467, 476, 477 and stabilizes a conformation of 23S rRNA/L11 that prevents the structural 
transitions necessary for translocation.410, 438, 442, 478 This means that even with transient EF-G binding, as 
suggested by some studies of thiostrepton-bound ribosomes,479-485 translation remains arrested. Conversely, 
micrococcin enhances EF-G GTPase activity without effecting its binding affinity and blocks the 
translocation process through a similar rigidifying and restriction of 23S rRNA/L11.423, 460, 486, 487  
Similarly, thiopeptides with 35-membered macrocycles (i.e. berninamycin-like thiopeptides) are 
known to target the 50S subunit and likely bind to the 23S/L11 complex.381, 488 The precise binding site and 
orientation are not known, but these larger thiopeptides almost certainly overlap with the primarily binding 
site of thiopeptides with a 26-member macrocycle based on partial competition with thiostrepton binding 
to ribosomes.488 Additionally, the thiostrepton resistance RNA methyltransferase, which methylates RNA 
at thiostrepton’s binding site, confers resistance to berninamycin, and the berninamycin producing 
organisms has the same RNA methylation activity and is also resistance to thiopeptides that bind the 
23S/L11 complex. This is in agreement with the BGCs for berninamycin262 and TP-1161260 which contain 
genes for a thiostrepton-like resistance methyltransferase. However, the binding orientation will likely be 
slightly different than thiostrepton/micrococcin based its larger marcrocycle size and slightly different 
effect on the ribosome. Only elongation is effected by berninamycin and EF-G GTP hydrolysis is slightly 
elevated compared to complete inhibition caused by thiostrepton and significant enhancement by 
micrococcin.488 Future structural studies may more precisely identify the binding site of thiopeptides with 
35-membered macrocycles. 
Beyond protein translation inhibitors, most thiopeptides are known to activate gene transcription 
independent of their antibiotic activity.386, 489  The primary mechanism for this is activation of the tipA gene 
(thiostrepton-induced protein A), which encodes TipAL and TipAS.32, 490, 491 TipAL is a transcriptional 
activator that upregulates a defined set of genes, including itself, upon thiopeptide binding to its C-terminal 
domain.492 TipAS, which is truncated and only possess the C-terminal binding domain, exists primarily to 
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sequester thiopeptides and represents a resistance mechanism found in some non-thiopeptide producers.493, 
494 Thiopeptides of various sizes and topologies are recognized by a common four-ring motif.346 Upon 
binding, dehydroamino acids often present in thiopeptides can undergo a Michael-like addition with Cys 
residues of TipA present within the flexible binding pocket.346, 495-497 However, thiopeptides with a 29-
membered macrocycles lack the conserved four-ring motif. Fittingly, they also do not induce or bind to 
TipA.346 Additionally, because TipA is highly responsive to thiopeptides, its induction has been applied in 
thiopeptide discovery.383, 384, 390, 394 
Another known activity of thiopeptides targets the malaria parasite, Plasmodium falciparum, which 
have an essential, plastid-like organelle (apicoplast) that contains a 70S ribosome as in bacteria.498 Thus, 
unlike other eukaryotes, P. falciparum is sensitive to many thiopeptides such as thiostrepton, micrococcin, 
and GE2270, and nocathiacin.499-508 Other protein synthesis inhibitors also have demonstrated a similar anti-
malarial activity.509-511 However, it should be noted that protease inhibitors are known to be active against 
the Plasmodium parasite because the proteasome is crucial for development.512-514 Given that thiostrepton 
has been reported to bear proteasome inhibition activity, its antimalarial activity is likely the result of 
multiple modes of action.515-517 
Another intensively studied activity for thiopeptides is the induction of apoptosis in human cancer 
cells.518-521 This occurs by down regulating the expression of an oncogene FOXM1,521-523 which is a 
transcription factor that activates cell proliferation and cell cycle progression. As an oncogene, FOXM1 is 
overexpressed in more than 20 types of human cancers and is recognized as a potential anticancer target.524, 
525 The anticancer activities of certain thiopeptides is also due in part to the inhibition of the proteasome, 
but this secondary activity appears limited to thiopeptides with a quinaldic acid side ring (i.e. thiostrepton-
like).515, 517, 526 However, there is also evidence that berninamycin downregulates FOXM1, possibly without 
proteasome inhibition.527 The proteasome is composed of numerous proteins but is split into two main parts, 
the core particle (CP) which contains the proteolytic active sites and the regulatory particle (RP) which 
controls access to the CP and unfolds substrates for degradation.528 Thiostrepton covalently binds the RP 
via Cys adducts to its dehydroamino acids, which dysregulates proteolysis.529 In an example of overlapping 
mode of action, proteosomal inhibition by thiostrepton stabilizes a negative regulator of FOXM1 
(Hsp70).530 It appears that thiostrepton can also directly bind FOXM1 and blocks its ability to activate gene 
transcription.531 These modes of action are likely most responsible for thiostrepton’s anticancer activity, but 
it remains possible that other means of contributing to apoptosis, such as inhibiting mitochondria protein 
synthesis, also play a role.532, 533 
Other functions for thiopeptides have been observed, however, they are less intensively researched 
and typically only apply to individual compounds. For instance, siomycin can act as an immunosuppressant 
and showed efficacy in a murine arthritis model.534 On the other hand, the cyclothiazomycins with their 
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atypical side ring and relative lack of heterocycles within its primary macrocycle have more unusual 
activities. They are not particularly effective against gram-positive organisms compared to other 
thiopeptides.266. Instead, the cyclothiazomycins have other reported activities such as inhibiting RNA 
polymerase378 and the growth of fungi by binding to chitin in the cell wall,379 although the antifungal activity 
seems to be narrow spectrum.266 Cyclothiazomycin inhibits renin,377 a protease involved in the renin-
angiotensin system that has links to hypertension, cancer, and other diseases.535-538 Geninthiocin also has 
reportedly weak antifungal activity.539 A10255 activates plasminogen, which is involved in fibrinolysis and 
other cell surface interactions.540, 541 Overall, the unique and constrained structure of thiopeptides enables 
them to effect multiple biological processes, but their poor solubility and large size limits their ability to be 
used directly as therapeutics. Nonetheless, thiopeptides have recently emerged as drugs leads. More soluble 
thiopeptide derivatives have been semi-synthetically prepared (e.g. LFF571, Figure 1.4) and are showing 
promise in human clinical trials for C. difficile infections.68-70 Alternatively, the re-engineering of 
thiopeptides with more hydrophilic sequences that retain bioactivity is also a promising avenue.229, 542 
Accordingly, there is still much value in investigating new thiopeptides and exploring their potential 
functions. 
 
1.4 Cyanobactins  
The cyanobactin family of RiPPs, produced by both free living and symbiotic cyanobacteria, comprises a 
family of highly modified peptides of ribosomal origin. As with all RiPPs, the characteristic of the family 
is that the final natural product derives from a core sequence that is embedded within a longer precursor 
peptide. Until recently, cyanobactins were synonymous with macrocyclic peptides coming from 
cyanobacteria543, however linear cyanobactins have now been identified.544 Cyanobactins vary in length 
from as short as a tripeptide for the linear cyanobactins up to around twenty amino acids in some 
macrocycles.544, 545 To date, the vast majority of isolated cyanobactins (and those bioinformatically 
predicted) are macrocyclic and between 6 and 10 residues in length.546 While some cyanobactins contain a 
high density of posttranslational modifications, the number and types of modifications are determined by 
the enzymes in the pathway, but larger cyanobactins (more than 15 amino acids) characterized to date 
appear to have less extensively modified amino acids.543, 546, 547 The list of modifications identified so far is 
extensive and has been reviewed in depth recently.546 Here we concentrate on cyclodehydration 
(heterocyclization) of specific Cys, Ser, and Thr residues that give rise to thiazoline and oxazoline 
heterocycles, which in turn can be, but are not always, oxidized to thiazoles and more rarely oxazoles.548, 
549  
As a whole, YcaO proteins are quite prevalent among cyanobactin gene clusters; only three families 
of compounds lack a ycaO gene and correspondingly have no azol(in)es: the anacyclamides, 
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prenylagaramides, and piricyclamides.546 This would suggest that cyclodehydration confers an 
advantageous change in the conformation and chemistry of the peptide backbone of the natural product. 
Generally speaking, Ser/Thr cyclodehydrations are less common in cyanobactins, but there are notable 
examples which do contain oxazol(in)e heterocycles such as patellamide48 of the pat pathway, 
ulithiacyclamide,550 and microcyclamide.549 For products of the tru pathway, (e.g. trunkamides and 
patellins) although a YcaO domain is present, it does not readily form oxazolines and Ser and Thr remain 
uncyclized. Their unmodified hydroxyl groups can instead undergo prenylation.49, 551 Prenylation of other 
amino acids is also known including C-prenylation of tryptophan552 and C- and O-prenylation of Tyr.553 In 
the case of C-prenylated Tyr, the prenyl group is first attached to the phenolic hydroxyl before undergoing 
a Claisen-type rearrangement (Figure 1.25).553 An additional posttranslational modification observed in 
several macrocycles, including patellamide A, is epimerization of the amino acids adjacent (N-terminal) to 
the thiazoline (or thiazole) to D-stereocenters.549, 554-556 Rarer modifications include Cys to disulfide bridges 
found for example in ulithiacyclamide, as well as N- and O-methylation.544, 549, 557 The disulfide in 
ulithiacyclamide hints at the ability to exercise regioselective control of which Cys are modified within the 
core peptide. Indeed, regioselectivity during cyclodehydration has been experimentally observed as well 
and is discussed later (section 1.6.3.2).548 Variation in amino acid identity, differing combinations of amino 
acid modifications, and differing lengths of products underscores the vast chemical diversity of the 
cyanobactins. 
In addition to biochemical interest in their biosynthesis, cyanobactins have attracted considerable 
attention as potential starting points for development of new therapeutics as they possess a diverse range of 
bioactivities.543, 546, 547 Patellamides A, B, C and D display IC50 = 2-4 μg mL-1 against L1210 murine 
leukemia cells.558 Patellamides B, C and D have each demonstrated activity in reducing multidrug resistance 
in CCRF-CEM and CEM/VLB100 leukemic cell lines through competitive inhibition of P-glycoprotein 
(Pg-p), the efflux pump responsible for removing anticancer compounds from tumour cells.559, 560 
Trunkamide A1, a seven residue cyclic cyanobactin, possesses cytotoxic activity (IC50 = 0.5 μg mL-1) 
against HT-29 human colon carcinoma and IC50 = 1 μg mL-1 against MEL-28 human melanoma cell lines.561 
Ulithiacyclamide is highly cytotoxic with IC50 = 350 ng mL-1 and IC50 = 35 ng mL-1 against L210 murine 
leukemia and KB cell lines respectively.550, 558 Antimalarial activity, but no specific cellular target, has been 
reported for the aerucyclamides B, C and D displaying IC50 = 1-6 μM.562 The compounds were selective 
for Plasmodium falciparum over L6 rat myoblast cells.562 Kawaguchipeptide B presents antibacterial 
activity with a minimum inhibitory concentration (MIC) = 1 μg mL-1 against Staphylococcus aureus.563  
The diversity in biological activity thus mirrors the diversity of the compounds. It is this diversity 
of cyanobactins that make them attractive starting compounds for fine-tuning to obtain useful clinical 
candidates. Most natural compounds currently have limitations that preclude their direct use in the clinic. 
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Nature may have propagated cyanobactins, and other RiPPs, precisely because of their malleable 
characteristics: simple nucleotide changes can yield new bioactivities. However, there is a large barrier to 
their use in medicinal chemistry in part because their de novo synthesis is problematic. Only a few 
compounds have been completely synthesized.555, 556, 564-570 In most cases, the routes are lengthy, complex 
and case specific, thus limiting the diversity achievable and so are incompatible with the drug development 
process. A strike against cyanobactins as drug candidates is that they violate the so-called rule of five for 
bioavailability571 derived by Lipinski from an analysis of orally active medicines. Indeed, all cyanobactins 
that contain more than five amino acids exceed the rule for molecular mass of 500 Da or less. Secondly, 
their peptidic nature all but ensures they have more than five hydrogen bond donors and ten hydrogen bond 
acceptors. Indeed, it is precisely because of these considerations that linear peptides are generally regarded 
as “non-starters” as bioavailable drugs; at best they serve as proof of concept. However, the demonstrated 
cell permeability and in some cases oral toxicity of macrocyclic peptides indicates a blanket assertion of 
unsuitability may be wrong.572, 573 Cyanobactins, and natural products more generally, are accepted to be 
exceptions to simple rule of five considerations. The term “beyond rule of five” has been coined to describe 
such molecules (this field has recently been reviewed in Doak et al.574) Given that many peptidic natural 
products used clinically are macrocyclic, they can adopt conformations that mask polar groups, of which 
cyclosporine is the most well-known example. Cyclosporine adopts a conformation where internal 
hydrogen bonds result in a conformation displaying a hydrophobic surface while masking polar regions to 
facilitate membrane transit.575, 576 In the specific case of cyanobactins, macrocyclization also removes the 
zwitterionic N- and C-terminal charges. Heterocyclization further increases the hydrophobicity of the 
natural product.577, 578 Additional modifications such prenylation or methylation also decreases polarity as 
well as the number of hydrogen bond donors.572, 578 Although rules are emerging for predicting the 
bioavailability of macrocycles,574, 579 it appears that the conformation of the macrocycle is an important 
consideration. For chemically complex macrocycles with multiple modifications and epimerizations, 
predicting the conformation remains challenging. In addition to advantages in cell permeability and 
decreased hydrogen bonding, the installation of azol(in)e heterocycles and macrocyclization also introduce 
conformational rigidity when compared to liner precursors. As a consequence of the reduced entropic 
penalty, rigid molecules that fit a binding site are always more potent than flexible molecules which have 
to freeze out a specific conformation (or set of conformations) to bind.578, 580 This is borne out by many 
examples where macrocyclization results in more potent compound compared to the linear analogue.578, 580 
 
1.4.1 Cyanobactin biosynthesis  
Since chemical synthesis is impractical for generating large libraries of these desirable compounds, 
attention has turned to protein engineering and biotechnology to produce these molecules at the scale, speed, 
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and diversity compatible with the drug discovery process. This has spurred investigation of cyanobactin 
pathways and the discovery of many new BGCs. Overall, 12 families have been identified, and 9 contain 
azol(in)e heterocycles.546 Similar to other RiPPs, the genes associated with cyanobactin biosynthesis are 
almost always clustered.26, 581 As mentioned previously, the primary features encoded within cyanobactin 
gene clusters are azol(in)e formation, N-to-C macrocyclization, and prenylation although other auxiliary 
modifications can also be present. Cyanobactin gene clusters mix and match the enzymes responsible for 
these modifications as well as the core sequences of their peptides to generate diverse products.49, 50 The 
known products from these cyanobactin pathways have recently been reviewed546 so in the remainder of 
this section we provide an overview of the key biosynthetic enzymes and BGC architectures of these 
pathways. 
In cyanobactin BGCs, the nomenclature follows the historic precedent set from the first cluster to 
be fully sequenced, the patellamide or pat cluster.48 Accordingly, the biosynthetic proteins are named A 
through to G in the order of their occurrence in the operon (Figure 1.26). In contrast to other RiPP BGCs, 
such as that for microcin B17 where the gene encoding the precursor peptide is located at the start of the 
gene cluster and thus designated “A” (e.g. mcbA),582, 583 the cyanobactin precursor peptide gene is located 
in the middle of the cluster and is designated “E” (e.g. patE, truE) 48, 584 even where it is not the fifth gene.  
Other than the precursor peptide, the minimal set of proteins encoded by cyanobactin gene clusters include: 
an A protein (N-terminal protease), a G protein (macrocyclase / C-terminal protease), and two hypothetical 
proteins, B and C, which are non-essential for patellamide biosynthesis in vivo.48 Other genes that often 
occur are a D protein (cyclodehydratase), oxidase (often fused to the G protein), and an F protein 
(prenyltransferase). Since not every cyanobactin gene cluster contains a YcaO protein, the class is defined 
by the presence of a precursor peptide and PatG-like protease which combine to form macrocyclic peptides.  
Much has been learned about the main cyanobactin processing enzymes through biochemical 
characterization and X-ray crystallography.585 The A protein is composed of two domains, an N-terminal 
protease domain which cleaves the precursor peptide immediately N-terminal to the core peptide, and a C-
terminal domain of unknown function (DUF).586, 587 The G protein is defined by a N-terminal macrocyclase 
domain and a C-terminal DUF homologous to that found in the A protein.588 The macrocyclase domain is 
also homologous to the protease domain of the A protein, and both belong to the subtilisin protein family.587 
Compared to subtilisin, however, there is a characteristic insertion that is found in all cyanobactin 
macrocyclase domains critical for preventing the enzyme from hydrolyzing the acyl enzyme intermediate 
and producing linear product.589 As pointed out above, the principal characteristic feature of cyanobactins 
is their macrocyclic nature, and there are certain instances where the primary posttranslational modification 
of the peptide is macrocyclization (due to a lack of additional biosynthetic enzymes) such as in the larger 
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macrocyclic anacyclamide545 and piricyclamide590 families (Figure 1.26.) In the compound piricyclamide 
7005E4, a disulfide bridge is also present,590 but this is likely a spontaneous modification. 
Cyanobactin cyclodehydratases catalyze the heterocylization of Cys and in some cases, Ser and 
Thr to form azoline heterocycles.548 The protein can be broken into three domains. The first domain is 
homologous to PqqD and serves as the RRE27, 591 while the second domain is homologous to the E1-like 
superfamily. Together, the first two domains are similar to the MccB protein,592 an adenylating enzyme in 
microcin C7 biosynthesis which catalyzes the formation of a five-membered heterocycle.591 Although 
similar to MccB, its ATP-binding site is not conserved in these first two domains.18 Instead, the YcaO (third 
domain) is responsible for ATP-utilization. In some previously described cyclodehydratase-containing 
BGCs, the YcaO domain is found as a discrete protein with the LAP C protein containing the first two 
domains.17, 18, 27 The canonical representatives of cyanobactin cyclodehydratases are PatD and TruD, from 
the patellamide (pat) and trunkamide (tru) pathways, respectively. These enzymes share 93% sequence 
similarity so it is surprising that PatD is able to cyclodehydratase Cys, Ser, and Thr whereas TruD only acts 
on Cys and skips over Ser and Thr residues.548  Thus, D proteins can be divided into two types: Cys-specific 
cyclodehydratases (e.g. TruD, LynD)592, 593 and broad spectrum cyclodehydratases (e.g. PatD, McaD, which 
process Cys, Ser, and Thr).549, 585 There is currently no sequenced-based rationale for discerning their 
reactivities. Given the leader-dependent nature of cyanobactin cyclodehydratases, it must act before 
macrocyclization and is presumably the first enzyme to act on the peptide.594, 595  
The cyanobactin dehydrogenase, which oxidizes YcaO-formed azolines into azoles, is flavin-
dependent. This enzyme can be a ‘freestanding’ protein, but frequently, the dehydrogenase domain is fused 
to the G protein.  In the patellamide BGC, PatG is a tridomain protein with an N-terminal dehydrogenase, 
macrocyclase middle domain, and C-terminal DUF. Sequence analysis of the dehydrogenase reveals a 
typical FMN-binding site signature. Sequence analysis also indicates that N-terminal to the flavin-binding 
site is at least one peptide clamp domain or RRE-like domain of the sort found in PatD.27 The dehydrogenase 
has been experimentally verified to be responsible for azole formation,546 and is homologous to the “B” 
protein in the LAP family of RiPPs.27, 72 However, unlike B proteins which are presumed to act quickly 
after cyclodehydration, the cyanobactin dehydrogenase is thought to act natively after macrocyclization.596 
Lastly, cyanobactin pathways also have a unique class of prenyltransferase (F protein).597 Due to 
independent naming conventions, the cyanobactin F protein (prenyltransferase) should not be confused with 
the HCA/thiopeptide F protein (Ocin-ThiF-like protein). In the pat pathway, PatF has been shown to be 
inactive as a prenyl transferase due to mutations at the active site598 consistent with the lack of any 
prenylated patellamides. No other activity has been ascribed to this protein. The prenyltransferase is 
functional in other gene clusters including trunkamide of the tru pathway599 (TruF1, a Ser/Thr 
prenyltransferase),589 aestuaramide597 (LynF, a Tyr prenyltransferase),597, 599 piricyclamide590 and 
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kawaguchipeptin.552 The structure of the prenyltransferase from the prenylagaramide biosynthetic pathway 
of Oscillatoria agardhii has been determined in complex to linear and cyclic substrate peptides.600 The 
enzyme has a very broad substrate specificity requiring only an N-terminal Tyr followed by an aliphatic or 
aromatic residue.  The structures show that the enzyme only recognizes this two reside motif. Despite this 
small motif, prenylation has also been shown to occur only after macrocyclization for LynF,597 but some 
must have relaxed substrate specificity given that linear cyanobactins are prenylated and  PagF accept linear 
substrates.544, 600 
Depending on the combination and order of the proteins encoded by different operons, cyanobactin 
biosynthesis has been classified into four genotypes.601 Genotype I, exemplified by the patellamide 
pathway, which also includes the trunkamide, teneucyclicamide and microcyclamide pathways, amongst 
others, is the most common. Genotype I comprises a single operon starting with “A” and ending with “G”601 
(Figure 1.26). Genes encoding both the cyanobactin cyclodehydratase and prenyltransferase are always 
present in genotype I. Indeed, azol(in)e heterocycles are universal in the final products; however, due to the 
previously mentioned inactivation of PatF, prenylation is not universal to genotype I cyanobactins. Further, 
genotype I pathways that encode dehydrogenases nearly invariably do so at the N-terminus of the G protein. 
When present, thiazole groups are always present in the final product. Notable examples where the 
dehydrogenase is omitted come from the tru pathway; fittingly, these products—the trunkamides and the 
patellins—contain only thiazolines (Figure 1.26). In some clusters, notably the patellamide pathway, the 
dehydrogenase is chemoselective for thiazolines since the final product contains thiazoles but not oxazoles. 
Other clusters that have similar enzymatic reactivity trends include the lissoclinamides and 
ulithiacyclamides. Conversely, the microcyclamide and teneucyclamide products contain thiazoles and 
oxazoles (Figure 1.26) suggesting the dehydrogenase has a wider activity.  
Genotype II is epitomized by the prenylagramide and anacyclamide pathways.601 Gene organization 
within this genotype is significantly different from that of genotype I with the B and C proteins located at 
the start of the operon, as well as the addition of multiple hypothetical open reading frames of unknown 
function. This is the only genotype that uniformly lacks a cyclodehydratase gene and whose final products 
consequently lack a Cys-, Ser-, and Thr-derived heterocycles (Figure 1.26).545, 601 Interestingly, the 
precursor peptides all contain Pro at the C-terminal position of the core peptide. The macrocyclase domain 
of PatG was shown to require either a thiazoline or Pro at the C-terminal position of the core peptide in 
order to carry out the macrocyclization reaction.602 The structure of the PatG macrocyclase domain reveals 
that these backbone conformation-restricting moieties are required for the substrate to bind effectively to 
the active site of the enzyme.589 Since the cyanobactin products of genotype II lack azolines, the 
biosynthetic clusters unsurprisingly also lack dehydrogenases. Genes encoding the prenyltransferase are 
always found in genotype II; however, the products are not always prenylated. For example, Leikoski and 
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co-workers identified the anacyclamides, which besides N-to-C macrocylization otherwise contain entirely 
unmodified amino acids, as well as the prenylagramides which contain prenylated amino acids.545 
Furthermore, the products of genotype II are typically larger (>11 amino acids) than those of genotype I.546  
The piricyclamide pathway contains the same compliment of genes as those found in genotype II, although 
the organization of genes within the operon is distinct (Figure 1.26).590 A cyanobactin gene cluster osc was 
identified from Oscillatoria sp. PC6506 and is considered a hybrid of genotype I and II as it contains all of 
the biosynthetic enzymes necessary to produce azole heterocycles (characteristic of genotype I) but the 
organization more closely reflects genotype II (Figure 1.26).601 To date, no products of the osc pathway 
have been identified.  
Genotype III contains only the trichamide biosynthetic pathway, and is the only known example of 
a cyanobactin gene cluster lacking a gene encoding the F protein.601 Like genotype I, cyclodehydratase and 
dehydrogenase genes are present, giving rise to thiazoles in the final product (Figure 1.26). In contrast to 
genotype I, the dehydrogenase is not fused into the G protein, but rather is encoded as a discrete gene. 
Genotype IV so far contains only the cyanothecamide (thc) pathway, which displays a unique gene 
organization.586, 601 Despite the presence of up to nine precursor peptides in a single operon, only three 
products have so far been identified.586 This pathway has a number of other features that are atypical 
including non-consensus protease signatures in some of its precursor peptides although it can still act on 
more canonical sequences as well.586, 595 Differences in the enzyme active sites between PatA and ThcA 
may explain the relaxed specificity of ThcA, but this has not been extensively investigated.586 
Given the vast number of cyanobactin pathways discovered to date it seems likely that more 
examples of each genotype, and possibly other genotypes, exist. Perhaps the most unusual example to date 
are the linear cyanobactins. Although N-to-C macrocyclization is the class-defining feature of cyanobactins, 
viridisamide and the aeruginosamides are linear, seemingly because their N- and/or C-termini are modified 
and prevent macrocyclization by the PatG macrocyclase domain which is still present in the BGC (Figure 
1.27). 544, 546 These and other emerging pathways are expected give rise to a plethora of diverse compounds 
suitable for pharmaceutical development, as well as a range of interesting enzymes suitable for 
biotechnological application.  
 
1.5 Miscellaneous azol(in)e-containing RiPPs 
Whereas most known azol(in)e-containing RiPPs clearly belong to one of the established subclasses 
previously mentioned, some other RiPPs with thiazol(in)e or oxazol(in)e heterocycles contain additional 
structural features and biosynthetic components that are not fully consistent with these taxonomies. For 
example, the nitrile hydratase- and Nif11-derived precursor peptides are likely similar to the LAPs, but 
their precursor peptide sequences connect them to multiple RiPP subclasses. On the other hand, YM-
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216391 is clearly similar to the cyanobactins, but because its BGC lacks the class-defining proteases that 
form its macrocycle and is quite unlike the cyanobactin gene clusters, it does not meet the subclass criteria. 
Accordingly, these two are currently part of an unassigned group. 
 
1.5.1 Nitrile hydratase- and Nif11-derived precursor peptides  
Because of their short length, RiPP precursor peptides are frequently unannotated (not predicted as a gene) 
in publicly available genomic databases.26 Complicating matters further for gene prediction is that many 
azol(in)e-containing RiPPs display a large degree of sequence variability so it is difficult to identify new 
precursors because they do not share sequence similarity to previously identified members.603 However, 
bioinformatic analysis of presumed azol(in)e-containing RiPP BGCs has revealed a new family with two 
widely recurring motifs in the putative precursor peptides.604 In each case, the leader peptides appeared to 
derive from other proteins, which presented a novel paradigm for RiPP biosynthesis. The first variety 
harbored leader peptides closely related to the alpha subunit of nitrile hydratase (NHase).605, 606 The nitrile 
hydratase-like leader peptide (NHLP) sequences are roughly half the size of actual NHases because a ~60 
amino acid region including the NHase active site has been lost. Accordingly, these NHLP sequences within 
putative precursor peptides are not expected to be catalytic but simply serve as part of the peptide substrate 
for post-translational modification. The second variety had leader peptides strongly resembling the Nif11 
protein, a nitrogen-fixing protein from cyanobacteria.607, 608 Nif11 remains of unknown function. 
 Because of the typically longer length of their leader peptides (~75 amino acids) and their 
conserved sequence motifs, NHLP- and Nif11-derived precursors are less likely to be skipped by automated 
gene prediction algorithms. For those associated with a cyclodehydratase, the core regions tend to be 
enriched with heterocyclizible residues (Cys, Ser, and Thr). They also possess a classic Gly-Gly leader 
peptide cleave site that is useful for predicting their products (Figure 1.28).143, 604 In addition to these well-
defined precursor peptides, there are usually fused cyclodehydratases and nearby transporters or other 
putative tailoring enzymes. Phylogenetically, BGCs for this class tend to be found in cyanobacteria, 
proteobacteria (Burkholderia order), and a few anaerobic bacteria, which are not typically known for 
production of secondary metabolites.163, 604 Despite this knowledge, no product from one of these clusters 
has yet been isolated so this putative azol(in)e-containing RiPP family remains hypothetical. 
On the other hand, NHLP/Nif11 derived natural products have been isolated for other RiPP classes 
including lanthipeptides609 and proteusins (i.e. polytheonamide).610 Additional potential natural products 
have also been identified through genome mining for these classes.163, 604 One notable lanthipeptide 
example, the prochlorisin BGC from Prochlorococcus MIT9313, contains nearly 30 different Nif11 
precursor peptides,609, 611 Interestingly, most of the Nif11 leader sequence is not required for prochlorisin 
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biosynthesis.612 However, it has yet to be investigated whether this is a general trend applicable to 
cyclodehydratase-containing NHLP/Nif11 pathways as well. 
 
1.5.2. YM-216391 
During screening for novel anticancer compounds, Streptomyces nobilis was found to produce a compound, 
YM-216391, with nanomolar activity towards several cell lines.613 NMR structure determination revealed 
YM-216391 to be a cyclic, pentazole-containing peptide, similar to the telomerase inhibitor telomestatin 
(Figure 1.29).614 All but one amino acid (Val) of the core peptide have been modified; Marfey’s analysis 
confirmed the presence of D-allo-Ile. The complete stereochemistry has also been confirmed through total 
synthesis.615, 616 Although the mode of action of YM-216391 is unknown, given its bioactivity and structural 
similarity to telomestatin, it may mediate cell death through inhibition of telomerase as well.617 
Given the structure of YM-216391, it was difficult to predict its biosynthetic origin. However, in 
2012, the BGC was discovered by mining for a peptide sequence (FIVGSSSC) that could give rise to the 
mature product (Figure 1.29). The BGC was confirmed by heterologous expression in S. lividans.618 The 
YM-216391 core sequence is flanked by motifs rich in Asp/Glu, reminiscent of cyanobactin precursors 
which also are macrocyclized peptides (section 1.4). However, YM-216391 is not considered a cyanobactin 
because the protease/macrocyclase characteristic of the cyanobactins is not present in the BGC, and thus it 
appears to employ a different strategy for macrocylization. With the function of very few biosynthetic genes 
being confidently predicted, the precise mechanism for macrocyclization remains unknown. Indeed, only a 
few proteins have passable similarity to characterized proteins. The YcaO protein (YmD) is proposed to 
install the 4 canonical azole heterocycles with the aid of an unusual fusion of the E1-like protein to the N-
terminus of the azoline dehydrogenase (YmBC). However, the E1-like protein appears to be truncated and 
is missing its N-terminal RRE, and an RRE seems absent from the gene cluster. The biosynthesis of the 
conjugated benzyloxazole moiety remains unknown. Putatively, -hydroxylation of Phe by a cytochrome 
P450 enzyme (YmE) sets the stage by installing a nucleophilic moiety for heterocyclization. After N-to-C 
macrocyclization (YmF? and YmI?), the hydroxyl could be heterocyclized and dehydrogenated by 
YmB1/C1, but these proteins do not resemble the YcaO or any other characterized proteins.618 YmG is 
homologous to lysine 2,3-aminomutase but lacks the SAM binding motif (CxxxCxxC) so it may cooperate 
with YmH to epimerize the side chain of L-Ile to D-allo-Ile. Heterologous expression studies have indicated 
that ymR1 and ymR2 are likely transcriptional activators. Conversely, YmR3 is a repressor that upon 
deletion increases YM-216391 production by 20-fold.618 Lastly, YmR4 is a transmembrane efflux protein 
that may provide resistance. The overall lack of similarity between the YM-216391 and other 
cyclodehydratase-containing BGCs suggests that it belongs to a distinctive group of cyclic azol(in)e-
containing RiPPs. Interestingly, marthiapeptide is structurally similar to YM-216391 yet its BGC remains 
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unknown, despite the availability of the whole genome sequence of the producing organism, 
Marinactinospora thermotolerans.619 
 
1.6 Characterization of RiPP cyclodehydratases 
Although the YcaO superfamily is associated with multiple chemical transformations, the best characterized 
are azoline-forming YcaOs which catalyze cyclodehydration of Cys, Ser, or Thr of a ribosomally 
synthesized peptide. As exemplified by the many azol(in)e-containing RiPPs, the ability to form these 
heterocycles through enzymatic modification is crucial for the creation of biologically active compounds. 
Consequently, there has been much interest in determining how azoline-forming YcaOs heterocyclize Cys, 
Thr, and Thr residues. As discussed previously, this began with work on McbBCD from MccB17 
biosynthesis. The second group to be characterized and which also helped to lay a foundational 
understanding of cyclodehydration were the cyanobactin cyclodehydratases TruD and PatD. After these, 
studies of cyclodehydratases rapidly expanded beginning in the late 2000s with the biochemical 
characterization of cyclodehydratases involved in cytolysin (e.g. SLS pathway) and thiopeptide 
biosynthesis. Ultimately, the function of the YcaO would be conclusively determined through investigation 
of BalhD (hakacin pathway) and more recent work continues to advance our understanding of YcaO-
mediated cyclodehydration. 
From these studies, there are currently four varieties of cyclodehydratases (Figure 1.30). Three of 
the four groups require a member of the E1-like superfamily as a partner protein for activity. This partner 
can be encoded as a discrete polypeptide or fused to the YcaO. In addition to an E1-like domain, certain 
fused cyclodehydratases are notably shorter by ~150 amino acid and only act when present with an “Ocin-
ThiF-like” protein. Members of this variety are referred to as F-protein dependent cyclodehydratases. 
Lastly, in rare cases, a standalone YcaO seems to independently form azoline heterocycles. Little is known 
about the standalone azoline-forming YcaOs as none have been reconstituted in vitro; consequently, this 
section is focused on insights into how the canonical cyclodehydratases catalyze azoline formation and 
recognize their substrates. Importantly, despite the differences in domain architecture, these enzymes share 
common features that apply to all types. 
 
1.6.1 Functional dissection of the cyclodehydratase 
Although the function of the YcaO protein and its partner proteins are now well established, the role of 
individual proteins was ambiguous for many years. Historically, the primary limitations for functionally 
dissecting the role of each protein in the cyclodehydratase were a lack of robust cyclodehydratases, in part 
due to the low amount of genomic information available and thus few known pathways, and the inability 
to characterize YcaO independent of its associated partner proteins. The first-studied cyclodehydratase from 
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the MccB17 BGC (section 1.2.1) was inactive unless the full trimeric synthetase was formed (i.e. the B, C, 
and D proteins).33, 37, 47, 620 Although the identity of the dehydrogenase was clear due to its yellow appearance 
from binding an FMN cofactor,620 the individual roles of the E1-like partner protein (McbB) and the YcaO 
protein (McbD), which composed the azoline-forming cyclodehydratase, were not readily distinguishable.37 
The first functional insights into the proteins that compose the cyclodehydratase came from 
examination of McbB (E1-like) and McbD (YcaO). The protein sequence of McbD revealed supposedly 
weak similarity to some ATP-binding motifs involved in phosphate or Mg2+ binding.621 However, McbD 
did not hydrolyze ATP by itself, and mutation of the ATP-binding residues affected both complex assembly 
and catalysis, which obscured interpretation of their role.620, 621 In another experiment, the McbA leader 
peptide was synthesized with a biotin purification handle and a photoactivable benzophenone group in order 
to crosslink and affinity purify the protein responsible for leader peptide binding. Upon exposure to UV 
light, McbD was identified, and this result suggested that McbD recognized the leader peptide, although 
crosslinking only occurred when the full McbBCD synthetase was present.620 On the other hand, the McbB 
protein was found to contain Zn2+ and thus was proposed to catalyze cyclodehydration by acting as a Lewis 
acid;620 however, later work indicated that the Zn, in the form of a tetrathiolate cluster, was only 
structural.622 Overall, these early studies suggested that McbB (E1-like protein) was the cyclodehydratase 
and the site of azoline formation while McbD (YcaO) regulated activity through leader peptide-binding and 
ATP hydrolysis.620 However, McbB was later suggested to be more likely responsible for ATP-binding 
based on sequence homology to members of the E1-like superfamily, which are also zinc tetrathiolate-
containing and ATP-utilizing enzymes.48, 188, 594 The YcaO protein then became known as the “docking” 
protein as it seemed less involved in catalysis, but these previously assigned functions for the azoline-
forming proteins are now known to be incorrect.  
 
1.6.1.1 YcaO protein 
After the pioneering studies on the microcin B17 azole-forming complex, other cyclodehydratases were 
investigated in vitro to further probe the role of the individual proteins. Work with the cyanobactin 
cyclodehydratases unequivocally showed that the dehydrogenase was not required for cyclodehydration,548, 
594 unlike in the previously studied examples (e.g. McbBCD and SagBCD).37, 51 However, the fact that the 
cyanobactin cyclodehydratases are a fusion of the E1-like and YcaO proteins meant their individual roles 
could not be separated. Upon investigating BalhD (YcaO from the LAP BGC in B. Al Hakam), the protein 
was shown to consume ATP and form azoline heterocycles independent of any other protein.17 The activity 
was modest, but this represented the first time a precise function could be ascribed to a YcaO protein. 
Later, follow up studies focused on determining the active site and ATP-binding residues of the 
YcaO protein since it was devoid of established ATP-binding motifs. Working towards this goal, the 
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structure of the fused cyclodehydratase TruD provided the first insight into the structure of the YcaO 
domain and its attached E1-like partner protein.592 However, no substrates were co-crystallized with the 
cyclodehydratase, so there was no evidence yet for how the YcaO domain might interact with ATP. The 
study drew attention to the fact that the canonical ATP-binding site of the E1-like protein was missing 
multiple key residues. TruD was also shown to produce adenosine monophosphate (AMP) and 
pyrophosphate (PPi) whereas previously studied cyclodehydratases produced adenosine diphosphate 
(ADP) and phosphate (Pi).17, 37, 594, 621 This difference in mechanism questioned whether the E1-like domain 
really was involved in adenylation or if the YcaO protein was truly the ATP-utilizing enzyme.592 This 
question was addressed when the structure of the enigmatic YcaO from E. coli (Ec-YcaO) was determined 
with a bound ATP analog.18 The analog indicates ATP was bound in a novel way and was coordinated by 
two Mg2+ ions (also see section 1.6.3.7). Although Ec-YcaO is not believed to be involved in azoline 
biosynthesis, the residues which interact with ATP were conserved among the entire YcaO superfamily, 
regardless of associated function. Furthermore, in the presence of ATP, Ec-YcaO exhibited slow hydrolysis 
of ATP to AMP and PPi, indicating that ATP can be hydrolyzed by YcaOs even in the absence of recipient 
substrate. Thus, with this discovery, a more conclusive and universal role for the YcaO protein was 
established. Later, another fused cyclodehydratase (LynD) was crystallized with an ATP analog, confirming 
the ATP-binding site for a bona fide azoline-forming YcaO and that the YcaO is the site of 
cyclodehydration.593 The study noted that the adenylation mechanism suggested from the original TruD 
study was incompatible with the binding of ATP. 
In addition to showing the site of ATP binding, the structure of the fused cyclodehydratase also 
revealed the interactions between the E1-like and the YcaO domain and the assembly of the overall 
cyclodehydratase.593 The structure was dimeric, with the two monomers interacting primarily through their 
E1-like domains (Figure 1.31). The peptide-binding region of the E1-like domain (also known as the RRE 
and discussed below) also forms dimerization contacts and is responsible for orienting the core region of 
the precursor peptide toward the active site of the YcaO from its own monomer. It is noteworthy that most 
azoline-forming YcaO proteins contain a Pro-rich C-terminus, often with the final five residues being a 
PxPxP motif. This portion of the YcaO points into the ATP-binding pocket and is crucial for organizing the 
active site residues and enabling the proper interaction of the E1-like and YcaO domains.18 Replacement of 
these Pro with Gly, truncation of the PxPxP motif, and shifting of the motif by even two residues by 
inserting a random sequence upstream all abolish cyclodehydratase activity. The structure of LynD reveals 
that the PxPxP tail region does not directly interact with the E1-like partner,593 so it likely helps maintain 
proper structure elsewhere for this critical interaction. 
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1.6.1.2 E1-like partner protein 
As experiments began pointing toward the YcaO protein as the component with cyclodehydratase 
activity, the function of the E1-like protein needed to be reconsidered. One of the first indications for the 
role of the E1-like protein was reveal from studies with SagC from SLS biosynthesis (Figure 1.6). When 
the azole synthetase components were individually tested for binding to an array of leader peptides, only 
SagC remained bound after extensive washing.136 Investigation of BalhC from the hakacin BGC (Figure 
1.9) also supported the LAP C protein (E1-like protein) as the site of leader peptide binding. BalhC bound 
a fluorescently labeled leader peptide whereas BalhD had no significant interaction.18 At this point, no 
binding site had been determined, but the structure of TruD demonstrated the similarity of the E1-like 
partner protein with the protein MccB, which is an adenylase involved in microcin C7 biosynthesis. 
During microcin C7 maturation, MccB binds the peptide substrate using its N-terminal, winged helix-
turn-helix (wHTH) domain like a peptide clamp. This same wHTH domain was present in LAP C 
proteins. However, as demonstrated by the leader peptide-bound crystal structure of the cyclodehydratase 
LynD, a peptide clamp binding mode is not employed during azoline biosynthesis (Figure 1.31). Instead, 
the leader peptide adds on to an existing three-stranded β-sheet structure as the fourth, antiparallel β-
strand in the wHTH domain of the E1-like domain. Although the YcaO portion of the cyclodehydratase is 
spatially close to the leader peptide, it does not appear to contribute much to substrate binding, which 
provides a possible explanation for the incorrect conclusions as to the role of individual proteins from the 
previously-mentioned photolabeling experiments with McbBCD. Importantly, the leader peptide-binding 
site of the cyclodehydratase was definitively revealed by the LynD structure and a concurrent study 
further supported the crystallographic data with binding data for different LAP C proteins mutated in this 
region.27 In addition to controlling and guiding substrate recognition, the E1-like partner protein is also 
crucial for allosterically activating the YcaO protein.18 Even in the absence of substrate, the partner 
protein enhances the background rate of ATP hydrolysis and lowers the KM for ATP.18 
Unexpectedly, comparison of the leader peptide-binding site on the cyclodehydratase with other 
protein structures revealed that another RiPP biosynthetic protein, the lanthipeptide dehydratase NisB, has 
a structurally similar leader peptide-binding domain and the same leader peptide-binding orientation.205, 
593 The structural similarity between these proteins was unanticipated because their protein sequences did 
not bear any noticeable similarity. However, upon the use of more sensitive profile-HMM comparisons, 
the leader peptide-binding domains from RiPP cyclodehydratases and lanthipeptide dehydratases were 
indeed sequence-related to each other, as both were homologous to the PqqD protein from PQQ 
biosynthesis. Further, these PqqD-like domains were present in many other prokaryotic RiPP biosynthetic 
pathways.27 The widespread prevalence of this domain in different RiPPs led to its naming as the RiPP 
precursor peptide recognition element (RRE). Thus, the RRE is a structurally conserved leader peptide-
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binding domain that guides RiPP biosynthesis in over half of all identified prokaryotic RiPP classes. 
While some RiPP pathways and enzymes have alternative mechanisms or protein regions for binding their 
leader peptides,28, 29 it appears that the most common and unified mechanism is the PqqD-like structural 
motif defined by the RRE as employed by canonical RiPP cyclodehydratases. 
 
1.6.1.3 Ocin-ThiF-like partner protein 
Even though most RiPP cyclodehydratases contain an E1-like and YcaO protein, bioinformatic analysis of 
the putative LAP BGCs from the heterocycloanthracins seemed to suggest yet another domain architecture 
for the cyclodehydratase. Within the heterocycloanthracins, the YcaO protein is fused to the E1-like protein, 
but unlike the cyanobactins, where the fusion protein length is about equal to the sum of two individual 
LAP C and D proteins, the heterocycloanthracins were shorter by ~100-150 amino acids. Additionally, even 
though a dehydrogenase was occasionally absent from the putative heterocycloanthracin gene clusters, the 
YcaO protein virtually always co-occurred with an uncharacterized protein.184 This uncharacterized protein 
was distantly related to ThiF, a member of the E1 superfamily, and was annotated as Ocin-ThiF-like (or F 
partner protein). 
 Indeed, the truncated, fused cyclodehydratases required the F partner protein for azoline 
formation.185 Although this protein is distantly related to the E1-like protein,  they do not detectably bind 
Zn and do not have any zinc-tetrathiolate motifis, indicating significant divergence from better known 
members of the E1 family. This discovery lead to the naming of this type of azoline synthetase as an F-
dependent cyclodehydratase. Upon closer inspection, the shortened length of the YcaO fusion in 
heterocycloanthracin BGCs was due to the lack of the PqqD-like N-terminal wHTH domain, which had 
been implicated in leader peptide binding.18, 591 Consistent with this hypothesis, the truncated (fused) 
cyclodehydratase HcaD did not bind the HcaA precursor whereas the cognate HcaF protein did.185 Later 
bioinformatic analysis indicated that the F partner protein contains a RRE at its N-terminus while the 
truncated cyclodehydratase fusion protein was missing this domain, rationalizing its shorter length and how 
the F partner protein binds its substrates via the leader peptide of the precursor.27  
However, little is known about how the Ocin-ThiF-like protein in HCA gene clusters interacts with 
the F-dependent cyclodehydratase because of a lack of structural data. Current evidence suggests that the 
F-protein interacts with the YcaO through the E1-like domain and that the active azoline synthetase is a 
complex of one F partner protein and one truncated YcaO fusion protein (Figure 1.31).185 Furthermore, F-
dependent cyclodehydratases are also found in thiopeptide BGCs and have been confirmed to be necessary 
for their biosynthesis.45, 53, 258, 265 Lastly, the leader peptide-binding site has been investigated through 
mutagenesis and binding experiments with all available data consistent with models based on the known 
structure of LynD.27 
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1.6.2 Mechanism of azol(in)e formation 
Cyclodehydration of Cys, Ser and Thr residues to form azoline heterocycles was known to require ATP and 
the YcaO domain from early in vitro reconstitution experiments with McbBCD (Figure 1.5).37, 621, 623 In 
contrast to McbBCD, which requires the entire heterotrimeric synthetase for azole formation, the 
cyanobactin cyclodehydratases, which are fusions of the E1-like and YcaO protein (LAP C and D proteins, 
respectively), are known to install azoline heterocycles in the absence of a dehydrogenase.548, 594 Other RiPP 
cyclodehydratases also do not require a dehydrogenase for activity.182, 185 These biosynthetic platforms 
allowed for separation of function between the cyclization and dehydrogenation events and ruled out a 
mechanism where dehydration may have preceded cyclodehydration.548, 594 
The role of ATP during cyclodehydration was, at this point, still unclear and multiple potential 
mechanisms for ATP utilization arose (Figure 1.32).17, 594 Direct activation of the peptide substrate was 
proposed to allow for nucleophilic attack on the carbonyl that proceeds through a hemiorthoamide 
intermediate that eliminates phosphate from the conversion of ATP to ADP. Alternatively, the ATP could 
have played an indirect role through allosteric activation of the YcaO, designated as the “molecular 
machine” hypothesis.594 Lastly, a mechanism related to intein splicing was proposed as a third possibility 
by which similar nucleophilic attack on the adjacent amide carbonyl generates a tetrahedral hemiorthoamide 
intermediate. With subsequent O-protonation, water is then eliminated. This intein-like mechanism 
appeared least likely as cyclodehydration was known to not proceed without ATP.51, 136 
 
1.6.2.1 Amide O-(pyro)phosphorylation and elimination 
Reconstitution of the Balh cyclodehydratase182 from Bacillus sp. Al Hakam shed critical light on the 
mechanism of ATP utilization by YcaO proteins. Indeed, it was determined that the YcaO protein, BalhD, 
and not BalhC (E1-like LAP C protein) was responsible for ATP hydrolysis to ADP and phosphate, 
disproving the previously proposed function of the YcaO as a “docking scaffold” for assembly of the 
trimeric azole synthetase. This result was further corroborated by the finding that BalhD alone was 
necessary and sufficient for cyclodehydration of the cognate precursor peptides, BalhA1 and BalhA2 
(Figure 1.9). In contrast to earlier reports regarding the cyanobactin cyclodehydratases,594 a stoichiometric 
consumption of ATP was seen when compared to azoline formation, though notably, reactions with BalhD 
alone produced deviations from this ratio, suggesting a potential dysregulation that is rectified by the 
addition of the BalhC partner protein.17 
To differentiate between direct activation and the molecular machine hypotheses, cyclodehydratase 
reactions were conducted in [18O]-H2O. In contrast to the direct activation mechanism, the molecular 
machine hypothesis involves bulk water in the hydrolysis of the γ-phosphate, and hence, 18O incorporation 
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into free phosphate would be expected if this mechanism were operative.17 Analysis by 31P-NMR was 
consistent with all [16O]-phosphate (18O imparts a shielding effect on the 31P nucleus), disproving the 
molecular machine mechanism. A complementary experiment utilized BalhA where the amide oxygen 
upstream of every cyclized position was replaced with 18O. The preparation of this key substrate was from 
a new procedure called AMPL, for Azoline-Mediated Peptide backbone Labeling (discussed further below 
in Figure 1.34).183 Isotopically labeled BalhA1 was then used as substrate for the Balh cyclodehydratase 
using non-labeled [16O]-H2O. This time, mono-[18O]-phosphate was detected by 31P-NMR, providing the 
strongest support to date that cyclodehydration proceeds via a hemiorthoamide intermediate using the direct 
activation mechanism (Figure 1.33). Analogous results were observed upon testing the MccB17 enzymes, 
suggesting more broadly that azoline-forming YcaOs use ATP to activate the amide backbone in the form 
of a phosphorylated hemiorthoamide, akin to a kinase, for modification during biosynthesis.17  
The crystal structure of the TruD enzyme was the first available for a YcaO domain and it displayed 
a novel fold.592  Alongside the structural study, an NMR-monitored reaction was carried out at 10 °C, which 
showed ATP consumption to be congruent with the rate of heterocycle formation (1 ATP hydrolyzed for 
every heterocycle formed). The TruD byproducts detected were AMP, phosphate (Pi) and pyrophosphate 
(PPi).592  This pattern of products is typically seen for adenylating enzymes, with Pi resulting from 
breakdown of PPi under the assay conditions. This study also looked for the production of ADP, as would 
be expected from a kinase mechanism, but failed to detect ADP either by NMR or by using an enzyme-
coupled assay, suggesting that the peptide backbone was adenylated rather than phosphorylated by TruD.592 
Studies on discrete cyclodehydratases (i.e. Mcb and Balh), however, detected only ADP, consistent with a 
kinase mechanism.17, 621 Further, AMP and PPi production was observed Ec-YcaO in the absence of 
substrate,18 suggesting that different YcaOs may employ either a kinase-like or adenylation mechanism. 
Structural and biochemical characterization LynD, a close homologue of TruD, showed that this enzyme 
produced AMP, PPi and Pi in an identical manner to TruD. However, the structures of both LynD593 and 
Ec-YcaO18 reveal a binding mode for the ATP that exposes only the γ-phosphate, making adenylation 
structurally hindered. At the same time, crystal structures only provide a snapshot and can be misleading. 
Further experimentation with LynD showed that [18O] can move from the peptide to both Pi and PPi, 
apparently at odds with a simple phosphorylation mechanism.593 Although multiple lines of evidence points 
to a kinase mechanism, the production of PPi by some enzymes remains an open mechanistic question, and 
it is possible that slightly different modes of activation are occurring within the YcaO superfamily. 
 
1.6.2.2 Azoline oxidation 
The oxidation (dehydrogenation) of thiazoline to thiazole is common in natural products, especially in 
RiPPs.543, 546 The tendency for RiPP BGCs to install thiazoles may reflect the increased chemical stability 
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of the aromatic thiazole relative to the non-aromatic thiazoline. Synthetically, thiazolines can readily be 
oxidized to thiazoles under mild conditions using molecular oxygen.624 In addition to their sensitivity to 
oxidation, peptidic thiazolines are relatively easily hydrolyzed to Cys by treatment with aqueous acid.548 
The hydrolytic susceptibility of thiazolines has been exploited to introduce [18O] labels into peptides for 
mechanistic studies (AMPL method).183 Ring opening of thiazolines in peptides with acidic [18O]-H2O 
results in the incorporation of [18O] at the preceding carbonyl oxygen position (Figure 1.34). In contrast, 
thiazoles cannot be hydrolyzed by simple acid or base treatment.  
In LAPs that contain Ser- and Thr-derived heterocycles, such as MccB17 and goadsporin, 
(methyl)oxazoles are more commonly found than (methyl)oxazolines. In contrast, in the cyanobactin family 
of natural products, (methyl)oxazolines are more common than (methyl)oxazoles. Oxazoles have 
significantly less aromatic character than thiazoles,625 which is reflected in their ability to readily undergo 
Diels-Alder cycloaddition reactions. This reactivity has been exploited synthetically, where the oxazole 
acts as a diene (Figure 1.35).626 Thiazoles can also undergo Diels-Alder chemistry, but they require harsher 
conditions,627 consistent with their greater aromatic nature. The lower aromaticity of oxazole means the 
oxidation of oxazolines requires a more electrochemically powerful reagent compared to a thiazoline.  
The so-called B protein in the LAP biosynthetic clusters is an FMN-dependent dehydrogenase that 
oxidizes the azol(in)e heterocycles during LAP biosynthesis.37 In addition to a characteristic FMN-binding 
site, B proteins contain a conserved Lys-Tyr motif that has been shown to be essential for catalytic 
activity.37, 72 Many B proteins, such as McbC (so-named based on historical precedent) from the MccB17 
pathway, dehydrogenate thiazoline and (methyl)oxazoline to the corresponding azole.37 The ability to 
process methyloxazoline is interesting and may indicate a stereochemical constraint on the mechanism. 
Starting from L-Thr, the corresponding methyloxazoline has the two hydrogens (one each on C and C) 
that are removed during oxidation. The simplest mechanism would be deprotonation of the more acidic C 
proton, followed by hydride transfer from C atom to the N5 atom of FMN (Figure 1.36). This mechanism 
is essentially an E2 elimination. If an E2 mechanism is operative for methyloxazoline, then it presumably 
operates in the same manner for thiazoline and oxazoline. An E2 mechanism would require an L-configured 
azoline and an anti-configured hydrogen at C. Such a requirement would mean that L-allo-Thr, D-Thr, D-
allo-Thr, D-Ser or D-Cys derived azoline rings would not be substrates for B proteins, as each would have 
at least one improperly positioned hydrogen. This prediction has yet to be tested experimentally. 
The presence of oxazolines alongside thiazoles in many natural products may indicate that not all 
B proteins are electrochemically capable of forming oxazoles. Indeed, one dehydrogenase from Bacillus 
cereus (BcerB) has been shown experimentally to be only capable of oxidizing thiazolines.72 The 
electrochemical potential of BcerB and McbC (which oxidizes both thiazolines and oxazolines) was 
measured and found to be identical for both enzymes within error. This finding indicates that the difference 
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in reactivity of these enzymes cannot be attributed to a simple difference in the electrochemical potential 
of the FMN cofactor.72  Since the potential is equal between these enzymes, it seems unlikely that the 
different energy of hydride transfer from an oxazoline vs a thiazoline would underpin the difference in 
reactivity. Alternatively, if an E2 mechanism is operative, it would suggest that the difference may lie in 
the deprotonation of C and/or in the larger sulfur atom being required for correct positioning of the ring.  
Cyanobactins tend to have oxazolines and thiazoles, suggesting their dehydrogenases share the 
same preferences as BcerB although this has yet to be established experimentally. There are, however, 
examples of oxazole-containing cyanobactins, (e.g. tenuecyclamides628) demonstrating that some 
cyanobactin dehydrogenases are capable of oxidizing oxazolines. In contrast to LAPs, the case of 
cyanobactins raises the question as to when during biosynthesis does oxidation occur.  In theory, the 
dehydrogenase could act before or after macrocyclization; alternatively, dehydrogenation could be 
independent of macrocyclization. Using purified enzymes, it has been established that the isolated 
dehydrogenase domain of ArtG is capable of oxidizing both linear and macrocyclic substrates whereas the 
dehydrogenase from the thc pathway586 only oxidizes macrocyclic substrates; however, no information on 
the relative rates was reported.596 LAP dehydrogenases, on the other hand, tend to immediately 
dehydrogenate azolines given that partially processed intermediates are typically found as azoles.182 A 
further complication in many cyanobactins is that the residue N-terminal to the thiazole is epimerized. 
Simple chemical considerations, such as avoiding the disruption of aromaticity by delocalization of the 
negative charge, would favor epimerization of the residue when it is adjacent to thiazoline rather than 
thiazole (i.e. before oxidation, Figure 1.37). Spontaneous epimerization has been observed previously for 
the thiazoline of lissoclinamide,629 and it likely occurs after macrocyclization.596 A related epimerization 
mechanism may explain the presence of D-Asp next to the thiazole in bottromycin,630, 631 but generally these 
epimerizations remain an enigmatic modification and are not common among RiPPs. Overall, the data are 
most consistent with epimerization and then oxidation as the final two steps during cyanobactin maturation 
(Figure 1.38). 
The crystal structure of the dehydrogenase domain from the cyanothecamide gene cluster has been 
determined (Figure 1.39). As expected, the protein has a fold characteristic to FMN-utilizing enzymes and 
the previously mentioned, conserved Lys-Tyr is adjacent to FMN in the active site. Intriguingly, the 
structure displays two PqqD-like RRE domains. The role of either RRE in substrate binding or 
dehydrogenation has yet to be elucidated. Given that the (leaderless) macrocyclic peptide is a substrate for 
the dehydrogenase,596 it may be that the RRE is non-functional, as has been previously observed in a 
thiopeptide pathway with multiple RRE-containing proteins.632 
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1.6.3 Enzymatic processing and promiscuity 
Based on the roles of their individual components and the determination of their structure with bound 
substrates, there is now an established model for the assembly and function of canonical RiPP 
cyclodehydratases (Figure 1.31). It is striking that YcaO proteins can process multiple positions within a 
single peptide substrate. Indeed, as highlighted in previous sections, azol(in)e-containing RiPPs with only 
one backbone heterocycle are rare (e.g. trifolitoxin and bottromycin). However, catalyzing multiple 
turnovers poses a challenge for these enzymes because each modification changes the substrate for the next 
turnover. In essence, each site of modification is a different substrate, which implies that the 
cyclodehydratase is inherently tolerant to a variety of substrates. Much of this ability can be attributed to 
the leader peptide. Upon a binding to the leader peptide and correct positioning via the RRE, the YcaO can 
promiscuously process variable core sequences.  
Insight into how the peptide substrate is handled by the cyclodehydratase has come from a number 
of biochemical investigations. YcaO domains utilize ATP directly for catalysis (section 1.6.2.1)17, 183 and it 
has been observed that these enzymes evolved to limit the non-productive hydrolysis of ATP. For example, 
ATP consumption is stoichiometric (1:1) with heterocycle formation so ATP is efficiently coupled to 
catalysis.17 ATP hydrolysis by RiPP cyclodehydratases is also slow in the absence of peptide substrate, 
although the presence of pseudosubstrates (e.g. modified substrate) seem to stimulate enhanced background 
hydrolysis rates.18, 594 Studies of cyclodehydratases from various BGCs have revealed many common rules 
for how residues are selected for heterocyclization and suggested an interplay between chemoselectivity, 
regioselectivity, and local sequence context during processing of multiple positions within a single peptide. 
These investigations have also demonstrated the importance and role of the leader peptide in allosterically 
activating the cyclodehydratase and placing the cyclizible residues properly within the active site.  
 
1.6.3.1 Chemoselectivity 
Among the standard cyclizible residues, azoline-forming YcaOs have demonstrated a clear preference (30- 
to >100-fold) for modifying Cys over Ser/Thr at the same position of a peptide, indicative of 
chemoselectivity for sulfur over oxygen nucleophiles.182, 548, 633 Indeed, some characterized 
cyclodehydratases act primarily on Cys residues,45, 182, 185 but several others also process Ser and Thr 
residues.37, 51, 173, 548 Examination of known azol(in)e-containing RiPPs (i.e. those discussed above) reveals 
that thiazol(in)e heterocycles are more common than (methyl)oxazol(in)e. Given the predicted formation 
of the hemiorthoamide as a key step in the reaction, the much higher nucleophilicity of the Cys side chain 
and its lower pKa compared to Ser or Thr explains this preference. 
It has also been shown that PatD will process selenocysteine-containing precursor peptides, which 
generates seleno analogues of cyanobactins in vitro.634 This in vitro method represented a new route to 
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selenazolines circumventing the need for stoichiometric amounts of highly toxic selenium donors, which 
are normally required for chemical synthesis.634 It has been speculated that since selenium was so easily 
accommodated, and selenocysteine is a natural compound, that seleno analogues of cyanobactins or LAPs 
may exist in nature, but these have yet to be discovered. Non-canonical β-nucleophilic amino acids have 
not been tested, but conceivably other amino acids could be cyclized (e.g. 2,3-diaminopropionic acid to 
imidazoline). However, amino acids with γ-nucleophiles are unlikely to be heterocyclized into the six-
membered ring as homocysteine was rejected by the McbBCD synthetase (Figure 1.5).633 
In thiocillin biosynthesis, the core peptide contains six Cys residues all of which are normally 
transformed to thiazole (Figure 1.18).229 When these six Cys residues were each individually replaced with 
Ser, the major product in each case contained an unmodified Ser residue at the substituted position;267 
oxazol(in)e-containing compounds were only observed as minor compounds, and then only at specific 
positions.267 In this case, a simple model based on chemical reactivity of the substrate is sufficient to explain 
the difference. However, this difference in chemoselectivity is not significant enough to derail downstream 
processing, as the GE37468 biosynthetic pathway tolerated Ser/Thr in place of Cys2 although Cys4 could 
not be substituted.361 Additionally, cyanobactins demonstrate a case where, with the same substrate, PatD 
from the patellamide pathway will produce both thiazolines and (methyl)oxazolines, while the very closely 
related TruD from the trunkamide pathway (>93% similar to PatD) will only produce thiazolines, skipping 
over Ser/Thr, which are subsequently prenylated by a prenyltranferase.548, 592 Thus the prevalence of 
thiazol(in)e is not simply a case of substrate reactivity, rather the enzyme itself plays a role.  
 
1.6.3.2 Regioselectivity 
Although Cys nucleophiles are favored for heterocyclization, the picture is more complex as the tolerance 
of these enzymes towards cyclizible residues is also dependent on their position in the sequence. This 
regioselectivity was shown first shown for the MccB17-forming McbBCD synthetase (section 1.2.1) where 
shifting a Cys one position backward in the core sequence reduced the processing rate by 50%.633 
Additionally, although McbBCD modifies Ser, only certain positions are processed.113, 635 Similar 
regioselectivity was seen in experiments with the hakacin synthetase (section 1.2.4). Variants of the hakacin 
substrate were constructed which had only one Cys per peptide, at each of the native sites, with all other 
heterocyclizible residues being substituted in order to see if one position was favored for cyclodehydration 
over the others.182 Only one variant was rapidly heterocyclized at nearly the rate of the native peptide 
whereas all others were cyclized ~20-fold slower. Intriguingly, the single favored position was also the first 
Cys normally cyclized within the native peptide.182 For cyanobactin cyclodehydratases, the majority seem 
to process all Cys in the core peptide regardless of position, and Ser/Thr are generally accepted at different 
positions in the core peptide.636 However, a different study found that Thr/Ser near the N-terminus of the 
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core tend to be skipped whereas more C-terminal Thr/Ser are more readily cyclodehydrated.548 A notable 
exception is ulithiacyclamide, where a pair of Cys residues remain unprocessed by the cyclodehydratase, 
forming instead a disulfide bond which thought to be critical for activity.557, 558, 637  
While the above examples of regioselectivity reveal the preferences of different cyclodehydratases, 
the selective control of this enzyme is much more crucial when it is involved in pathways with multiple 
enzymes that act on the same residues. In these cases, strict regioselective control is usually displayed. For 
example, in cyanobactin pathways, when a prenyltransferase is present, certain Ser/Thr residues must 
remain uncyclized in order for it to be able to act on the substrate and may explain why TruD is a Cys-
selective cyclodehydratase since tru pathways tend to include prenylation.548 Similar selectivity is 
demonstrated by the azole synthetase (GodD/E) from goadsporin biosynthesis (section 1.2.7) which 
processes all Cys and Thr but only one of four Ser are converted to oxazoles in the mature compound.204, 
213 Of the other three Ser residues, two become dehydroalanine while the third remains unmodified.204, 213  
As for thiopeptide biosynthetic pathways (section 1.3), the cyclodehydratase skips over Cys involved in 
side ring macrocycles (e.g. nosiheptide or lactocillin), but the basis for this site-specificity has not been 
explored. More investigated is the regioselectivity during Ser/Thr cyclodehydration. Because 
dehydroalanine formation at certain Ser residues is necessary for macrocyclization, proper thiopeptide 
maturation requires control of these potentially competing processes. Most thiopeptide BGCs appear to 
avoid this problem by cyclizing only Cys residues, although there are multiple berninamycin-like 
thiopeptides where Thr/Ser residues in certain positions are cyclized whereas others are left unmodified or 
are dehydrated (Figure 1.17).260, 262 This control is especially notable given that the cyclodehydratase acts 
before the dehydratase.45 Additionally, the dehydratase responsible for forming dehydroalanine and 
dehydrobutyrine must also be regioselective as most known thiopeptides have an unmodified Thr 
immediately next to a dehydrobutyrine. 
 
1.6.3.3 Order and directionality 
Closely related to regioselectivity is the directionality of processing. If one position is favored for the first 
heterocyclization, the second might also have a preferred position, as will each subsequently modified 
position. The sum of this selectivity results in the order and direction of processing when the 
cyclodehydratase cyclizes multiple residues within a peptide. In this view, each successive 
heterocyclization would enhance the processing of the next site. This is indeed the case as indicated by 
experiments with the hakacin cyclodehydratase and previously mentioned single Cys variants of its 
substrate which showed that only one position was initially favored for heterocyclization. Notably, when a 
Pro was introduced at this favored position (as a crude azoline structural mimic) in the substrate with only 
one Cys at the site of the second modification, processing became 6-fold faster relative to the substrate with 
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Ala at the first cyclized position. In general, there is no defined order for all cyclodehydratases. The 
formation of azol(in)e rings on the MccB17 (section 1.2.1) and the PZN precursor (section 1.2.3) were 
shown proceed in a N- to C-terminal direction173, 623 while TruD (section 1.4.1) has been shown to modify 
peptide peptides with the opposite C- to N-terminal directionality (Figure 1.40).592 However, the order of 
heterocyclization is not always linear as the hakacin synthetase (section 1.2.4) processes BalhA1 in an 
overall C- to N-terminal direction but doubles back to the most C-terminal position during processing.182 
Similarly, the thiomuracin cyclodehydratase (section 1.3.2.4) has a non-linear preferred order but only for 
first three cyclodehydrations, as the remaining thiazolines are installed without detectable intermediates or 
order.632  
The importance of the order of heterocyclization and the presence of previous azol(in)e 
heterocycles for further modification has also been shown by substituting a cyclizable residue (Cys/Ser/Thr) 
with a non-cyclizable Ala residue in other examples.173, 182, 592  This is best illustrated by the PZN synthetase, 
whereby substitution of Cys/Ser/Thr with Ala in the PZN precursor peptide BamA, prevents processing of 
all succeeding cyclizable residues; however, all residues N-terminal to the substitution are processed 
normally (Figure 1.7).173 While substitution of a cyclizable residue with a Pro has been shown to be tolerated 
by some cyclodehydratases as a steric mimic of an azoline ring,136, 182, 589, 592 Pro also blocked processing by 
the PZN synthetase, indicating its strict requirements. For a cyanobactin example, when the C-terminal core 
peptide Cys of an engineered patellamide precursor peptide was substituted with Ala, processing of the 
internal Cys by TruD was impaired; however, substitution of the same Cys residue with Pro enabled 
complete processing at the internal site,592 similar to the previous observations with cyanobactins.548  At 
least for the patellamide system, the reason for this is that the cyclodehydratase binds as tightly to the Ala 
variant as the Cys-containing native substrate; thus, the enzyme appears locked onto the wrong place. The 
Pro variants binds much more weakly allowing the enzyme to sample and thus process the other Cys 
residues.592 
 The thiopeptide BGCs have also given some insight into how altering the normal number and 
position of heterocyclized residues affects complete maturation of the peptide product. 267, 344 The thiocillin 
azole-synthetase complex seems to be very tolerant in skipping over normally cyclized residues substituted 
with Ala, with only one thiazole position (Cys11) being required for production of the macrocyclic product 
(Figure 1.18).267 The requirement for the thiazole moiety at the Cys11 position was noteworthy and mirrors 
the observation that a C51A PatE mutant aborts further processing.592 Two other positions also did not 
produce a product, Ser1 and Ser10, but have previously been shown to be critical in construction of the 
central pyridine ring.236 Therefore, the inability to isolate any product when Ser1 or Ser10 are substituted 
cannot be attributed to failure of processing by the thiocillin cyclodehydratase and reinforces the importance 
of cyclodehydratase regioselectivity in biosynthetic pathways. In another example, the biosynthetic 
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pathway of GE37468 was unable to tolerate substitution of its azole heterocycles with non-cyclizable 
residues, but again it was not clear if it this was due to the cyclodehydratase or downstream processing 
events.361 On the other hand, the thiomuracin cyclodehydratase has no difficulty in processing around 
altered Cys sites.632 A molecular level understanding of these preferences has yet to be determined. 
Because the cyclodehydratase processes the same substrate at multiple locations, there has also 
been interest in determining whether the enzymes is distributive or processive. A distributive enzyme will 
processes a single site, release the substrate, and then process a second site after reengaging the substrate, 
resulting in the easy detection of intermediates. In contrast, a processive enzyme will process every site 
before releasing the substrate. Some enzymes can even be partially processive, in that they will process 
several sites, release, then process additional sites in a distributive fashion. It has been shown that 
trunkamide, hakacin, and MccB17 azole synthetases are distributive.182, 592, 620, 623 Logically, distributive 
enzymes have faster dissociation rates for the enzyme-substrate complex than kcat. Processive enzyme are 
the opposite: they must have a kcat that is faster than the dissociation rate of the enzyme-substrate complex.  
 
1.6.3.4 Tolerance of flanking residues 
Given the diversity of azol(in)e-containing RiPPs found in nature, it is difficult to determine a universal set 
of rules that govern substrate tolerance of RiPP cyclodehydratases. While chemo-/regeioselectivity 
influence their promiscuity, another crucial variable in processing is tolerance, or lack thereof, for the 
identity of the residues that immediately flanking the Cys, Ser or Thr undergoing cyclodehydration. The 
first insights into the effect of flanking residues came from studies of the MccB17 azole synthetase (section 
1.2.1). Substitution of the native Gly in the position immediately before the first cyclizible residue with 
charged amino acids gave no turnover and actually was an effective inhibitor to processing of the native 
substrate.638 Thus, the Gly in the -1 position appears to be essential as even substitution with Ala was not 
accepted by McbBCD. The enzyme was somewhat more tolerant towards variation in the +1 position 
(immediately following a cyclized residue).638 The effect of flanking heterocycles was also studied with the 
MccB17 cyclodehydratase because an azole in the -1 position would theoretically decrease the 
electrophilicity of the proceeding amide bond through conjugation. Experimentally, this could inhibit 
heterocyclization,633, 639 but only at one position.623 This effect does not carry a significant catalytic 
consequence in other cases, given the contiguous heterocycles found in PZN (section 1.2.3), and 
presumably the SLS-like cytolysins (section 1.2.2).51, 173 
Similar trends in the tolerance for flanking residues were also observed during investigation of the 
hakacin azole synthetase (section 1.2.4).182 Analyzing the sequence of the BalhA1 precursor peptide and 
homologues revealed that Gly nearly always preceded a Cys whereas hydrophobic amino acids were usually 
in the succeeding position.182 To develop an experimental basis for these observations, the Gly in the -1 
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position (relative to Cys) was substituted with Ala, Asp, or Lys, and these replacements decreased the rate 
of ATP consumption, and by extension, the heterocyclization reaction.182 However, since the heterocyclic 
product was observed, Gly was clearly not an essential feature for the enzyme. Rather, the preference of 
the enzyme for Gly was predicted to arise from its unique conformation, which enables a greater sampling 
of Ramachandran space,182 and thus increases flexibility of the neighboring Cα positions for faster 
processing. Substitutions of the residues in the +1 position (relative to Cys) were widely tolerated, including 
charged amino acids, but Pro was not accepted.182 Pro is not tolerated in either flanking position in PZN 
biosynthesis,173 but another cyclodehydratase from Corynebacterium urealyticum is able to cyclize Cys 
with a preceding Pro (see also the thiopeptides GE2270, amythiamicin, and baringolin, Figure 1.17), 
However, the cyclodehydratases associated with PZN biosynthesis are generally less tolerant than other 
cyclodehydratases given their requirement for contiguous heterocycles.173, 178 As a whole, this highlights 
that each cyclodehydratase will have a unique set of requirements and tolerance for flanking residues.  
In cyanobactin sequences, there appears a general preference for hydrophobic amino acids flanking 
the heterocyclic moiety.543, 546 The cyanobactin cyclodehydratases TruD/PatD process non-native substrates 
with hydrophobic flanking residues, presumably by mimicking native sites of modification.596 However, 
examples with polar and charged amino acids are known.549, 586 Additional work by Goto et al. demonstrated 
that PatD could tolerate charged residues flanking Cys and install multiple contiguous heterocycles in 
vitro.636 In a more extensive study, the promiscuity of trunkamide biosynthesis was examined in vivo, with 
the natural trunkamide (tru) biosynthetic pathway.584 A library of precursor peptide mutants was 
constructed using the NNK codon (where N = A/C/G/T and K = G/T),640 but Cys was fixed at position 7 of 
the core peptide since this was required for macrocyclization. Over 300 unique compounds were 
identified.584 It is worth noting that only final macrocyclic products were isolated as a measure for enzyme 
activity. Since the reaction intermediates were not detected, definitive conclusions about the specific 
preference of TruD for flanking residues cannot be made. However, Arg, Lys, Asp, Gly, Glu, and Pro were 
never found in position 6, N-terminal to the cyclizable terminal Cys residue. In other cyanobactins, Pro and 
Gly residues are found N-terminal to thiazole moieties; however, two sequence motifs “Pro-Cys” and “Gly-
Cys” were always located in the middle of the core peptide, and never at the C-terminus.546 This implies 
that the absence of Pro and Gly at position 6 might not be due to a failure of the cyclodehydratase, but due 
to difficulties in macrocyclization. Overall, these data highlight the combinatorial potential of these 
enzymes is not limited by substrate specificity, and point to the wider substrate tolerance of the 
cyclodehydratases, beyond the immediately flanking residues. While certain sequence combinations or 
individual residues may not be processed, the TruD/PatD cyclodehydratases display a remarkable level of 
promiscuity. One caveat, however, is that the rate at which substrates were processed was not considered 
in these studies. 
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In addition to processing core peptides with a wide range of natural amino acids, both in vitro and 
in vivo, the cyanobactin cyclodehydratases have been shown to tolerate peptide substrates containing 
unnatural amino acids.599, 641 Four Phe analogues, p-chloro-Phe, p-bromo-Phe, p-methoxy-Phe and p-azido-
Phe were incorporated immediately adjacent to the C-terminal Cys within the core peptide and all such 
substrates were processed by TruD in vivo.599 In vitro, an engineered variant of the aestuaramide 
cyclodehydratase LynD was shown to process a synthetic peptide substrate containing a derivatizable 
azidoalanine residue,641 demonstrating that cyclodehydratases can tolerate unnatural, and unusual 
functionality only three residues away from the cyclizable Cys. The thiocillin BGC has also been shown to 
accept unnatural amino acids in the core peptide.230 
Continuing the general trend observed, thiopeptides tend to tolerate small or hydrophobic residues, 
with charged residues being disfavored.267, 305, 361 Substituting Ala next to Cys within the thiocillin precursor 
peptide only failed to produce a mature product upon replacement of two Ser residues (Ser1 and Ser10) that 
are directly involved in macrocyclization.267 Multiple positions of GE37468 were also selected for codon 
randomization and revealed a variety of resides are accepted in positions flanking Cys residues, but no 
compounds with charged residues were produced.361 Substitution of the -1 position of a thiazole in 
berninamycin further corraborates this pattern for thiopeptide cyclodehydratase.262 Thus, cyclodehydratases 
generally have broad tolerance for residues in flanking positions except for a tendency to disfavor charged 
groups, but as previously stated, there are no hard and fast rules; each cyclodehydratase will have its own 
preference for the local sequence context around a cyclizible residue.  
 
1.6.3.5 Tolerance of core peptide length 
While cyclodehydratases have certain preferences as discussed above, they appear to more broadly tolerate 
expansions or contractions to core regions. Many of the earliest experiments with the MccB17 azole 
synthetase were performed with a core region truncated by 23 amino acids.633, 639 Other LAP 
cyclodehydratases have been similarly shown to process shorter substrates including the PZN and cytolysin 
synthetases,145, 173 but heterocyclization of longer core regions has yet to be thoroughly investigated for 
LAPs. Altering the length of thiopeptide core regions also seems to be tolerated,344 but this has not been 
systematically investigated either. On the other hand, the ability of cyanobactin cyclodehydratases to 
tolerate variations in the length of the core peptide has been extensively studied and appears to be highly 
promiscuous. Addition or deletion of one or two amino acids from the core has been accepted in all known 
cases.173, 596, 636 Following from this, much more drastic changes to the length of the substrate were shown 
to be tolerated as well.636 PatD, for which the core sequence of the substrate naturally contains eight amino 
acids, is capable of processing much smaller substrates, with just two core peptide residues, and much larger 
substrates with thirty-six core peptide residue.636 Given that cyanobactin precursors can have multiple core 
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peptide regions extending from the single leader, it seems that cyanobactin YcaOs may be generally 
insensitive to increased core peptide length. 
However, this general flexibility regarding length has two caveats. The first is that no 
cyclodehydratase has been shown to cyclize the terminal residue of a peptide. In all known RiPPs, the last 
azol(in)e always has one or more residues after it (which may be removed by proteolysis as in the case of 
cyanobactins and bottromycins). This was most clearly demonstrated for PZN because it normally contains 
a C-terminal methyloxazoline-Phe-COOH, but replacing Phe with a stop codon resulted in an unmodified 
Thr-COOH.173 There are other instances where residues near the C-terminus  are also not modified (hakacin 
and MccB17),113, 182 but it is not clear if this is due to a length requirement or the flanking residues.  
The other caveat is that the core region must be long enough to reach into the active site of the 
YcaO protein when the leader peptide is bound. Although the leader peptide is responsible for driving the 
formation of the enzyme-substrate complex, the binding site of the canonical cyclodehydratases is in a 
different protein domain from the active site.18, 27, 185, 593 This means that spatially, there must be a spacer 
region between the residues in the leader peptide that interact directly with the RRE and the core residues 
which are modified. Indeed, shortening the distance between crucial leader peptide residues and the first 
cyclizible residue has been shown to reduce heterocyclization for the MccB17 synthetase.638 The spacer 
region in MccB17 contains a Gly10 sequence (Figure 1.5). Deletion of one or three Gly resulted in 5-fold 
and 13-fold decreased heterocyclization rates, respectively, whereas inserting one additional Gly (Gly11) 
enhanced heterocycle formation 2-fold.638 Substrates lacking more than thee Gly were only partially 
processed, whereas no heterocycles were detected when the spacer was reduced to three Gly.638 Generally 
the composition of these spacer regions is not important as demonstrated for cyanobactin 
cyclodehydratases. Insertions of protease signatures and extensive site directed mutagenesis has no 
observable effect upon processing.592, 636 In hindsight this was not surprising since PatE, the natural substrate 
of the cyanobactin cyclodehydratase PatD, contains two core peptides within the same precursor peptide, 
but only a single leader peptide. By definition, the two core peptides have very different numbers and types 
of intervening residues. Thus, while extensions are generally tolerated, there is a certain minimum 
requirement. 
 
1.6.3.6 Leader peptide recognition and binding site 
The natural hypervariability of RiPP core peptides indicate cyclodehydratases are able to process Cys with 
few restrictions.581, 642 It would appear that the core peptide can be varied almost at will and that a 
cyclodehydratase can be found to convert Cys within the core sequence.113, 173, 182, 592, 595, 636 In contrast to 
the promiscuity within the core peptide, cyclodehydratases have specific requirements for the leader peptide 
(this is removed during processing to the final product). It is this specificity that drives binding of the correct 
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peptide so that other peptides within an organism are not erroneously cyclodehydrated. Although the active 
site must have some sufficient affinity for the core region to catalyze azoline formation, the core does not 
appreciably add to the binding affinity of the overall peptide.173 It would seem that orientation of the core 
peptide into the active site by the leader region upon binding is sufficient for catalysis, but the exact 
mechanics of this process are unknown. Beyond binding and orienting the core, the leader also appears to 
activate the cyclodehydratase (see below). 
The leader peptide has been known to be important for RiPP cyclodehydratases since the study of 
the MccB17 machinery, in which two key hydrophobic residues were identified as crucial for binding 
(Phe12 and Leu16, Figure 1.5).643 These residues were later recognized as part of an important binding 
FXXXB motif (B is any branched chain amino acid) that is found in many LAPs.136  Conservation of this 
leader motif enabled the cytolysin azole synthetase to process non-cognate precursor peptides from other 
LAP pathways.136 However, LAP precursor peptides are usually highly divergent between different families 
as demonstrated by a PXX(L/V) motif found to be important for binding of the PZN precursor peptide by 
its synthetase (Figure 1.7).173 However, given the promiscuity of processing, as long as the native leader 
peptide is present, core peptides from different LAP pathways have been shown to create functional 
chimeric precursor peptides, albeit with different degrees of success.136, 173, 182 
The key residues within the leader peptide of cyanobactins have also been mapped out based on 
bioinformatic, biochemical, and structural data.592, 595, 601, 636 These studies have identified the crucial part 
of the leader is a LAELSEEAL-like sequence, and given the generally high similarity of cyanobactin 
precursor peptides, most contain this motif and can be moved from one pathway to another.644 The 
thiopeptides also tend to have similar leader sequences, with a region rich in hydrophobic and acid residues, 
that were recently shown to be important for binding by the cyclodehydratase.632 Given its role in binding, 
the leader peptide is sensitive to variation of residues within these important recognition regions .  
Although the leader peptide is crucial for activity, some cyclodehydratases have shown the ability 
to act on leaderless substrates, albeit it less efficiently.183, 185, 592, 636 Interestingly, for patellamide-like 
substrates lacking the leader peptide, the cyanobactin azole synthetase could only processed one position: 
the most C-terminal Cys.592, 636 The addition of exogenous leader peptide was shown to accelerate the rate 
at which the enzyme processed the terminal Cys while also partially restoring heterocyclization elsewhere 
in the peptide substrate.592, 636 These studies suggested that leader peptide binding may allosterically activate 
the cyclodehydratase as the leader peptide has been shown to enhance processing of leaderless core peptides 
in other cases.183, 185, 593, 636 This has also been demonstrated for other unrelated RiPP subclasses like the 
lanthipeptides.645  
Beyond these findings, the most powerful insights came from crystallization of the LynD 
cyclodehydratase bound to its leader peptide. This structure showed that the highly conserved region of the 
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cyanobactin leader peptide was bound to the first domain within the cyclodehydratase, with a few minor 
contacts to the third (YcaO) domain (Figure 1.41). 593 This binding mode was first structurally characterized 
in nisin biosynthesis (NisB protein),205 where the leader peptide adopts a similar -strand conformation on 
the exposed edge of the -sheet region of the conserved, PqqD-like peptide-binding domain of the 
enzyme.27 Noticeably, binding of the leader seems to induce a change in conformation, possibly providing 
an explanation for its enhancement of catalysis.593 The domain that binds the leader peptide is conserved in 
all cyclodehydratases and in many other RiPP modifying enzymes, and is denoted as the RiPP precursor 
peptide recognition element (RRE).27 For example, the RRE domain is found in the aforementioned NisB 
and in the PatG protein of the patellamide pathway where it precedes the dehydrogenase domain. The 
appearance of this conserved RRE domain in very different enzyme reactions, suggests the RRE and the 
leader peptide evolved distinctly from the cyclodehydratase reaction. What links these enzymes is the 
physical and spatial separation of recognition from catalysis. The normal intimate connection between 
recognition and catalysis, shaped by evolution of enzymes and their substrates, often limits the use of 
enzymes as catalysts since mutations that alter recognition often reduces catalysis. With the use of the RRE 
domain and disposable leader peptide, nature has evolved an elegant strategy to have enzymes with very 
broad substrate profiles as previously discussed. 
  
1.6.3.7 ATP Analogs 
Although heterocyclization in azol(in)e-containing RiPP pathways was originally shown to be an ATP-
dependent reaction,621 subsequent investigations have established there is some flexibility in the 
triphosphate nucleotide that can be used to catalyze the reaction. The LAP cyclodehydratases BalhD, 
McbBCD and the cyanobactin cyclodehydratase TruD have each been shown to accept GTP.17, 592, 621 TruD 
has been shown to be active with dTTP592 as well, but curiously dTTP only supported heterocyclization of 
the single terminal Cys. Crystal structures of LynD in complex with three different nucleotides, AMP, 
ADP/Pi and AMPPNP, and the Ec-YcaO in complex with AMP and AMPCPP have been determined.18, 593 
In all structures, the adenosine ring is bound in essentially the same fashion, predominantly through cation-
π stacking and van der Waals interactions (Figure 1.42).593 The analysis of the crystal structures reveal a 
lack of specific hydrogen bonding between the protein and the adenosine base which rationalized the ability 
of the YcaO domains to accept other nucleotide triphosphates as co-substrates.18, 593 The phosphate groups 
are, however, specifically coordinated by metal ions which bridge to the protein. 
 
1.7 Non-canonical YcaOs 
In contrast to the BGCs discussed above, a significant number of YcaO family members are present in 
genomic contexts that deviate from the established patterns of characterized YcaOs. Specifically, many 
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YcaOs in the sequence databases do not occur near  or fused to an E1-like646, 647 or ThiF-like partner proteins 
(Figure 1.30),648  Given that these partner proteins are essential for azoline-formation, it would suggest 
these most of these other types of YcaOs are not involved in azoline formation, unless they are able to act 
as a standalone YcaO. As discussed in the Introduction (section 1.1), not all protein superfamilies are iso-
functional so it cannot be assumed that all YcaO proteins participate in thiazoline/oxazoline formation. 
Thus, to differentiate the different types of YcaOs, we have introduced a nomenclature based on the inferred 
function and whether there is an identifiable protein that co-occurs with the YcaO. These features are crucial 
because the function of the active site and whether a protein complex is required for activity will have a 
profound effect on the conserved motifs present in each type of YcaO. Moreover, establishing these 
categories is useful when predicting function for large numbers of bioinformatically-identified YcaOs for 
which only a genome is known because when a function is inferred for one type of YcaO, the similarity of 
a new YcaO sequence to the different types can help assign its function.647 
Examples of YcaOs that act without an E1-like or ThiF-like partner have been markedly less well-
characterized than their more established azoline-forming YcaO counterparts. However, local genomic 
neighborhoods and connections to intriguing natural product structures suggest that these less-studied types 
of YcaOs could harbor distinct functions or biosynthetic capabilities. For example, in addition to the 
plasmid-born BGC for MccB17 (in section 1.2.1), E. coli also encode a YcaO protein (Ec-YcaO) that does 
not appear to be related to natural product biosynthesis based on the identity of its flanking genes, although 
it does utilize-ATP (section 1.7.1).18 Current evidence suggests a role in enhancing RimO-dependent -
thiomethylation of ribosomal protein S12 and is postulated to function as a scaffolding protein.23 However, 
no mechanism has been proposed for how ATP might be used so Ec-YcaO remains an enigmatic YcaO. As 
another example, the bottromycin BGC encodes two YcaO proteins with no obvious candidates for partner 
proteins. Seeming to correspond with the two YcaOs, the structure of bottromycin includes two amide 
backbone modifications: a thiazoline and amidine. There is no clear cyclodehydratase partner protein so 
the azoline-forming YcaO has been classified as “standalone.” The nature of the second, putative amidine-
forming YcaO is not clear (section 1.7.2). For a final example of new biosynthetic modifications, the 
thioviridamide BGC contains a YcaO but is associated with thioamide formation (section 1.7.3). Lastly, 
this section also covers the molecule trifolitoxin, which does not have a fully elucidated structure, but the 
partial structure includes a thiazoline. Based on its BGC and the lack of any partner proteins, this appears 
to be another instance of a standalone azoline-forming YcaO (section 1.7.4).18  
 
1.7.1 Escherichia coli enigmatic YcaO 
The YcaO from E. coli (Ec-YcaO) has a cryptic function and is thus categories as an enigmatic YcaO. 
Unlike those involved in typical azoline formation, this YcaO does not seem to be in a RiPP BGC and lacks 
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a partner protein.18 Although the exact function of this YcaO is not known, it has been implicated in a post-
translational modification of ribosomal protein S12.  
The S12 ribosomal protein, a component of the 30S subunit, contains an Asp88 residue that is 
universally conserved across all domains of life and known to be crucial for organism viability. In select 
organisms, such as Rhodopseudomonas palustris649 and Thermus thermophilus,650 the Asp88 residue was 
found to be β-thiomethylated in vivo, whereas in eukaryotes this modification is not present.651, 652 Studies 
have shown that RimO, a member of the radical SAM superfamily, is responsible for β-thiomethylation of 
S12-Asp88.653 RimO is homologous to MiaB, an enzyme involved in the β-thiomethylation of tRNA.654  
Affinity enrichment experiments using recombinant E. coli S12 protein demonstrate the expected 
association with RimO, but the Ec-YcaO and several other proteins, were found to co-purify as well. 
Deletion strains lacking RimO and YcaO were then analyzed for the relative amounts of S12 β-
thiomethylated Asp88 by quantitative mass spectrometry. The strain lacking RimO contained no detectable 
level of Asp88 β-thiomethylation while the strain lacking the YcaO showed an 18% reduction.655 It is 
hypothesized that this YcaO functions in a multi-protein complex with S12 and RimO, although the details 
of the mechanism have not yet been elucidated and will require more effort to firmly establish the role of 
YcaOs in S12 modification. 
Despite being associated β-thiomethylation, the actual function of Ec-YcaO is unknown. It does 
hydrolyze ATP in vitro with KM comparable to other characterized YcaOs and has had its structure solved 
by X-ray crystallography (Figure 1.43).18 This structure was the first conclusive evidence for the site of 
ATP binding in YcaO proteins and revealed that the region around this binding site was conserved among 
all members of the YcaO superfamily. For example, even though Ec-YcaO has only 20% identity to the 
azoline-forming YcaO from Bacillus sp. Al Hakam (BalhD), the sequence conservation is centered around 
the ATP binding site, and mutation of the corresponding residues in BalhD abolish ATP binding and 
cyclodehydration activity. Furthermore, comparison of the Ec-YcaO structure and the cyanobactin 
cyclodehydratases TruD656 and LynD593 further verify the conservation of structure and ATP-binding site 
predicted based on sequence homology. These results suggest that insights from one YcaO protein, 
regardless of any potential involvement in natural product biosynthesis, can inform broadly on other YcaOs. 
 
1.7.2 Bottromycin standalone YcaOs 
The bottromycin family of natural products was first reported in 1957 from Streptomyces bottropensis.657 
The proposed structure of bottromycin underwent several revisions. Initially proposed to be a linear 
peptide,658-660 the major bioactive component bottromycin A2 was later determined to contain several non-
proteinogenic amino acids and a macroamidine.661 On the basis of 15N-NMR, the macrocycle vertex was 
determined to be located in between two t-butyl-containing amino acids, consistent with condensation 
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between the N-terminus and a backbone amide carbonyl.662 Minor congeners bottromycin B2 and C2 
displayed different methylation patterns.663 The structure of bottromycin A2 was finally confirmed by total 
synthesis, which also resolved any stereochemical ambiguity.664 Several notable structural features include 
the 12-membered macroamidine, Asp O-methylation/epimerization, and a single thiazole that are shared by 
all currently known members (Figure 1.44). The variation in structure of the analogs comes from differing 
patterns of Pro, Val, and Phe β-methylation.  
The antimicrobial properties of bottromycin have been described since the initial isolation reports, 
but characterization of its activity has, like its structure, been incremental over decades. Bottromycin A2, 
whose biological activity is best characterized, was found to have extremely potent antimicrobial activities 
against Mycoplasma gallisepticum,665 methicillin-resistant Staphylococcus aureus (MRSA), and 
vancomycin-resistant Enterococcus (VRE)664 with MIC of 12 nM, 1.2 µM, and 0.6 µM, respectively. 
Studies to elucidate the mechanism have indicated a role in protein synthesis inhibition, as demonstrated 
by synthetic polynucleotide in vitro translation systems, which localized bottromycin A2 binding to the A-
site of the 50S subunit.666, 667 Moreover, experiments on polysomes showed both a lack of inhibitory activity 
towards the translocation and peptidyl transferase steps, but released aminoacyl-tRNA.668, 669 Hence, 
bottromycin is believed to interfere with the binding of charged aminoacyl-tRNA to the ribosome, and as 
such, would act in a manner distinct from other ribosome translation inhibitors such as erythromycin (which 
does not bind to the A-site), tetracycline, and micrococcin (which interact with the A-site, but neither release 
aminoacyl-tRNA).668 
Efforts to explore the structure-activity relationship have demonstrated the importance of the Asp-
derived methyl ester in biological activity. Amide derivatives of bottromycin B/C outperformed ester 
analogs in assays against S. aureus in vivo, while esters tended to be more active than amides in vitro, 
suggesting a possible difference in pharmacokinetic properties.660 Indeed, upon addition of bottromycin A2 
in mouse plasma, rapid degradation of the side chain ester to acid was observed (compared to a chemically 
hydrolyzed standard), and hypothesized to contribute to the poor antimicrobial efficacy.670 Additional 
amide, thioester, and ketone derivatives of bottromycin A2 at this position recapitulated these trends: the 
thioester analogs showed the lowest plasma stability, but most potent MIC values. Conversely, the ketone 
analogs showed equivalent in vitro activity (compared to the original natural product), with better plasma 
stability compared to the thioesters. 
 Upon genome sequencing of producing organisms, bottromycin’s complex structure was found to 
originate from a ribosomal precursor peptide, cementing its identity as a RiPP. Whole genome sequencing 
of Streptomyces bottropensis38, 671 and Streptomyces sp. WMMB272672 uncovered the BGC by matching 
peptides with the deduced sequences for bottromycin A2/B2/C2 (GPVVVFDC) and bottromycin D 
(GPAVVFDC). Heterologous expression confirmed that these BGCs were indeed responsible for 
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bottromycin biosynthesis. For Streptomyces sp. WMMB272, mutagenesis via a shuttle vector was 
employed to mutate the bottromycin D core peptide Ala3 to Val3, resulting in the production of bottromycin 
A2 from the native producer. An additional bottromycin BGC was identified in Streptomyces scabies, which 
showed significant sequence similarity to the ones from S. bottropensis and S. sp. WMMB272.673 Unlike 
the vast majority of RiPPs, the bottromycin precursor peptide displays an N-terminal core sequence and, 
instead of an N-terminal leader peptide, the precursor has a C-terminal extension called a “follower” 
peptide, which presumably contains residues required for binding and subsequent modification by the 
biosynthetic enzymes.38  
The current proposed biosynthetic pathway for bottromycin was deduced using heterologous 
expression systems and untargeted metabolomics approaches (Figure 1.45). Individual deletions of the three 
radical SAM methyltransferases halted production of bottromycin A2 and produced either B2, D2 or E2, 
allowing the roles of each radical SAM to be assigned.674 From mass spectral network analysis of 
metabolites produced by strains individually lacking each standalone YcaO, among other tailoring genes, 
a more complete picture of bottromycin biosynthesis was revealed. Thiazoline formation was indeed 
dependent on the YcaO encoded next to the precursor peptide (Figure 1.44), thus this protein is established 
as a standalone azoline-forming YcaO. Also confirmed was that the all of the -methylation events occur 
prior to macroamidation, which is consistent with their functions being follower peptide-dependent.27 
Conversely, thiazoline oxidation and O-methylation occur late in the maturation pathway.631 The genes 
required for macroamidine formation include the second YcaO and a putative macrocyclase partner with 
similarity to amidohydrolases; therefore, these proteins were proposed to act together in macroamidine 
formation.15 The nature of their interaction has not yet been characterized so it is uncertain if the hydrolase 
should be considered a YcaO partner protein, analogous to the E1-like protein in RiPP cyclodehydratses. 
The involvement of a YcaO in transforming an N-terminal Gly and internal Val into a macroamidine is 
clearly distinct from the cyclodehydration of Cys, Ser, or Thr, but at a conceptual level, there is a clear 
similarity; in both cases a nucleophile attacks the peptide bond, formally eliminating water in an ATP-
dependent process (Figure 1.46).  
 
1.7.3 Thioviridamide TfuA-associated YcaO 
During bioassay-guided isolation for compounds with antitumor activity, a novel natural product was 
isolated from Streptomyces olivoviridis. This compound, thioviridamide, was reported to induce apoptosis 
selectively against two oncogene-expressing cell lines as well possessing antibiotic activity.675 Structural 
elucidation revealed thioviridamide contained several unusual functional groups, including a 2-hydroxy-2-
methyl-4-oxopentanoyl moiety, five peptide backbone thioamides, β-hydroxylation and N1, N3-
dimethylation of His, and an S-(2-aminovinyl) Cys macrocylization (Figure 1.47).676 The latter modification 
66 
 
has been previously observed in other RiPPs677 including gallidermin, mutacin 1140, mersacidin, and 
cypemycin, suggesting that thioviridamide would also be of ribosomal origin.  
Thioviridamide was confirmed to be a RiPP after sequencing the S. olivovidiris genome and 
identification of the precursor peptide, TvaA, which contained the core sequence VMAAAASIALHC. 
Heterologous expression in S. lividans confirmed the gene cluster tvaA-O to be responsible for 
thioviridamide biosynthesis. Of these genes, tvaH belongs to the YcaO superfamily, although 
thioviridamide contains no azolines. Moreover, no genes in the tva cluster are similar to known partner 
proteins (E1-like or Ocin-ThiF-like) normally associated with azol(in)e biosynthesis, further underscoring 
a distinc role for this YcaO. The authors suggest that thioamide formation may be catalyzed by tvaH, 
representing the first example of a thioamide-forming YcaO. Interestingly, TvaI which is annotated as a 
“TfuA-like” protein is often found immediately adjacent to a YcaO protein in many other genomic contexts 
which has also given rise to this type of YcaO being referred to as TfuA-associated YcaOs.18  
 The potential for a thioamide-forming reaction is fascinating, because if it does indeed follow the 
proposed YcaO-like chemistry (Figure 1.42), then the atom which ultimately replaces the peptide backbone 
oxygen is not substrate-derived but rather exogenously delivered in a form chemically equivalent to H2S. 
If the YcaO domain is confirmed to carry out this transformation, it would significantly enhance the 
synthetic scope of this enzyme superfamily, since one could imagine other types of nucleophiles being used 
in similar ways.  
 
1.7.4 Trifolitoxin standalone azol(in)e-forming YcaO 
Because plant growth is generally limited by access to mineral nitrogen (NO2–, NO3–, NH4+), many plants 
form symbiotic relationships with nitrogen-fixing bacteria.678, 679 This symbiosis is especially prevalent 
among legumes because most are able to form special structures in their roots (i.e. nodules) that provide 
bacteria with an exclusive living space and nutrients in exchange for fixed nitrogen, in the form of 
ammonium or Ala.678, 679 Nitrogen-fixing bacteria of this variety are generally referred to as Rhizobia, and 
the region in or around plant roots is known as the rhizosphere.678, 679 Living in root nodules is advantageous 
due to the supply of nutrients from the host, so Rhizobium leguminosarum bv. trifolii T24 produces a 
bacteriostatic, anti-Rhizobial compound named trifolitoxin (TFX) that inhibits the growth of other 
Rhizobia, which provides a competitive edge in colonizing root nodules.680-686  
Investigation into the genetic components responsible for TFX production revealed that 
tfxABCDEFG, were necessary to confer TFX production and resistance,687-689 but an additional gene, tfuA, 
located outside of the BGC, was later also found to be involved (Figure 1.48). Based on sequence similarity, 
TfxB, TfxC, and TfxF are oxidoreductases.27 TfxD has weak similarity to multidrug and toxic compound 
extrusion (MATE)-like proteins, but its deletion results in a strain that does not produce TFX but retains 
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TFX resistance. TfxE is considered a standalone azoline-formingYcaO protein since it is the only candidate 
for installing the thiazoline ring in TFX. Deletion of TfxE causes sensitivity to TFX;690 however, it was not 
reported if this strain was deficient in TFX production. Intriguingly, no E1-like or Ocin-ThiF-like protein, 
is present in the TFX BGC, so it is presently unclear if TfxE forms the thiazoline as a standalone protein or 
if an additional, unidentified partner protein is required. TfxG is related to protein kinases and has an 
undescribed role in producing TFX isomers.690 Some TfxG homologs have been implicated in alkali 
tolerance in Sinorhizobium meliloti, but such organisms lack all other TFX genes so this relationship is 
likely unrelated to any potential role in TFX biosynthesis.691 One final distally encoded gene, tfuA, also 
appears related to production of TFX, as insertional mutagenesis of this gene was reported to abolished 
TFX production, but how it affects the biosynthesis is unknown since it is not required for TFX production 
in heterologous hosts.692 It should be noted that this R. leguminosarum tfuA gene is what gave rise to the 
naming of TfuA-like proteins (i.e. TvaI thioviridamide biosynthesis, Figure 1.47); however, the “TfuA-
like” protein has no sequence similarity to the R. leguminosarum TfuA (GenBank accession AAB17513), 
which instead has transcriptional activation, TolB, and multiple TPR repeat domains. The two genes 
downstream of tfuA (accession: AAB17513) in R. leguminosarum are homologous to TvaH (YcaO; 
AAB17514) and TvaI (“TfuA-like”; AAB17515) but are completely unrelated to TFX production so we 
believe an error was made when the TfuA-like genes were originally named. In fact, we predict that in 
addition to TFX, R. leguminosarum may possibly also produce a thioamide-containing RiPP. 
Despite the isolation and purification of mature TFX, the chemical structure remains elusive. A 
partial structure is available, but Arg and Gln are posttranslationally modified to form an unknown 
chromophore.693 Expression of precursor peptides in a tfxA deletion strain has allowed introduction of non-
native precursor peptides to investigate the pathway. These experiments showed that substitution of Arg, 
Gln, and Cys lead to loss of activity. The C-terminal Ala of TFX is also crucial for activity.694  
 
1.8 Biotechnology 
The biotechnological interest in YcaO proteins has centered on their ability to produce RiPPs with diverse 
biological activities. This has driven, and to some extent, justified the interest in azol(in)e-containing RiPP 
biosynthetic pathways and RiPPs more generally. In practical terms, purification of RiPPs from the natural 
producer in sufficient quantities for detailed pharmacological or medicinal chemistry studies is not practical 
for most compounds. Total chemical synthesis to make analogues with more desirable properties is also not 
attractive due to the chemical complexity of these natural products. Since heterocyclization profoundly 
changes the chemistry and structure of a compound,577 such modifications are essential for the biological 
activity of the natural product. This means that quickly accessing a broad range of azol(in)e-modified 
peptide variants requires use of the native biosynthetic systems. 
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For many complex biomolecules, engineering their pathways to produce new variants is well 
established, but often the diversity is limited because enzymes have coupled catalysis with recognition at 
the same site. The combinatorial nature of RiPP biosynthesis suggests RiPPs may be particularly suitable 
for biotechnological exploitation. The separation of substrate binding from catalysis by using the leader 
peptide, which is removed from the final product, and the presence of the RRE permit variation in the final 
product, including non-natural elements, while relying on enzyme catalysis. These factors make RiPPs 
easier to engineer for library generation and the production of new bioactive peptides compared to other 
enzyme systems, in which substrate binding and catalysis are mediated by the same site.  
There are multiple approaches to further developing azol(in)e-containing RiPPs. One approach is 
genome mining and genetic engineering to combine enzymes and substrates in new ways to make novel 
molecules, as exemplified by the work of Schmidt and colleagues.49, 50, 584, 599, 695, 696 These approaches are 
flexible and can be combined with amber codon suppression technology to include unnatural amino 
acids.230, 599, 697 The use of unnatural amino acids has even allowed the creation of derivatives which can be 
labeled with fluorophores or other tags to aid in mode of action studies or visualization in cells.230, 599 In 
general, in vivo combinatorial biosynthesis has seen been successful in generating diverse molecules given 
the wide ranges of compounds detected in culture which could be screened for desired activity. A few 
individual compounds have been made in quantity, isolated and characterized using these methods,599 but 
the success is limited as an acknowledged drawback is the low yields of most compounds made in this way 
and the difficulty in their isolation. Thus, efficiently obtaining milligram quantities of a library of pure 
compounds by this approach remains a major obstacle.  
However, a recent breakthrough in the culture conditions for cyanobactin pathways, by 
augmentation with Cys, increased the cultured yield of patellins by over 150 fold.695 Addition of mevalonate 
further increased the yield of final product. The effect of these compounds was not due to a simple increase 
in substrate peptide, whose stability and expression level remained unaltered. The study also ruled out 
changes to redox or energy status in the cell.695 The authors concluded from an in vitro experiment, that 
sulfide derived from Cys regulated the activity of one enzyme, and by ensuring it acted at the correct point 
in the sequence of biosynthetic events, greatly increased the yield of the final desired product.695 If this 
approach is indeed general then it will transform in vivo production and the insights into the critical nature 
of the timing of the reactions have wider implications. 
Other azol(in)e-containing RiPPs have also been produced through heterologous expression and 
have potential for making new bioactive molecules through precursor peptide reprogramming.178, 342, 361 
Heterologous expression of the LAP BGC of PZN has been carried out. PZN (section 1.2.3) is normally 
produced by Bacillus velezensis and has antibiotic activity against Bacillus anthracis. A large array of 
substrates for the pathway were made by varying the sequence of the precursor peptide in an E. coli 
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heterologous expression system, and 11 compounds were tested for their biological potency.178 New 
thiocillin and GE37468 derivatives have also been made and tested in a similar fashion.262, 267, 342, 361  
As an alternative to in vivo approaches discussed above, the possibility of combining enzymes in 
vitro has been explored.596, 644 The patellamide system has attracted considerable attention in this regard.48 
As a consequence of the structural and biochemical characterization of the enzymes,585 it has been possible 
to replicate the biosynthesis of patellamides. Fourteen patellamide-like precursor peptides were processed 
in vitro by either TruD or PatD, and subsequently other, cyanobactin biosynthetic enzymes. Taking 
advantage of the different chemoselectivities of the enzymes, the result was 16 new, non-natural 
patellamide analogues, 13 of which contained different amino acid sequences from the natural 
compounds.596 Chemically synthesized peptides with non-peptidic moieties such as polyketide-like linkers 
or triazoles have been macrocyclized by the PatG protease.602, 698 An early drawback to these in vitro 
approaches was the slow kinetics of the enzymes, most particularly the protease, PatA, which removes the 
leader peptide. The reason for the inefficient turnover is unclear, although recent studies indicate that PatA 
is redox sensitive.595, 695  A structural study also showed that the catalytic triad was not optimally aligned.586 
This problem can also be overcome by removing reducing agents from in vitro reaction, which are usually 
added to prevent disulfide bond formation in their Cys-rich precursors. This enabled one-pot synthesis of 
cyanobactins using purified enzymes and the creation of unnatural derivatives.595 Another approach for in 
vitro biosynthesis is to insert an alternative protease site between the core peptide and the leader and swap 
PatA for another protease (both trypsin and tobacco etch virus have been used),596 and thus a non-cognate 
protease can be used, greatly accelerating the process. 
Another improvement to in vitro generation of cyanobactins was the design of a biosynthetic 
scheme that does not require the leader peptide. Normally, the leader peptide is necessary for processing 
multiple Cys and, due to the cost of synthesizing the longer leader peptide-containing peptides, the number 
of substrates tested in vitro would be limited. However, the discovery that the addition of the leader peptide 
in trans activated the cyclodehydratase, such that it could process substrates without the leader636 stimulated 
further investigation. The significance of this was that by dispensing with the leader peptide altogether, one 
could move to much shorter substrate peptides that could be made entirely synthetically, allowing for 
greater levels of diversification. Inspired by the trans activation of the cyclodehydratase and informed by 
the structure of LynD from Lyngbya sp., this cyclodehydratase was engineered such that a portion of the 
leader peptide was fused to the N-terminus of the enzyme.593 The fused enzyme was almost as active on 
leaderless substrates and the native enzyme on full-length substrates (Figure 1.49). Crucially, the fused 
enzyme was able to completely process the substrates rather than producing mixtures.593 With the need for 
a leader peptide alleviated, the process of exploring the synthetic utility of the enzymes can now begin for 
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substrates which can be made in cost-effective manner by solid-phase chemical synthesis and the results 
could be of high impact.  
In addition to the cyanobactin examples discussed above, total in vitro biosynthetic reconstitution 
of other azol(in)e-containing RiPPs has also been achieved. The first example was with a MccB17 analog 
which could not be produced in vivo so the peptide was purified and treated with the azole synthetase and 
digested with commercial proteases to test the activity of the new compound.113 Along the same lines, a 
combination of in vitro biosynthesis and synthetic modification has been used produce a PZN derivative 
named CZN.173 However, a most complicated example is the recent case of the total in vitro biosynthesis 
of a thiomuracin derivative (a thiopeptide). The core scaffold of thiomuracin (termed thiomuracin GZ) was 
formed entirely through in vitro reconstitution of the core thiopeptide biosynthetic genes from 
Thermobispora bispora.45 Although thiomuracin GZ lacks many of the additional tailoring steps, it has 
comparable bioactivity to naturally produced thiomuracins and thus indicated that even more complex 
products are within the realm of total in vitro biosynthesis.45 Moreover, in vitro approaches allow increased 
enzyme concentrations and control compared to in vivo heterologous systems which can lead to increased 
range of product generation.45, 173  
Although much focus has been put on enzymes from azol(in)e-containing RiPP pathways for their 
ability to produce new potential natural products, their mechanisms can be taken advantage of in vitro to 
accomplish different ends. This is most clearly demonstrated by the AMPL methodology previously 
described (section 1.6.2.2). This method takes advantage of the mechanism of azoline-forming YcaOs to 
install thioamides or [18O]-labeled amides into peptides for downstream biochemical investigations (Figure 
1.34).183 
 
1.9 Summary and outlook 
Nature has settled on proteins, polymers of amino acids linked by amide bonds, to provide the bulk of the 
biomaterial that makes life possible. The chemical properties of the amide bond is taught to all 
undergraduate chemistry majors as an example of how resonance structures stabilize molecules and impart 
new chemical properties. Unlike ketones and most other carbonyl groups, the amide carbon is not 
particularly electrophilic, and unlike amine relatives, the amide nitrogen atom is not particularly basic or 
nucleophilic. Consequently, the amide bond is very stable and a good choice by nature for the framework 
of proteins that carry out life processes. Indeed, specialized catalysts (proteases) or harsh base or acid 
treatments are required to hydrolyze the relatively inert amide bond. The ability of the YcaO superfamily 
to perform chemistry on the peptide backbone is thus of considerable scientific interest. When one thinks 
of a posttranslational modification, most think of a side chain modification. When YcaOs are at work, it is 
the main chain that undergoes modification. Moreover, this ability within the functionally diverse 
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superfamily is unified through a common structural fold that binds ATP for the activation of peptide amide 
bonds. This role has been studied most extensively in natural product biosynthesis for the creation of azoline 
heterocycles from the peptide backbone. Although some azoline-forming YcaOs have been extensively 
characterized, there remain some key questions, such as an unambiguous description of the transition state, 
a molecular rationale for the order of heterocyclization, and how some YcaOs act without a partner protein 
or RRE to manage substrate recognition. We have also highlighted the emergence of thioamide-forming 
and amidine-forming YcaOs. These enzymes utilize different nucleophiles from the better characterized 
azoline case (Figure 1.46). How these transformations occur, and what other proteins might participate in 
these reactions will be of considerable future interest. The new insight into these processes will likely reveal 
unique protein chemistry and set new precedents for biological catalysis.  
In addition to studying YcaOs associated with non-canonical functions, further exploring azoline-
forming YcaOs in BGCs with no known product also promises to be a fruitful endeavor. The relationship 
between natural product structure and YcaO similarity, means that identifying the product of a YcaO in one 
BGC often informs on other sequence similar YcaOs. Current estimates of the abundance of azoline-
containing RiPP BGCs indicate that the majority remain to be discovered.699, 700 Already YcaOs have shown 
their versatility in coordinating modifications with other primary modifying enzymes like dehydratases  (i.e. 
thiopeptides) and macrocyclizing proteases (i.e. cyanobactins) so new combinations with other modifying 
enzymes may be found in nature to produce entirely different molecular structures. With all these exciting 
opportunities for discovery related to YcaOs, their products, and their mechanism, we anticipate a wealth 
of new discoveries that will expand our knowledge of this impressive superfamily. 
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1.11 Figures 
  
Figure 1.1 (a) Generic RiPP pathway. (b) Overview of common steps in maturation of RiPP natural 
products. (c) Example of a posttranslational modification within a RiPP biosynthetic pathway. Here, a 
peptidic azoline is generated by the ATP-dependent cyclodehydration of a Cys, Ser, or Thr residue. This is 
the best characterized function for a YcaO protein.  
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Figure 1.2. Overview of YcaO superfamily. Asterisk denotes putative functions. 
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Figure 1.3 Representative thiazole-containing compounds that are of non-ribosomal or synthetic origin. 
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Figure 1.4 Derivatization of the thiopeptide GE2270A enhances water solubility (in parentheses). 
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Figure 1.5 Microcin B17 biosynthesis and structure. (a) BGC for MccB17 (b) Precursor peptide sequence 
of McbA and structure of MccB17. The two bisheterocyclic sites are known as the A- and B-sites. (c) 
Biosynthetic scheme for the cyclodehydratase/dehydrogenase. 
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Figure 1.6 Streptolysin S biosynthetic components. (a) Representative BGCs for members of the SLS-like 
cytolysin family. (b) Precursor peptide sequences. The leader peptide cleavage site is unknown but 
suspected to be directly N-terminal to the NPH region in the core region. The final structure for any 
cytolysin remains unknown. 
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Figure 1.7 Plantazolicin biosynthesis and structure. (a) PZN BGC from Bacillus velezensis. (b) Structure 
of PZN and sequence alignment of precursor peptides. 
 
 
 
  
Figure 1.8 The synthetic Me2-Arg-Az5 analog of PZN. 
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Figure 1.9 Hakacin biosynthetic components. (a) Representative hakacin BGCs (b) Precursor peptide 
sequences for BalhA1 and BalhA2 with emphasized heterocyclizible residues. The final structure for 
hakacin is also unknown. 
 
 
 
  
Figure 1.10 HCA biosynthetic components. (a) Heterocycloanthracin (HCA) gene clusters from related 
Bacillus organisms. (b) Sequence of HcaA from B. sp. Al Hakam. 
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Figure 1.11 Azolemycin biosynthesis and structure. (a) Azolemycin BGC. (b) Precursor peptide and 
structure for azolemycin A. 
 
 
 
 
 
Figure 1.12 Goadsporin biosynthesis and structure. (a) The goadsporin BGC. (b) Precursor peptide and 
structure for goadsporin. 
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Figure 1.13 Overview of thiopeptide biosynthesis and macrocycle architecture. (a) Thiopeptide BGC 
highlighting the enzymes that form the minimal thiopeptide scaffold. (b) Structure of micrococcin P1  with 
hallmark modifications color-coded: YcaO-catalyzed cyclodehydration (blue), lanthipeptide-like 
dehydrations (purple) and [4+2] cycloaddition (orange). The four-ring motif important for TipA recognition 
is also highlighted (red). (c) Biosynthesis of the 6-membered nitrogenous heterocycle and corresponding 
series designations.  
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Figure 1.14 Thiopeptide secondary macrocycles. (a) Quinaldic acid derived ring in siomycin (red). (b) 
Indolic acid derived ring in nosiheptide (blue). (c) Thioether crosslink formed ring in cyclothiazomycin 
(purple). Attachment points to the main scaffold are highlighted (yellow). 
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Figure 1.15 Formation of quinaldic (a) and indolic (b) acid moieties. 
 
 
 
 
 
Figure 1.16 Two mechanisms of thiopeptide C-terminal amidation illustrated from nosiheptide (a) and 
thiostrepton (b) biosynthesis. 
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Figure 1.17 Sequence comparison of the core regions for all known thiopeptides. Thiopeptides with the 
same precursor peptide vary in ancillary tailoring to give different compounds. Groups of related 
thiopeptides are separated based on azol(in)e position (gray shading), ring size, and secondary ring. Group 
representatives are in bold font. Azol(in)e, blue; dehydroamino acids, orange; piperidine/pyridine, green; 
secondary ring, magenta. aName of the most common congener or parent compound. bCore sequences are 
from BGCs or inferred from the structure of the mature product. cThe number of atoms in the primary 
macrocycle. dThe moiety that serves to link the secondary side ring to the primary macrocycle. eKnown 
BGC. 
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Figure 1.18 Thiostrepton biosynthesis and structure. (a) Thiostrepton BGC. (b) Precursor peptide and 
structure for thiostrepton A. 
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Figure 1.19 Nosiheptide and nocathiacin biosynthesis and structure. (a) BGCs for nosiheptide and 
nocathiacin. (b) Precursor peptide and structure of nosiheptide with characteristic, thioester-linked indole 
macrocycle. (c) Precursor peptide and structure of nocathiacin with characteristic glycone and additional 
oxidations when compared to nosiheptide. 
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Figure 1.20 Thiocillin biosynthesis and structure. (a) BGC of thiocillin. (b) Precursor peptide and chemical 
structure of thiocillin I. 
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Figure 1.21 GE2270A and thiomuracin A biosynthesis and structure. (a) BGC for GE2270 and thiomuracin 
A showing ancillary tailoring enzymes that C-methylate thiazoles and further decorate various side chains. 
(b) Precursor peptide and structure of GE2270A. (c) Precursor peptide and structure of thiomuracin A. 
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Figure 1.22 Cyclothiazomycin biosynthesis and structure. (a) Cyclothiazomycin BGC (b) 
Cyclothiazomycin A precursor peptide and structure. 
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Figure 1.23 Lactazole biosynthesis and structure. (a) The lactazole BGC. (b) Precursor peptide and 
structure of lactazole A. Stereochemistry has not been rigorously established but each amino acid is 
presumed to be in natural L configuration. 
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Figure 1.24 Berninamycin and TP-1161 biosynthesis and structure. (a) BGCs for berninamycin/TP-1161 
(b) Precursor sequence and structure for berninamycin A. (c) Precursor sequence and structure for TP-1161. 
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Figure 1.25 Tyrosine C-prenylation. (a) After O-prenylation by a LynF-homolog, a spontaneous Claisen 
rearragenement generates an ortho C-prenylated product. (b) Example of C-prenylation in the aestuaramide 
A. 
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Figure 1.26 Cyanobactin genotypes I-IV and associated structures. (a) Genotype I. (b) Genotype II. The 
piricyclamides are likely genotype II, but this has not been strictly classified. (c) Genotype III. (Conintued 
on next page) (d) Genotype IV. 
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Figure 1.26 (Continued) 
 
 
 
  
Figure 1.27 Linear cyanobactin biosynthesis. (a) BGC for the aeruginosamides. (b) Structure of 
aeruginosamide B an C. 
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Figure 1.28 Cyclodehydratase-associated NHLP and Nif11 biosynthesis and structure. (a) Representative 
BGCs putatively encoding azol(in)e-containing RiPP products. (b) C-terminal portion of precursor 
sequences from the NHLP family, highlighting the proposed leader peptide cleavage site is (after VAGG). 
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Figure 1.29 YM-216391 biosynthesis and structure. (a) The BGC for YM-216391 (b) Precursor peptide 
and structure for YM-216391 (c) Structure of marthiapeptide. 
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Figure 1.30 Overview of different types of RiPP cyclodehydratases. Until the bottromycin and 
trifolitoxin YcaOs are reconstituted in vitro, their status as a “standalone YcaO” remains a bioinformatic 
prediction. 
 
 
 
 
 
 
Figure 1.31 Diagram of active canonical RiPP cyclodehydratases. (a) Crystal structure of LynD (PDB ID: 
4VLT). Colored regions represent the YcaO (blue), E1-like (green), Ocin-ThiF-like (orange), leader peptide 
(yellow), core (black) regions.  Dark and light colors denote different monomers. (b) Schematic model of 
the dimeric cyclodehydratase shown in panel A. (c) Schematic model of the F-dependent cyclodehydratase.  
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Figure 1.32 Proposed mechanisms for azoline biosynthesis by YcaO domains. (a) Direct activation 
suggests the incorporation of phosphate(s) directly into the heterocyclized intermediate, providing a leaving 
group (Pi) for elimination. (b) The molecular machine hypothesis proposes an allosteric activation role for 
ATP in which an active conformation of the cyclodehydratase is generated by ATP hydrolysis. (c) An 
intein-splicing-like mechanism, by which protonation of the hemiorthoamide intermediate allows for 
elimination of water to generate the azoline in a manner independent of ATP.  
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Figure 1.33 Stable isotope labeling experiments support the direct activation mechanism. 31P-NMR was 
used to monitor the oxygen isotope status of the phosphate byproduct. Cyclodehydratase reactions in [18O]-
H2O (top) showed no [18O] enrichment in the phosphate. When [18O]-BalhA was used as the substrate 
(bottom), the 18O label was incorporated into the free phosphate. 
 
 
 
 
  
Figure 1.34 Acidic hydrolysis of thiazoline in [18O]-H2O site-selectively introduces an [18O] label into the 
carbonyl of the adjacent amino acid. This is the key aspect underlying the AMPL method.  
 
 
 
 
  
Figure 1.35 Oxazoles are used in organic synthesis in Diels-Alder [4 + 2] cycloaddition reactions. This 
chemistry is a feature of a conjugated di-ene, and not of an aromatic ring. Thiazoles, which exhibit greater 
aromatic nature than oxazoles, do not readily undergo this chemistry.  
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Figure 1.36 A plausible mechanism for the dehydrogenation of methyloxazoline catalyzed by B enzymes. 
The conserved Lys-Tyr motif is likely involved in deprotonating the Cα of the azoline, which is followed 
by hydride transfer, in what is essentially an E2 mechanism.  
 
 
 
 
  
Figure 1.37 A plausible mechanism for cyanobactin epimerization.  
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Figure 1.38 Order of biosynthetic enzymes in patellamide biosynthesis. The exact timing of epimerization 
is not known.   
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Figure 1.39 X-ray crystal structure of the dehydrogenase from cyanotheceamide biosynthesis. (a) Structure 
of the dimeric dehydrogenase or (b) as a single monomer. (c) The FMN molecule (magenta) is bound at the 
dimer interface.  (d) Ligand interaction diagram of FMN binding. Putative hydrogen bonds are shown in 
green with distances, light red arcs indicate hydrophobic interactions.    
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Figure 1.40 Cartoon illustrating cyclodehydratase processing of cysteine residues. The precursor peptide, 
composed of the leader (green) and core (peptide), can be cyclodehydrated in an ordered fashion that 
depends on the cyclodehydratase although the preferred order can non-linear as well.  
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Figure 1.41 PatE leader peptide binding by LynD. Ordered residues (sticks) of the leader region (yellow) 
interact with the RRE (green, domain 1). PatE residues are marked with an apostrophe. Presumed salt 
bridges are shown with dashed lines. 
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Figure 1.42 Nucleotide binding in YcaO domains. (a) A ligand interaction diagram for AMPPNP bound to 
LynD. (b) Residues involved in adenosine and ribose recognition in LynD-AMPPNP (purple) and Ec-
YcaO-AMPCPP (green) complex structures. (c) Residues involved in Mg2+ and phosphate coordination in 
LynD-AMPPNP (purple) and Ec-YcaO-AMPCPP (green) complex structures. 
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Figure 1.43 Ribbon structure of dimeric Ec-YcaO. Colored regions represent the YcaO domain (blue), 
tetratricopeptide-like domain (gray), ATP (orange spheres), or different monomers (dark vs. light coloring).  
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Figure 1.44 Bottromycin biosynthesis and structure. (a) Bottromycin BGC from Streptomyces bottropensis. 
(b) Structure of bottromycin and table of congeners. Modifications attributed to YcaOs in red. (c) Sequence 
alignment of bottromycin precursor peptides. 
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Figure 1.45 Biosynthesis of bottromycin determined through gene deletion in a heterologous host (S. 
coelicolor) and analysis of detected intermediates.   
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Figure 1.46 YcaOs catalyze diverse reactions through a similar backbone-activating mechanism. We 
hypothesize that YcaOs ubiquitously use ATP to O-phosphorylate peptide backbones, generating a 
common hemiorthoamide intermediate upon nucleophilic attack. Phosphate elimination yields different 
functional groups dependent on the identity of the nucleophile.  
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Figure 1.47 Thioviridamide biosynthesis and structure. (a) The BGC for thioviridamide from Streptomyces 
olivoviridis. (b) Sequence of precursor peptide TvaA and structure of thioviridamide and analog JBIR-140. 
Stereochemistry of some JBIR-140 residues was determined by Marfey’s method and assumed to be 
consistent in thioviridamide. 
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Figure 1.48 Trifolitoxin biosynthesis and partial structure. (a) BGC for TFX. (b) Precursor sequence and 
partial structure of TFX.  
 
 
 
  
Figure 1.49 Cartoon schematic of LynD and the engineered “activated” cyclodehydratase (AcLynD). (a) 
The LynD dimer undergoes a conformational rearrangement (blue and green move closer together) 
following binding of PatE (yellow/black) generating an “active” enzyme. In the absence of leader peptide, 
the conformational rearrangement is not possible and heterocyclization of the core peptide is inefficient. 
(b) Covalent attachment of the leader peptide to the enzyme (orange) in AcLynD mimics the “activated” 
native LynD, allowing for efficient wild-type-like processing of the core peptide. 
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Chapter 2: A Prevalent Peptide-Binding Domain Guides Ribosomal Natural Product Biosynthesis2 
 
2.1 Introduction 
Natural products, in particular polyketides and non-ribosomal peptides, have provided a wealth of 
pharmaceutically important molecules1 and chemical probes for biology.2 More recently, ribosomally 
synthesized and posttranslationally modified peptides (RiPPs) have been recognized as another major sector 
of natural products3 with a similar capacity for probing biological systems4 and for serving as new drug 
scaffolds.5 RiPPs can be exceedingly complex in structure and are further categorized based on the set of 
modifying enzymes encoded by their biosynthetic gene clusters and the corresponding structural features 
present within the final products. Consequently, RiPP gene clusters are not identified or defined by a shared 
biosynthetic enzyme; rather, they are unified by a common biosynthetic logic of posttranslationally 
modifying an unrestrained, ribosomally synthesized peptide (Figure 2.1a).3 RiPP precursor peptides are 
usually bipartite, being composed of an N-terminal leader and C-terminal core regions. RiPP biosynthetic 
enzymes recognize conserved sequence motifs in the leader region and install residue-specific 
modifications to the core, yielding structurally complex compounds.3, 6. Because of the bipartite nature of 
RiPP precursor peptides, the modifying enzymes can be specific for a particular substrate while also 
displaying a high tolerance towards unnatural core sequences. This fact, combined with their gene-encoded 
nature, makes RiPPs attractive targets for biosynthetic engineering.3, 7-9 Previous efforts relied on 
maintenance of native leader peptide sequences because omission of the conserved binding motifs 
significantly limits processing.3, 10 Although some residues of the leader peptide that are recognized by the 
biosynthetic enzymes have been identified6, there are only a few RiPP classes where it is known which 
protein(s) physically associate with the leader and which residues of these proteins govern the interaction. 
Our group and others have made progress towards the general mechanistic understanding of 
substrate binding and catalysis for the cyclodehydratase involved in thiazole/oxazole-modified microcin 
(TOMM) biosynthesis.11 TOMM cyclodehydratases are found in >1,000 biosynthetic gene clusters,12 and 
most are found within three RiPP classes: linear azole-containing peptides (LAPs), azole-containing 
cyanobactins and thiopeptides.3, 11 Occurring as fused or discrete polypeptides,13-15 the TOMM 
cyclodehydratase consists of an adenosine 5’-triphosphate (ATP)-utilizing YcaO domain (D protein)12, 16, 17 
and a member of the E1 ubiquitin activating-like (E1-like) superfamily (C protein).18  In collaboration, the 
C/D protein(s) form azoline heterocycles from Cys, Ser, and Thr residues of the core peptide (Figure 
                                                     
2 This chapter is reproduced with permission from Burkhart, B. J.; Hudson, G. A.; Dunbar, K. L.; Mitchell, D. A. A Prevalent 
Peptide-Binding Domain Guides Ribosomal Natural Product Biosynthesis. Nat. Chem. Biol. 2015, 11, 564-570. Copyright 2015 
Nature Publishing Group. Experiments were designed by D.A.M. and B.J.B. and performed by B.J.B. K.L.D. generated FITC-
HcaA-FP, and G.A.H. produced FITC-TbtA-LP. The manuscript was written and edited by D.A.M. and B.J.B. 
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2.1b).13-15 Often a third component (B protein) is present, which is a flavin mononucleotide (FMN)-
dependent dehydrogenase that oxidizes select azolines to azoles.  
Work on a TOMM cyclodehydratase from Bacillus sp. Al Hakam,19 which comprises discrete C 
and D proteins, has revealed that BalhD catalyzes azoline formation (Balh) has revealed that the D protein 
(BalhD) catalyzes azoline formation16 whereas the C protein (BalhC) mediates peptide substrate 
recognition.12 Although the leader peptide–binding site remains unknown, the N-terminal winged helix-
turn-helix (wHTH) domain has been implicated in this function on the basis of its homology to the 'peptide 
clamp' of MccB,20 another E1-like RiPP-modifying enzyme involved in microcin C7 biosynthesis. Even 
though MccB and other related E1-like enzymes (such as PaaA and Rv3196) are not part of TOMM 
biosynthetic pathways, these E1-like enzymes possess N-terminal wHTH domains and produce ribosomal 
peptide–derived compounds,18 prompting the hypothesis that the wHTH domain guides the peptide to the 
active site. In support of this hypothesis, recently solved structures of LynD (PDB 4V1T, a fused 
cyclodehydratase involved in cyanobactin biosynthesis14, 21)  and NisB (PDB 4WD9, a lanthipeptide 
dehydratase involved in nisin biosynthesis22) show that the leader peptides of their respective substrates are 
bound by structurally similar wHTH motifs. This suggests that additional, seemingly unrelated RiPP 
biosynthetic enzymes might employ the same strategy for substrate binding. However, the connection 
between these 'recognition' domains and the RiPP enzymes that directly engage the leader peptides remains 
unexplored. 
Here, we bioinformatically identified a conserved domain linking the homologous wHTH motifs 
in NisB, LynD, and MccB. Through reevaluation of reported structures and experimental validation of 
additional RiPP biosynthetic enzymes, we demonstrated that this previously unrecognized conserved 
domain is present in the majority of prokaryotic RiPP classes. Given its broad distribution and identified 
role, we named this shared domain the RiPP precursor peptide recognition element (RRE). Importantly, 
these findings revealed previously unidentified similarities between disparate RiPP gene clusters and will 
guide future investigations of RiPP biosynthetic pathways. 
 
2.2 Results 
2.2.1 RREs are related to a PQQ biosynthetic protein 
We began our investigation of RiPP precursor peptide recognition by searching for a link between the 
peptide-binding wHTH domains of NisB and LynD. Amino acid sequence homology was not detected 
using routine methods (e.g. BLAST23), likely due to high divergence and lack of similarity to any annotated 
domains in the Conserved Domain Database (CDD).24 However, HHpred,25 a highly sensitive homology 
detection tool based on profile hidden Markov model (HMM) comparisons,26 revealed that the wHTH 
domains of LynD (residues 2–81) and NisB (residues 153–223) were related to the protein PqqD 
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(probability > 90%). HHpred probabilities give the most relevant representation of significance with > 90% 
usually being considered a true positive.25, 27 PqqD itself is a small protein (~90–100 residues) involved in 
the biosynthesis of another RiPP, pyrroloquinoline quinone (PQQ).28 PQQ is posttranslationally derived 
from Glu and Tyr residues of the PqqA precursor peptide. Although PQQ biosynthesis is not fully 
understood, PqqA maturation likely relies on PqqB (putative oxygenase), PqqC (oxygenase), PqqD 
(“peptide chaperone”), and PqqE (radical SAM).28 PqqD is known to interact with PqqE, but until a recent 
report showing that PqqD binds to PqqA,29 its function was unknown; however, this finding is consistent 
with its homology to the peptide-binding domains of NisB, LynD and MccB. 
The structure of PqqD has been solved,30 and we queried the Dali server31 to assess structural 
similarities between MccB, LynD, NisB and PqqD as an additional verification of homology. Searches with 
MccB, LynD and NisB did not return PqqD as a structural homolog. When we submitted only the PqqD-
like region (i.e., the wHTH domain) of these proteins, however, LynD matched PqqD with a relatively weak 
similarity score (Z-score 5.3, with Z < 2.0 being viewed as spurious). The reverse search using bona fide, 
full-length PqqD as the query returned LynD and MccB with similar Z-scores (5.4 and 3.0, respectively). 
Visual comparison of the PqqD structure (PDB entry: 3G2B) with these proteins corroborates the 
HHpred/Dali alignment results (Figure 2.2). Thus, structural homology to PqqD links the structurally 
similar domains of NisB, LynD, and MccB. 
 
2.2.2 RREs are present in > 50% of prokaryotic RiPP classes 
Building on the finding that at least three enzymatically unique RiPP biosynthetic enzymes harbor PqqD-
like domains with distant homology, we hypothesized that the same could be true for additional RiPP 
biosynthetic proteins. Indeed, PqqD-like domains have been previously identified in AlbA,32  which is 
involved in subtilosin A (sactipeptide) biosynthesis, and in a protein with an unknown function in lariatin 
(lasso peptide) biosynthesis;3, 33 however, the role of these domains have remained largely enigmatic. We 
speculated that PqqD-like domains function as an RRE. To determine the prevalence of such domains, we 
constructed a sequence similarity network of the ~4,000 members of the PqqD InterPro family (IPR008792) 
at an e-value threshold of 10−16 (Figure 2.3). Analysis of the network revealed proteins from sactipeptide 
and lasso peptide biosynthesis, but homologs of lanthipeptide dehydratases and TOMM cyclodehydratases 
were absent (i.e., they are not members of IPR008792). As an alternative approach, we queried the 
Conserved Domain Architecture Retrieval Tool (CDART)34 for proteins containing an annotated PqqD-like 
domain and found over 40 unique architectures (Table 2.1). While some architectures were related to known 
RiPP biosynthetic proteins (such as AlbA, LynD and NisB), many did not appear to be RiPP related. 
Moreover, the small set of returned sequences that were RiPP related indicated that CDART34 was not 
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sensitive enough to identify RRE-containing proteins, likely as a consequence of their general lack of 
annotation. 
To overcome these shortcomings, we again returned to HHpred to search RiPP biosynthetic gene 
clusters for RREs (on the basis of homology to PqqD). A representative gene cluster for previously defined 
RiPP classes3 was chosen, and each protein was individually queried using HHPred (Table 2.2). Because 
eukaryotic RiPP biosynthesis is bioinformatically less tractable, the current analysis included only 
prokaryotes. Our results indicated that over half of all known prokaryotic RiPP classes harbor a PqqD-like 
domain, underscoring a broad distribution of RREs (Figure 2.4 and detailed results in Table 2.3). 
As described above, the RRE for canonical discrete (e.g. BalhC-D) and fused (e.g. LynD) 
cyclodehydratases is the N-terminal wHTH domain of the C protein portion, which itself is not annotated 
in the CDD.24 We recently identified a third cyclodehydratase architecture which is confined largely to the 
thiopeptides and heterocycloanthracins (Hca; a subclass of LAPs).35, 36 These fused cyclodehydratases are 
N-terminally truncated by ~150 residues such that the RRE is ablated. Almost invariably, TOMM clusters 
that contain 'truncated' cyclodehydratases also encode a partner protein (annotated in the CDD as 
“ocin_ThiF_like”; hereafter referred to as the TOMM 'F protein') that contains the RRE (Figure 2.4). As 
predicted, we have confirmed that the responsibility for binding the leader peptide resides with the RRE-
containing TOMM F protein (such as HcaF in the Hca cluster) rather than with the fused cyclodehydratase.36 
Consequently, we refer to this class of (truncated) enzymes as F-dependent cyclodehydratases. 
Because of its shared homology to the E1 ubiquitin-activating superfamily, the TOMM C protein 
is related to the microcin C7 adenylase MccB. The RRE present within MccB has previously been defined 
as a 'peptide clamp' based on its interaction with the MccA peptide substrate.20 The gene encoding MccA 
is one of the shortest known and produces a 7-residue leaderless peptide substrate.3 Perhaps this explains 
why the MccA binding mode is somewhat different from that displayed by NisB and LynD (Figure 2.2). 
Regardless, the MccB RRE interacts with the N-terminal residues of MccA and is essential for substrate 
binding. We predict that the same holds true for PaaA (pantocin biosynthesis3) owing to its similarity to 
MccB (microcin C7 biosynthesis; Figure 2.4).18, 37 
In class I lanthipeptides, the LanB and LanC enzymes (NisB and NisC, respectively, for nisin 
biosynthesis) form the lanthionines. LanB enzymes are serine-threonine dehydratases composed of a 
glutamylation and elimination domain, which occur as separate ('split') polypeptides in thiopeptide gene 
clusters (e.g., TbtB and TbtC).22 Subsequent to LanB dehydrations, LanC cyclases catalyze the Michael-
like addition between the dehydrated serine and threonine residues and particular cysteine residues. In class 
II lanthipeptides, dehydration and cyclization are performed by a bifunctional synthetase composed of an 
N-terminal dehydratase domain (with no homology to NisB) and a C-terminal LanC-like cyclase domain. 
Class III and IV lanthipeptide synthetases are trifunctional, with N-terminal lyase, central kinase and 
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variable C-terminal cyclase domains.3 HHpred was unable to identify RREs in class II–IV lanthipeptide 
synthetases; however, RREs appear to be ubiquitous in class I LanB dehydratases and in their 'split' 
counterparts in thiopeptide biosynthesis (Figures 2.2c and 2.4). 
While the majority of RREs are not explicitly annotated in public databases, the CDD identifies 
“PqqD” in a subset of lasso peptide gene clusters.33 Canonical lasso peptide clusters harbor a precursor 
peptide, a transglutaminase-like protease, an asparagine synthetase–like protein and an ABC transporter. In 
many recently discovered lasso peptide gene clusters, the protease appears to be encoded by two discrete, 
adjacent genes38 (Figure 2.5). In these cases the C-terminal portions are identified by their homology to 
transglutaminases (e.g., LarD; annotated as “Trans_glutcore_3” in Figure 2.4) and the N-terminal domains 
are annotated PqqD (e.g., LarC). Consistent with the hypothesis that the larger lasso proteases are fusions 
of the PqqD-like and transglutaminase-like proteins, the N-terminus of the fused protease involved in the 
biosynthesis of the lasso peptide astexin-1 (AtxB)3 is similar to PqqD (HHpred probability >90%). 
Surprisingly, some lasso peptide proteases (such as McjB from microcin J25 biosynthesis) do not display 
detectable homology to PqqD (HHpred probability <20%); however, because AtxB and McjB fulfill the 
same role in their respective gene clusters, we predict that McjB also possesses an RRE, even though 
HHpred cannot identify it. 
Another example where RREs are annotated as PqqD-like are the sactipeptide rSAM enzymes.32 
Sactipeptide rSAMs (such as AlbA from subtilosin biosynthesis) install Cα-S thioether crosslinks and 
contain auxiliary [4Fe-4S] clusters within a C-terminal 'SPASM' domain (named for its presence in 
subtilosin, PQQ, anaerobic sulfatase and mycofactocin clusters).39, 40. To investigate whether RREs are 
prevalent among other rSAM- and SPASM-containing gene clusters with short peptide substrates, we 
scanned the mycofactocin gene cluster (mft) from Thermomicrobium roseum with HHpred. Notable 
homology to PqqD (probability >90%) was found in MftB, with a genetic arrangement similar to that of 
PqqD-E (Figure 2.4). We also detected RREs in two additional small mycofactocin-like40 gene clusters: the 
SCIFF (six cysteines in forty-five residues) and KxxxW rSAM families.41 Consistent with the proposed 
role of the RRE in RiPP biosynthesis, anaerobic sulfatase-maturating enzymes (anSMEs) lack 
bioinformatically or structurally (PDB entry: 4K39)42  detectable RREs and are not associated with RiPP 
biosynthesis. These assignments are in agreement with a recent independent report that identified PqqD-
like domains in rSAMs.29 Additional examples that further suggest RREs co-occurrence with RiPP rSAM 
enzymes include two enzymes involved in proteusin biosynthesis. RREs were located in the C-termini of 
the rSAM epimerase PoyD and the B12–dependent methyltransferase PoyB (Figure 2.4).3  PoyD has been 
characterized, and its function is known to be dependent on the presence of a leader peptide,43 as would be 
expected for an RRE-bearing protein. Although the PoyB B12-dependent methyltransferase has not been 
functionally dissected, we hypothesize that it will similarly be a leader peptide–dependent enzyme. 
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Lastly, we identified RREs in proteins involved in bottromycin3 and trifolitoxin biosynthesis.44, 45 
These two gene clusters are characterized by the presence of a discrete TOMM D protein,12 which 
apparently acts in the absence of a TOMM C protein. Intriguingly, these 'stand-alone' D proteins do not 
bear discernable RREs; however, HHpred found RREs (probability >90%) in the N-termini of two 
trifolitoxin oxidoreductases (TfxB and TfxC) and the C-termini of three bottromycin rSAMs (BmbB, BmbF 
and BmbJ), which are architecturally similar to the proteusin C-terminal methyltransferases (Figure 2.4). 
Unusually, the bottromycin precursor peptide harbors a 'follower' peptide rather than a leader peptide.3 
Despite this unconventional arrangement, we predict that the follower peptide of bottromycin is engaged 
by the rSAM RRE. 
 
2.2.3 Experimental validation of bioinformatically predicted RREs 
Our findings have revealed a broad distribution of bioinformatically identified RREs among various RiPP 
classes and enzymes, with strong support for the RRE's role gleaned from the substrate-bound structures of 
the LynD cyclodehydratase (4V1T), NisB dehydratase,22 and MccB adenylase.20 To provide further 
evidence that the predicted RREs can recruit precursor peptides during RiPP biosynthesis, we corroborated 
the functions of additional RREs through site-directed mutagenesis and fluorescence polarization (FP) 
binding assays. We surmised that specific residues within the RRE would engage the peptide and thus used 
site-directed mutagenesis to explore the nature of the interaction in five proteins that were derived from 
three additional RiPP classes (LAPs, thiopeptides and lasso peptides). On the basis of the known structures, 
sequence alignments and homology models, we targeted residues in the β1–β3 and α1–α3 regions for 
mutagenesis (Figure 2.2 and Figure 2.6). The purity and integrity of the mutant proteins were visually 
evaluated by Coomassie-stained SDS-PAGE gels (Figure 2.7). 
 
2.2.4 LAP discrete cyclodehydratase 
With some exceptions, the discrete cyclodehydratases (separate C and D proteins) tend to be found within 
LAP gene clusters.13 Having used an FP assay to previously narrow down that the leader peptide binds to 
the C protein,12 we introduced alanine substitutions into the BalhC RRE and similarly compared binding 
constants of the mutants using a fluorescently labeled BalhA1 leader peptide (FITC-BalhA1-LP). The 
resulting data showed that most alanine substitutions within the RRE substantially (>10-fold) reduced the 
interaction between BalhA1 and BalhC (Table 2.4 and Figure 2.6). Three BalhC mutations (K20A, D23A 
and E66A) had a moderate effect, while two (D32A and H38A) had a minor effect. For comparison, residues 
outside of the RRE were also substituted. These had essentially no effect on leader peptide binding except 
for those mutations that appeared to weaken the structural stability of BalhC by rendering it more 
susceptible to proteolytic degradation during expression (Table 2.5 and Figure 2.7). 
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Because an extended region of the BalhC RRE was sensitive to substitution, we examined a second 
LAP cyclodehydratase, this one from Corynebacterium urealyticum DSM 7109 (Cur) and a member of the 
plantazolicin subclass (Figure 2.8).46 When CurC was tested for binding to the FITC-labeled CurA leader 
(FITC-CurA-LP), a dissociation constant (Kd) of 7 ± 1 μM was obtained. CurD did not have an appreciable 
binding response, nor did it enhance CurA binding by CurC (Figure 2.9). This result was consistent with 
previous studies of BalhC12 and C proteins involved in LAP cytolysin biosynthesis.10 To assess the 
importance of the putative RRE in CurA binding, various residues were substituted with alanine. The 
binding data indicated that the CurC RRE was not as sensitive as BalhC to mutation as only CurCY31A in β3 
and CurCR68A and CurCI75A in α3 resulted in substantial (≥10 fold) reduction in affinity (Table 2.4; Figure 
2.6). The dissociation constants for peptide binding for the remaining substitutions in β1, β2 and α1 were 
within two-fold of that for CurCWT. Collectively, these data indicated that the RREs of discrete 
cyclodehydratases, especially the residues lining β3 and α3, are essential for peptide binding and suggested 
a binding mode similar to that of LynD and NisB. 
 
2.2.5 F protein-dependent cyclodehydratase 
Recent work from our group36 has revealed the dependence of truncated cyclodehydratases found in 
thiopeptide3 and Hca gene clusters35 are functionally dependent on a newly recognized biosynthetic protein 
(TOMM F protein). For these 'F-dependent' cyclodehydratases, it has been demonstrated that the F protein 
(HcaF) binds the precursor peptide (HcaA), but the involvement of the RRE remained undetermined. 
Therefore, we probed the HcaF protein from Bacillus sp. Al Hakam by replacing numerous residues of the 
RRE with alanine. The results indicated that residues lining the groove between β3 and α3 (Phe35, Arg73 
and Ile80) are important for binding (Table 2.6 and Figure 2.6). Mutation of nearby residues (HcaFD38A, 
HcaFN72A and HcaFE79A) had minimal effects on FITC-labeled HcaA leader peptide (FITC-HcaA-LP) 
affinity, probably because they are oriented away from the likely binding groove owing to their relative 
positioning. Asp38 is on the opposite side of β3 compared to Phe35 while Asn72 and Glu79 are 
orthogonally oriented relative to Arg73 and Ile80, respectively. Given that HcaFD21A (in β1) also had nearly 
WT-like binding, HcaF most probably engages HcaA in a manner analogous to peptide binding by LynD 
and NisB. 
 Because HcaF is a LAP-related protein, we chose to examine a non-LAP F-dependent 
cyclodehydratase. Thermobispora bispora (Tbt) is bioinformatically predicted to produce a GE2270A-like 
(thiopeptide) compound and, like Hca, harbors an F-dependent cyclodehydratase (TbtG).47 Initial 
experiments with TbtF (F protein) demonstrated that it could bind the FITC-labeled TbtA leader peptide 
(FITC-TbtA-LP), whereas TbtG had no discernable interaction with the peptide (Figure 2.10). Mutation of 
the TbtF RRE gave results similar to those for HcaF, with residues in β3 and the N-terminal portion of α3 
174 
 
being important for peptide binding (Val30, Phe68 and Arg71). TbtFD19A and TbtFL24A in β2 had no 
differences in peptide binding compared to TbtFWT, suggesting that the peptide binds between β3 and α3. 
We generated a homology model for TbtF based on the structure of LynD. From this structure, we did not 
expect the side chains of Gln74 and Arg79 in TbtF to make significant contact with the peptide and, 
consistent with this model, substitution of these residues had no measurable effect on the affinity toward 
FITC-TbtA-LP (Table 2.6 and Figure 2.6). 
 
2.2.6 Lasso peptide split protease 
With the role of the RRE established for TOMM cyclodehydratases, we turned next to the lasso peptides to 
test a RiPP class where little is known about precursor peptide recognition. Recently our group reported on 
an unusual lasso peptide, streptomonomicin (STM), from Streptomonospora alba.48 Genome sequencing 
revealed that the STM gene cluster contains a 'split' protease (StmE and StmB, Figure 2.5). Initial binding 
studies using size-exclusion chromatography indicated that the RRE-containing StmE bound the StmA 
precursor peptide, whereas the separate protease domain (StmB) had no interaction with either StmA or 
StmE under the tested conditions and appeared substantially degraded after expression (Figures 2.7 and 
2.11). The interaction between StmA and StmE was further corroborated by an FP binding experiment with 
FITC-labeled StmA leader peptide (FITC-StmA-LP, Figure 2.12). Encouraged by the correct functional 
prediction for StmE, we prepared eight alanine-substituted proteins and evaluated their binding to FITC-
StmA-LP. In accord with earlier examples, substitution of residues along the side of α3 nearest to β3 (D69A 
and L73A) resulted in dramatically (>500-fold) reduced peptide binding while alanine replacements of the 
adjacent Asp68 and Asp75, with their relative positions on the opposite side of α3, had no effect (Table 
2.7). Unlike in previous examples, β1 (StmCV12A) and β2 (StmCN22A) mutants displayed reduced binding, 
whereas StmEY28A and StmEQ76A, in which the mutations reside near the groove between β3 and α3, 
displayed nearly WT affinity. While these homology model–based mutant protein–binding results imply 
that lasso peptide proteases employ a slightly different subset of RRE residues to bind the leader peptide, 
the fact remains that irrespective of RiPP class or the RRE-containing protein's function, the RRE appears 
to govern substrate recognition. 
 
2.3 Discussion 
Here we implicate a conserved PqqD-like domain in precursor peptide recognition in over half of all 
currently known RiPP classes (reflecting multiple thousands of gene clusters; Tables 2.2 and 2.3). Highly 
sensitive bioinformatics, known crystal structures (Figure 2.2) and FP binding assays provide substantial 
experimental support for the role of the RRE in leader peptide binding. Further, albeit indirect, evidence 
for the importance of RREs derive from two additional observations: (i) RREs are routinely identified in 
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RiPP biosynthetic proteins but are lacking in homologs not involved in processing RiPPs (e.g., RiPP rSAMs 
and E1-like enzymes; see above) and (ii) RiPP enzymes which act subsequent to leader peptide cleavage 
do not harbor RREs (e.g., methyltransferases involved in plantazolicin49 and linaridin3 biosynthesis). Based 
on these findings, we predict that PqqD-like domains associated with peptide-modifying enzymes will 
function as RREs whenever present (as has been recently reported for PqqD).29 
In addition to demonstrating the role of RREs, our work also provided insight into how RREs bind 
their respective peptides. Binding experiments with BalhC (LAP) indicated that nearly the entire RRE was 
affected by mutation. Accordingly, the precise orientation of BalhA1 could not be inferred; however, CurC 
(52% similar), which displays considerably improved solution-phase behavior, had reduced peptide-
binding affinity only upon substitution of residues in β3 and α3. Given that β3 and α3 were the primary 
affected regions in the TOMM F proteins (HcaF and TbtF) and that LynD interacted with its peptide 
substrate using the same strategy (Figure 2.6), it appears that TOMM cyclodehydratases bind their 
substrates in a similar orientation irrespective of domain organization. However, there were other RREs 
that interacted with peptide substrates in alternate orientations (e.g., MccB). Perhaps this should not be 
surprising as RREs are as divergent as the proteins and pathways they are found within. Other sequence-
divergent, but structurally similar, peptide-binding domains also have varied binding modes.50 Logically 
RREs must bind their substrates in a manner conducive to post-translational modification; therefore, proper 
presentation of the peptide to the modifying enzymes is essential. Perhaps this explains why residues in β1 
and β2 of the StmE RRE are important for binding (owing to the mechanics necessary for forming the lasso 
topology). It is important to note, however, that bioinformatics and binding assays alone do not reveal 
atomic-level details of the substrate-binding interactions. 
The real power of our findings resides in the ability to accurately predict which protein(s), even 
those of unknown function and in pathways that require numerous enzymes, will recruit the precursor 
peptide to the modifying enzymes during RiPP biosynthesis. As a case in point, the identification of an 
RRE within a small protein (StmE) implicated in lasso peptide biosynthesis allowed us to assign a function 
where none had previously been proposed.3, 38 Similarly, the biosynthetic logic and inclusion of an 
“ocin_ThiF_like” (TOMM F) protein in certain TOMM biosynthetic gene clusters could be understood 
through identification of the RRE-containing protein. However, such insights are limited to systems where 
RREs are detectable and, accordingly, leader recognition remains enigmatic in many RiPP classes (Table 
2.2). It is possible that additional RREs will be found as homology detection algorithms become more 
sensitive and more sequences become available for building HMMs. Another possibility is that RiPP 
pathways lacking identifiable RREs have evolved other peptide recognition modules which are unrelated 
to the RRE in both sequence and structure. Nonetheless, RREs appear to be the most prevalent solution to 
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precursor peptide recognition among prokaryotic RiPPs, and they functionally link a diverse array of 
biosynthetic platforms and enzymes (Figure 2.4). 
These findings suggest several future applications, including the engineering of new precursor 
peptide specificities via RRE swapping and the use of RRE as a marker to discover new RiPP classes. 
Indeed, it is difficult to predict the peptide substrates and modifying enzymes of a novel RiPP class a priori,3 
which is why most first-in-class RiPPs have been found through phenotypic screens. However, if an RRE 
is bioinformatically identified in a novel genomic context, the flanking regions could be scanned for 
potential biosynthetic proteins and precursor peptides. As a starting point, we noted that many PqqD 
homologs we found belong to uncharacterized gene clusters and appear ripe for the above approach (Figure 
2.3 and Table 2.1). 
Overall, this work advances our understanding of RiPP biosynthesis and should serve to guide 
future studies. More work will be required to unequivocally establish the function of RREs in additional 
RiPP biosynthetic pathways but, importantly, our study lays a foundation indicating which proteins should 
be prioritized. 
 
2.4 Methods 
2.4.1 General methods 
All materials were purchased from Fisher Scientific or Sigma-Aldrich unless indicated otherwise. DNA 
sequencing was performed by the Roy J. Carver Biotechnology Center (University of Illinois at Urbana-
Champaign) or ACGT Inc. DNA oligonucleotides were purchased from Integrated DNA Technologies 
(IDT). All fluorescently-labeled leader peptides were purchased from GenScript (>90% purity) with an N-
terminal FITC-Ahx (fluorescein isothiocyanate with an amino hexyl linker) conjugated to a single glycine 
spacer before the leader peptide, except for the FITC-labeled leader peptides for HcaA and TbtA, which 
were prepared as previously described36. Full sequences are given in Table 2.8. 
 
2.4.2 Cloning 
The genes encoding CurC-D and StmA-B-E were amplified from the genomic DNA of their respective host 
organisms. PCR was performed with Platinum Taq DNA Polymerase High Fidelity (Invitrogen) or Pfu 
DNA polymerase using the primers listed in Table 2.9. BamHI-HF, NotI-HF, SalI, or HindIII (New England 
Biolabs, Inc., NEB) restriction sites were designed into these primers to avoid internal restriction enzyme 
cut sites. The amplified genes were PCR purified using DNA-binding spin columns (Qiagen, following 
manufacture’s instruction) and digested with appropriate restriction enzymes. After an additional PCR 
purification step, the digested inserts were ligated with T4 DNA ligase (NEB) into similarly digested and 
purified pET28 vector in frame with an N-terminal, maltose-binding protein (MBP) tag. Codon optimized 
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TbtF and TbtG were synthesized by Genscript with 5’ BamHI and 3’ XhoI cut sites, and after digestion 
with BamHI and XhoI, the excised genes were purified from a 1% agarose gel using a gel extraction kit 
(Qiagen). His6-tagged HcaF was previously generated36. 
 
2.4.3 Site-directed mutagenesis 
Site-directed mutagenesis was carried out using the Quikchange (Agilent) method or a modified method 
where primers were designed to overlap ~11 bp upstream and ~27 bp downstream of the targeted codon for 
mutation (to minimize primer-primer annealing). All mutagenesis primers are given in Table 2.9. 
 
2.4.4 Protein expression and purification 
All proteins were expressed and purified as tobacco etch virus (TEV) protease-cleavable fusions with MBP 
as previously described16 except for HcaF and its mutants which were purified by a N-terminal His6 tag36. 
The purity of all expressed proteins was examined by SDS-PAGE (Figure 2.7) 
 
2.4.5 Fluorescence polarization (FP) binding assay 
The interaction between fluorescently labeled leader peptides and various RiPP biosynthetic proteins was 
quantified using an FP assay. To maximize the polarization signal, all proteins remained MBP tagged. In 
general, protein was serially diluted into binding buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 2.5% 
(vol/vol) glycerol, 0.5 mM TCEP) and mixed with 25 nM of the appropriate fluorescently labeled leader 
peptide. Binding assays were carried out in nonbinding-surface, 384-black-well polystyrene microplates 
(Corning) and measured using a FilterMax F5 multimode microplate reader (Molecular Devices) with λex = 
485 nm and λem = 538 nm. Prior to measurement, the dilutions were equilibrated with shaking for 15 to 30 
min at 23 °C. Dissociation constant (Kd) values were calculated from the 50% saturation point using a dose-
response curve fit in Origin Pro 9.1 (OriginLab) with three independent titrations. Background fluorescence 
from the proteins alone was subtracted from the fluorescence polarization signal obtained with the 
fluorophore. 
 
2.4.6 Sequence alignments 
Initial sequence alignments of proteins within the same RiPP class were made using ClustalW2 using 
default parameters51. Due to divergence between different RiPP classes, homology model sequence 
alignments were generated using HHpred as described below. (http://toolkit.tuebingen.mpg.de/hhpred)25, 
26. 
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2.4.7 Detection of protein homologs 
BLAST23 was used to identify closely related homologs of proteins. To identify more distantly related, yet 
homologous, regions of RiPP biosynthetic proteins, we employed HHpred25, a sensitive homology detection 
tool based on profile hidden Markov model (HMM) comparisons26. HHpred queries were performed using 
the pdb70_30Apr15 database. The multiple sequence alignment (MSA) for the input sequence was 
generated with HHblits (iterative HMM-HMM comparison, maximum of 3 iterations), and secondary 
structure was scored with local alignment mode. All other options were left on their default settings except 
the “max number of hits in hit list” was increased to 500 so all hits above the 20% probability threshold 
would be returned. The hit list was then searched for PqqD or matches to the N-terminus of MccB, LynD, 
or NisB; however, we discovered that PqqD was a superior marker of RREs as the others frequently had 
lower probability scores if they appeared at all in the results. Only hits ≥ 90% probability were considered 
true hits. Because the MSA is dependent on the input sequence and can affect the probability score, all 
discovered PqqD-like domains were verified by re-submitting smaller sections of the input sequence, 
centered on the identified PqqD-like region. In practice, this was only necessary for the RiPP 
methyltransferases because the HHblits MSA generation tended to include non-RiPP rSAM enzymes (due 
to the similarity of their iron-sulfur binding domains), diluting the PqqD signature in the HMM. A 
representative gene cluster for each RiPP class (where the DNA sequence was available) was chosen from 
a comprehensive review of known RiPPs3, and the biosynthetic proteins were individually assessed for 
homology with PqqD (Table 2.2).  
 
2.4.8 Homology model generation 
Models were created using the HHpred interface, using LynD (PDB entry: 4V1T) as the manually selected 
template. In this method, the HHpred based alignment is automatically used as input for MODELLER52, 53 
to generate a 3D model. 
 
2.4.9 Sequence similarity network 
A sequence similarity network of InterPro family IPR008792 was generated with the Enzyme Function 
Initiative Enzyme (EFI) Similarity Tool (http://www.enzymefunction.org/)54. The resulting network was 
visualized using the organic layout of Cytoscape55, with an e-value threshold of 10–16, and each node 
represents sequences with 80% or greater sequence identity. The function of different clusters with at least 
3 nodes was investigated using the EFI Genome Neighborhood Tool56. A neighborhood size of 7 was chosen 
with 20% co-occurrence limit. Most nodes appeared to be part of uncharacterized gene clusters, but some 
lasso peptide gene clusters were identified by to co-occurrence with “Transglut_core3” and 
“Asn_synthase”. 
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2.4.10 Size-exclusion chromatography 
Size-exclusion chromatography (SEC) was performed on a Flexar HPLC (Perkin Elmer) with analytical 
Yarra SEC-3000 (300 x 4.6 mm, Phenomenex). The column was pre-equilibrated with 5 column volumes 
(CVs) of binding buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol) at 4  C. Protein 
samples (50 μM) were made up on ice in the same buffer, injected (5 μL), and monitored at 280 nm. Traces 
were exported to Microsoft Excel for analysis and normalized to the highest absorbance value. Oligomeric 
state and apparent mass were determined based on a standard curve generated from the elution times of 
molecular weight standards 12-200 kDa (Sigma).  
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2.6 Figures 
  
Figure 2.1 Overview of RiPP biosynthesis and the TOMM subclass. A generic RiPP biosynthetic gene 
cluster is displayed. The precursor peptide is composed of a leader peptide (LP) and core. While the LP 
contains binding motifs for the modifying enzymes, the core contains residues that undergo enzymatic 
processing to diverse functional groups. After removal of the LP and any additional tailoring processes, the 
mature RiPP is exported. (b) One RiPP biosynthetic class, the TOMMs, installs azoline-azole heterocycles. 
TOMMs arise from the action of an ATP-dependent cyclodehydratase (C and D proteins) and a flavin 
mononucleotide (FMN)-dependent dehydrogenase (B protein). X = S or O; R = H or CH3. 
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Figure 2.2 Structural comparison of four RiPP-modifying enzymes. (a–d) Shown are structurally 
equivalent sections of RiPP biosynthetic proteins involved in the biosynthesis of the Trojan horse antibiotic 
microcin C7 (MccB, an adenylating enzyme; PDB 3H9J; a), antitumor cyanobactins (LynD, a 
cyclodehydratase; PDB 4V1T; b), the lantibiotic nisin (NisB, a dehydratase; PDB 4WD9; c) and the 
bacterial dehydrogenase cofactor PQQ (PqqD, an rSAM-associated protein, 3G2B; d). The purple β-sheets 
and cyan α-helices constitute a conserved RRE. In a–c, the precursor peptide is shown in yellow stick 
formats. Dashed line indicates missing electron density. 
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Figure 2.3 PqqD sequence similarity network. A sequence similarity network54 for the PqqD InterPro 
family (IPR008792) is shown. Each circle (node) represents a single protein sequence or group sequences 
with ≥80% identity while the lines (edges) denote homology at or below an E-value threshold of 10–16. 
Proteins previously annotated as sactipeptide57, lasso peptide38, 58, and PQQ59 biosynthetic clusters were 
colored in cyan, purple, and red, respectively. Groups of nodes form clusters which indicate probable 
isofunctionality, as indicated by the co-clustering of colored nodes. The two PQQ associated proteins 
(Uniprot ID: A0A017T8W2_9DELT and S4YFB4_SORCE) in the sactipeptide cluster are PqqD-PqqE 
fusions, and their co-clustering with the sactipeptide group is a result of increased similarity score due to 
their rSAM domains (direct BLAST comparison of their PqqD-like domains with their sactipeptide 
neighbors do not meet the 10–16 threshold). The functions of other clusters were investigated by examining 
the local genome neighborhoods (7 genes)56, but most appeared to be part of conserved, uncharacterized 
biosynthetic gene clusters. Regardless, a few additional lasso peptide clusters were identified by the 
presence of adjacent transglutaminase and asparagine synthetase genes. 
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Figure 2.4 RREs are present in diverse RiPP biosynthetic proteins. RREs were found in a myriad of RiPP 
biosynthetic proteins using HHpred to search for PqqD homology (thick black bars). Solid lines represent 
protein sequences with N/C-termini labeled as “N” and “C.” Colored sections indicate the annotations for 
the conserved domains identified by the Conserved Domain Database24. Asterisks denote RRE assignments 
based solely on HHpred findings. Abbreviations: LAP, linear azole-containing peptide; PQQ, 
pyrroloquinoline quinone; rSAM, radical SAM. More details can be found in Table 2.3. 
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Figure 2.5 Genetic arrangement and comparison of lasso peptide biosynthetic enzymes. The microcin J25 
gene cluster represents the canonical lasso peptide gene cluster and consists of four genes: a precursor 
peptide (A), protease (B), Asn synthetase homolog (C), and a transporter (D). A growing number of 
biosynthetic clusters contain five essential genes38, 60, apparently due to the splitting of the protease (B 
protein). Note that the lariatin gene cluster does not follow the more recently established nomenclature 
rules3. 
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Figure 2.6 Homology models of RiPP biosynthetic protein RREs. To probe the role of the RRE in LAPs, 
thiopeptides, and lasso peptides, homology models of the RRE from BalhC, CurC, HcaF, TbtF and StmE 
were built with HHpred25 using LynD (PBD entry 4V1T) as the template. Residues across various locations 
of the RRE were substituted with alanine, and the effect on leader peptide binding was measured. (a) The 
structures of MccB, LynD, and NisB are shown with spheres for the beta carbon of side chains within 4 Å 
of the peptide. The non-hydrolyzable ATP analogue (α,β-methyleneadenosine 5′-triphosphate, orange 
sticks) indicates the active site of MccB. Although relatively few residues near MccA are from the RRE, 
ablation of the RRE eliminates enzyme activity, which can be partially restored by addition of the RRE in 
trans20. For clarity, 1–2 residues from outside of the RRE are not shown for NisB and LynD since they 
block the view many other important residues. The coloring of the spheres only indicates the secondary 
structure to which the residue belongs. (b) Homology models are shown with spheres representing the 
location and magnitude of the effect of alanine substitutions (see Tables 2.4, 2.6, and 2.7 for precise values). 
(c) The underlying sequence alignments on which the models were created are displayed and similarly 
colored. Figure continued on next page. 
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Figure 2.6 (Continued) 
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Figure 2.7 SDS-PAGE analysis of purified proteins. Heterologously expressed, MBP-tagged or His6-
tagged proteins were purified via affinity chromatography. Protein purity was assessed using Coomassie-
stained 11% SDS-PAGE gels. Proteins from Balh (a), Cur (b), Hca (c), Tbt (d), and Stm (e) are labeled 
along with the isolated yield per liter of culture (mg/L). BalhCR192A and BalhCE281A were deemed structurally 
destabilized due to poor yields relative to WT (6 and 19 mg/L, respectively) and band distortion. To a 
greater extent, MBP-StmB also was proteolytically degraded as judged by the visible MBP (~45 kDa) band. 
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Figure 2.8 Description and genetic organization of the plantazolicins. The plantazolicins46 are a subclass 
of LAPs and derive from a group of related gene clusters that are predicted to produce closely related 
derivatives. (a) Chemical structure of plantazolicin (PZN). Blue, heterocycles installed by the TOMM 
cyclodehydratase and dehydrogenase. Green, Nα,Nα-dimethylarginine formed by BamL after leader peptide 
cleavage. (b) Genetic organization of the genes involved in PZN biosynthesis. Bam, Bacillus 
amyloliquefaciens FZB42; Bpum, Bacillus pumilus ATCC 7061; Cms, Clavibacter michiganensis subsp. 
sepedonicus; Cur, Corynebacterium urealyticum DSM 7109; Blin, Brevibacterium linens BL2. (c) PZN 
precursor peptide alignment. Color-coding is identical to panel (a) and are predicted for Cms, Cur, and Blin. 
* known peptidase cleavage site; ^ inferred cleavage site.  
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Figure 2.9 CurC is necessary and sufficient for leader peptide recognition. FP binding experiments were 
performed using CurC and/or CurD with FITC-labeled CurA leader peptide (FITC-CurA-LP). The rise in 
polarization for CurD alone is likely due to non-specific binding at high protein concentrations and 
dissociation constant was not able to determined (n.d.). Error bars represent s.d. of three independent data 
points. Error on Kd values are the s.e.m. given by regression analysis. 
 
 
 
 
  
Figure 2.10 TbtF is necessary and sufficient for leader peptide recognition. FP binding experiments were 
performed using TbtF and/or TbtG with FITC-labeled TbtA leader peptide (FITC-TbtA-LP). The dashed 
line indicates no binding. Error bars represent s.d. of at three independent data points. Error on Kd values 
are the s.e.m. given by regression analysis. 
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Figure 2.11 Size-exclusion chromatography (SEC) of Stm proteins. The interaction between maltose-
binding protein (MBP)-tagged StmA, StmB, and StmE were assessed via SEC and monitored by absorbance 
at 280 nm. MBP-fusions were used to maximize column separation efficiency. No visible interaction was 
detected between MBP-StmB and MBP-StmA; however, the clearly shifted elution volume of MBP-StmA 
with MBP-StmE indicated a binding interaction. Asterisk indicates aggregated StmB, which by SDS-PAGE 
(Figure 2.7) has some structural stability issues upon heterologous expression. Traces are representative 
results from two different HPLC injections. 
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Figure 2.12 StmE is necessary and sufficient for leader peptide binding. StmE was tested for binding to the 
FITC-labeled StmA leader peptide (FITC-StmA-LP). StmB was not included due to significant degradation 
during heterologous expression and the aggregated state of the purified protein (Figures 2.7 and 2.11). Error 
bars represent s.d. of three independent data points. Error on Kd valueis the s.e.m. given by regression 
analysis. 
 
 
 
 
  
Figure 2.13 CurANS9 mutation does not affect binding by CurC. Using a competition FP binding assay, 
CurAWT and CurAN9S were shown to interact identically (within error) with CurC. MBP-tagged peptides 
were serially diluted and mixed with 30 nM of the FITC-labeled CurA leader peptide (FITC-CurA-LP) and 
25 μM CurC. IC50 values and their uncertainty were calculated using a dose response fit with Origin Pro 
9.1. Error bars represent s.d. of three independent data points. 
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2.7 Tables 
Table 2.1 PqqD domain architectures identified by CDART. CDART (conserved domain architecture 
retrieval tool)34 was used to identify sequences and domain architectures containing an annotated PqqD 
domain. Many domain architectures match proteins from RiPP biosynthetic gene clusters, but unique 
architectures could represent proteins in unidentified RiPP pathways or false positive hits. The low number 
of sequences for some domain architectures is likely due to high divergence of sequences so that they no 
longer meet the requirements to be annotated as “PqqD.” For example, only 9 sequences match 
“PqqD~hypothetical_protein~YcaO” (which represents a fused cyclodehydratase), but there are hundreds 
of fused cyclodehydratase sequences in genbank so these values represent minimum estimates. 
 
Domain Architectures Sequences Accessions 
PqqD 4242 cl05126 
PqqD~Radical_SAM~SPASM 203 cl05126~cl18962~cl14869 
AdoMet_MTases~PqqD 61 cl17173~cl05126 
PqqD~ABC_ATPase 42 cl05126~cl21455 
PqqD~E1_enzyme_family 42 cl05126~cl22428 
PqqD~S2P-M50 41 cl05126~cl10020 
PqqD~S2P-M50~Biotinyl_lipoyl_domains 40 cl05126~cl10020~cl11404 
ABC_ATPase~PqqD 31 cl21455~cl05126 
DUF59~PqqD 25 cl00941~cl05126 
ATP-grasp_4~PqqD 20 cl17255~cl05126 
HemeO~PqqD 19 cl15243~cl05126 
PqqD~Radical_SAM 19 cl05126~cl18962 
B12-binding_like~Radical_SAM~PqqD 17 cl00293~cl18962~cl05126 
PqqD~Transglut_core 15 cl05126~cl17362 
PqqD~SPASM 11 cl05126~cl14869 
PqqD~AdoMet_MTases 11 cl05126~cl17173 
Thioredoxin_like~GST_C_family~PqqD 10 cl00388~cl02776~cl05126 
SCM_chp_ScmC~PqqD 9 TIGR04249~cl05126 
PqqD~hypothetical_protein~YcaO 9 cl05126~TIGR03882~cl19253 
HTH_XRE~PqqD 9 cl21459~cl05126 
PqqD~Biotinyl_lipoyl_domains 7 cl05126~cl11404 
Lactamase_B~PqqD 5 cl00446~cl05126 
PqqD~hypothetical_protein 5 cl05126~TIGR03882 
PqqD~Extradiol_Dioxygenase_3B_like 5 cl05126~cl00599 
CAP_ED~PqqD~S2P-M50 4 cl00047~cl05126~cl10020 
Glycosyltransferase_GTB_type~PqqD 4 cl10013~cl05126 
Radical_SAM~PqqD 4 cl18962~cl05126 
PqqD~UBN2 4 cl05126~cl15874 
PRTases_typeI~PqqD 3 cl00309~cl05126 
FHA~PqqD~S2P-M50 3 cl00062~cl05126~cl10020 
Lant_dehyd_N~PqqD~Lant_dehyd_C 3 pfam04737~cl05126~pfam04738 
RRM_SF~PqqD 2 cl17169~cl05126 
PqqD~SCM_chp_ScmC 2 cl05126~TIGR04249 
Radical_SAM~SPASM~PqqD 2 cl18962~cl14869~cl05126 
HSDR_N~ABC_ATPase~PqqD 2 cl14958~cl21455~cl05126 
ISOPREN_C2_like~PqqD 2 cl08267~cl05126 
PDDEXK_2~PqqD 2 pfam12784~cl05126 
terB_like~PqqD 2 cl11965~cl05126 
PqqD~Radical_SAM~RRM_SF~SPASM 2 cl05126~cl18962~cl17169~cl14869 
PqqD~YcaO 2 cl05126~cl19253 
PqqD~PHA02726 2 cl05126~PHA02726 
PqqD~B12-binding_like~Radical_SAM 2 cl05126~cl00293~cl18962 
Glyco_tranf_GTA_type~PqqD 1 cl11394~cl05126 
GluZincin~PqqD~PDZ 1 cl14813~cl05126~cl00117 
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Table 2.2 Representative RiPP biosynthetic gene clusters examined for PqqD-like domains. To determine 
if RREs were widely distributed among additional RiPP classes, a well-studied, representative gene cluster 
(taken from a comprehensive RiPP review article3) was searched for proteins with homology to PqqD using 
HHpred25. While most RiPPs are part of a specific class based on this review article, we have listed 
thioviridamide61 as unclassified because it has unique modifications but was discovered after publication 
of the review. Additionally, trifolitoxin and mycofactocin are not (fully) structurally characterized so they 
are left unclassified. Listed below are all the gene clusters searched with the accession code (GenBank) for 
the given product precursor peptide. Clusters harboring at least one protein with an identified RRE are 
further described in Table 2.3. Asterisk denotes compounds without fully elucidated structures. 
 
Class Product Accession RRE present 
Bottromycin Bottromycin CCM09443.1 Yes 
Cyanobactins (azole/azoline-containing) Patellamide AAY21154.1 Yes 
Lantipeptides (class I) Nisin CAA48380.1 Yes 
Lasso peptides Astexin-1 ADU13884.1 Yes 
Lasso peptides Lariatin BAL72546.1 Yes 
Linear azole-containing peptides (LAPs) Plantazolicin CBJ61635.1 Yes 
Microcins Microcin C7 CAA40808.1 Yes 
Pantocins Pantocin A AAD00512.2 Yes 
PQQ biosynthesis PQQ ACI09106.1 Yes 
Proteusins Polytheonamide AFS60639.1 Yes 
Sactipeptides Subtilosin NP_391616.1 Yes 
Thiopeptides GE2270 AGY49587.1 Yes 
Unclassified Mycofactocin* ACM06841.1 Yes 
Unclassified Trifolitoxin* AAA26363.1 Yes 
Autoinducing peptides AIP-1 AAG03056.1 No 
ComX and derivatives ComX CAB15158.1 No 
Glycocins Sublancin 168 CAB14066.1 No 
Head-to-tail cyclized peptides Enterocin AS-48 CAA72917.1 No 
Lantipeptides (class II) Prochlorosin CAE20422.1 No 
Lantipeptides (class III) Labyrinthopeptin CAX48972.1 No 
Lantipeptides (class IV) Venezuelin CCA53908.1 No 
Linaridins Cypemycin ADR72962.1 No 
Methanobactins Methanobactin E3YBA4.1 No 
Microviridins Micoviridin B CAQ16116.1 No 
Unclassified Thioviridamide BAN83916.1 No 
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Table 2.3 Detailed HHpred results. HHpred25 was used to search RiPP biosynthetic proteins from well-
known gene clusters (Supplementary Table 2) for homology to PqqD (additional proteins discussed in the 
main text are also included). Listed are the regions of query proteins that align to PqqD along with the 
significance of the “hit” (% Probability, E-value, and P-value). Additionally, for each protein, the number 
of homologous sequences is estimated to provide a measure of the prevalence for each RiPP subclass. For 
this estimation, a protein sequence was searched in CDART34 and all retrieved sequences with the same 
domain architecture were counted; dashed lines indicate overlapping sequence counts due to gene cluster 
homology. However, CDART could not always properly distinguish RiPP homologs from non-RiPP 
homologs, in which case, the bioinformatics performed by others was utilized: aCDART34, bMicrocins37, 
cEpimerases43, dIPR023984, ePQQ59; n.d., not determined. Asterisk denotes structurally uncharacterized 
compounds. 
 
RiPP Class Product Protein Accession PqqD-like region Probability E–value P–value Sequences 
LAPs Plantazolicin (PZN) BamC CBJ61637.1 1–92 98 2.1E–04 6.2E–09  
LAPs PZN derivative* CurC CAQ05603.1 1–83 99 4.0E–08 1.1E–12  
LAPs Hakacin* BalhC ABK83869.1 2–86 98 1.2E–05 3.6E–10  
LAPs Heterocycloanthracin* HcaF WP_000067633.1 1–88 98 1.4E–05 3.9E–10  
Cyanobactins Patellamide TruD ACA04490.1 3–81 97 1.1E–03 3.2E–08 >1500a 
Cyanobactins Aestuaramide LynD WP_009787121.1 1–82 97 5.2E–04 1.5E–08  
Thiopeptides GE2270 PbtF AGY49592.1 2–83 98 1.7E–04 4.9E–09  
Thiopeptides GE2270 PbtB AGY49588.1 234–317 94 3.2E–01 9.3E–06  
Thiopeptides GE2270 derivative* TbtF ADG87281.1 3–83 98 1.9E–04 5.3E–09  
Thiopeptides GE2270 derivative* TbtB ADG87277.1 262–350 96 8.2E–03 2.4E–07 
Lanthipeptides  
(class I) Nisin NisB CAA48381.1 138–223 94 7.8E–02 2.2E–06 700a
Microcins Microcin C MccB CAA40809.1 1–79 97 8.9E–04 2.6E–08 
≥ 41b
Pantocins Pantocin A PaaA AAD00512.2 1–89 98 7.1E–05 2.0E–09 
Lasso peptides Astexin-1 AtxB ADU13885.1 2–61 96 3.7E–03 1.1E–07 900a
Lasso peptides Lariatin LarC BAL72548.1 1–84 100 4.0E–25 1.2E–29 
Lasso peptides Streptomonomicin StmE KIH99640.1 1–81 100 2E–24 5.8E–29 
Sactipeptides Subtilosin AlbA WP_003242599.1 8–98 98 6.3E–06 1.8E–10 170d
PQQ  PQQ PqqD  ACI10478.1 1–88 100 2.5E–30 7.1E–35 ≥ 125e
Mycofactocins Mycofactocin* MftB ACM06913.1 9–95 92 1.5E+00 4.4E–05 300a 
Proteusins Polytheonamide PoyD AFS60640.1 427–519 94 3.3E–01 9.6E–06  
Proteusins Polytheonamide PoyB AFS60637.1 528– 609 97 7.4E–03 2.1E–07 100d 
Bottromycins Bottromycin BmbB CCM09442.1 515–587 96 1.8E–02 5.3E–07  
Trifolitoxins Trifolitoxin* TfxB AAA26364.1 1–85 94 9.8E–02 2.8E–06 n.d. 
  
194 
 
Table 2.4. Discrete LAP cyclodehydratase RREs bind the leader peptide. BalhC and CurC were tested for 
binding to FITC- BalhA1-LP and FITC-CurA-LP, respectively. The peptide binding affinity for many 
BalhC mutants (D14A, Y16A, F18A, E21A, F29A, R31A, Y34A, I35A, Y71A, I75A, L78A, and K82A) 
appeared beyond the testable range of our assay (>150 μM). Error on Kd values represents the s.e.m. from 
curve fitting analysis of triplicate data. Abbreviation: WT, wild-type. 
 
Protein Kd (μM) Position of mutation 
BalhC WT 10 ± 1  
BalhC K20A 52 ± 4 β1 
BalhC D23A 50 ± 4 β2 
BalhC D32A 21 ± 3 β3 
BalhC H38A 21 ± 3 β3 
BalhC E66A 60 ± 7 α2 
CurC WT 7 ± 1  
CurC D18A 3.3 ± 0.2 β1 
CurC Q21A 8 ± 1 β2 
CurC E25A 4.3 ± 0.3 β2 
CurC Y31A >150 β3 
CurC E36A 3.1 ± 0.2 α1 
CurC R68A 79 ± 6 α3 
CurC I75A 66 ± 6 α3 
 
 
 
Table 2.5 BalhC alanine substitutions outside of the RRE have little effect on leader peptide binding. 
Because most alanine substitutions tested within the BalhC RRE resulted in greatly reduced leader peptide 
affinity, positions outside of the RRE were also mutated for comparison. FP binding assays with these 
mutants indicated that residues outside the RRE contributed little to binding while some appeared to have 
a structural role based on low protein yield and appearance by Coomassie-stained SDS-PAGE (Figure 2.6). 
Error bars represent s.e.m. from regression analysis of triplicate data. 
 
Protein Kd (μM) 
BalhC WT 10  1 
BalhC R192A structural 
BalhC Q196A 5  1 
BalhC Y199A 10  3 
BalhC E281A structural 
BalhC N292A 8  2 
BalhC N294A 7  1 
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Table 2.6. F-dependent cyclodehydratase RREs bind the leader peptide. Protein components of the Hca 
and Tbt F-dependent cyclodehydratases were tested for binding to FITC- HcaA-LP and FITC-TbtA-LP, 
respectively. Error on Kd values represents the s.e.m. from curve fitting analysis of triplicate data. 
Abbreviation: WT, wild-type. 
 
Protein Kd (nM) Position of mutation 
HcaF WT 89 ± 9  
HcaF D21A 130 ± 15 β1 
HcaF F35A 1,700 ± 300 β3 
HcaF D38A 77 ± 7 β3 
HcaF N72A 79 ± 7 α3 
HcaF R73A >10,000 α3 
HcaF E76A 250 ± 50 α3 
HcaF E79A 75 ± 6 α3 
HcaF I80A 500 ± 60 α3 
TbtF WT 66 ± 5  
TbtG WT >10,000  
TbtF/G 66 ± 5  
TbtF D19A 57 ± 2 β2 
TbtF L24A 65 ± 3 β2 
TbtF V30A 210 ± 15 β3 
TbtF F68A 7,700 ± 400 α3 
TbtF R71A 190 ± 22 α3 
TbtF Q74A 49 ± 3 α3 
TbtF R79A 79 ± 5 α3 
 
  
196 
 
Table 2.7. Split lasso peptide protease RRE binds the leader peptide. StmE binding to FITC-labeled StmA 
leader peptide was investigated by FP. Error on Kd values represents the s.e.m. from curve fitting analysis 
of triplicate data. Abbreviation: WT, wild-type. 
 
Protein Kd (nM) Position of mutation 
StmE WT 35 ± 10  
StmE V12A 160 ± 50 β1 
StmE N22A 410 ± 120 β2 
StmE Y28A 28 ± 5 β3 
StmE D68A 38 ± 7 α3 
StmE D69A 2600 ± 400 α3 
StmE L73A >10,000 α3 
StmE D75A 35 ± 9 α3 
StmE Q76A 75 ± 25 α3 
 
 
 
Table 2.8 Sequence of fluorescent peptides used in this study. Fluorescein isothiocyanate (FITC)-
conjugated peptides were purchased from Genscript with an amino hexyl linker (Ahx) spacer, with the 
exception of the FITC-labeled leader peptides (LP) for HcaA and TbtA, which were prepared by labeling 
the N-terminus of a heterologously expressed peptide (Dunbar et al., submitted). FITC-labeled CurA-LP 
represents the CurA leader with an N6S substitution (the wild-type sequence for BlinA46, see Figure 2.8). 
This peptide binds to CurC with the same affinity as the wild-type CurA peptide (Figure 2.13). 
 
Peptide Sequence 
FITC-BalhA1-LP FITC-Ahx-GMEQKKILDIKLTETGKINYAHKPDD 
FITC-CurA-LP FITC-Ahx-GMSTLISKLPPAVSTDSSKIVSEVQAFEPT 
FITC-HcaA-LP FITC-SGSMNQFQQELQSLNLNDYQTGNVVYWDPQQSQYPYYYIQDDAR 
FITC-TbtA-LP FITC-SRRGSMLNLSDLPMDVFEMADSGMEVESLTAGHGMPEVGA 
FITC-StmA-LP FITC-Ahx-MSAYEIPTLTRIGKFKDVTK 
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Table 2.9 Oligonucleotides used for cloning and site-directed mutagenesis. The cloning primers are named 
for the amplified gene and whether the primer was for the forward (F) or reverse (R) direction. The 
restriction enzyme sites are also given. For the mutagenic primers, the resultant amino acid substitution is 
indicated in parentheses. 
 
Cloning Primer Oligonucleotide Sequence Restriction site 
CurA F AAAGGATCCATGTCCACACTAATCAACAAGCTGCCTC BamHI 
CurA R AAAGCGGCCGCTTAACCGCCGCAGCAGCA NotI 
CurC F AAAAGGATCCATGACTGAAACTCAGAGGTACCAAG BamHI 
CurC R AAAAGCGGCCGCTCACTCCTCATGAAACCAAATTTGTG NotI 
CurD F  AAAGTCGACATGGCCGCATCAGCAGAATTTTCG SalI 
CurD R AAAGCGGCCGCTTATGGGAATGGGTGGGGAAGAGG NotI 
StmA F AAAAAGCTTGATGAGCGCTTACGAGATCCCCACTC HindIII 
StmA R AAAGCGGCCGCTCACGGGTAGATGACGATCAGAGCC NotI 
StmE F AAAAAGCTTGATGAGAGTCCAGATGCGGCCCAACG HindIII 
StmE R AAAGCGGCCGCTCATGAGTGCCGCACCTCGACCAGC NotI 
StmB F AAAAAGCTTGATGAGCTCCCCGATCCTGCCCGAGG HindIII 
StmB R AAAGCGGCCGCTCACGCACTGGGGCGCGCCGAAC NotI 
Mutagenic Primer Oligonucleotide Sequence 
BalhC (D14A) F TGAGGTTCTTAATTATAAACCTATAATAGCTAGCTATTGTTTTGTAAAAGAAGATGATG 
BalhC (D14A) R CATCATCTTCTTTTACAAAACAATAGCTAGCTATTATAGGTTTATAATTAAGAACCTCA 
BalhC (Y16A) F CTATAATAGATAGCGCTTGTTTTGTAAAAGAAGATGATGAAGG 
BalhC (Y16A) R CTTTTACAAAACAAGCGCTATCTATTATAGGTTTATAATTAAGAACC 
BalhC (F18A) F GATAGCTATTGTGCTGTAAAAGAAGATGATGAAGGAC 
BalhC (F18A) R CTTCTTTTACAGCACAATAGCTATCTATTATAGGTTTATAATTAAGAACC 
BalhC (K20A) F CTATTGTTTTGTAGCAGAAGATGATGAAGGACTAACATTTTTTAATAG 
BalhC (K20A) R CCTTCATCATCTTCTGCTACAAAACAATAGCTATCTATTATAGG 
BalhC (E21A) F GTTTTGTAAAAGCAGATGATGAAGGACTAACATTTTTTAATAG 
BalhC (E21A) R CCTTCATCATCTGCTTTTACAAAACAATAGCTATCTATTATAG 
BalhC (D23A) F GTAAAAGAAGATGCTGAAGGACTAACATTTTTTAATAGGGATA 
BalhC (D23A) R GTTAGTCCTTCAGCATCTTCTTTTACAAAACAATAGCTATC 
BalhC (F29A) F GGACTAACATTTGCTAATAGGGATACATATATAAATTTTCATGGAG 
BalhC (F29A) R TATCCCTATTAGCAAATGTTAGTCCTTCATCATCTTCTTTTAC 
BalhC (R31A) F AACATTTTTTAATGCGGATACATATATAAATTTTCATGGAGGTTC 
BalhC (R31A) R AATTTATATATGTATCCGCATTAAAAAATGTTAGTCCTTCATCATCTT 
BalhC (D32A) F ATGAAGGACTAACATTTTTTAATAGGGCTACATATATAAATTTTCATGGAGGTTC 
BalhC (D32A) R GAACCTCCATGAAAATTTATATATGTAGCCCTATTAAAAAATGTTAGTCCTTCAT 
BalhC (Y34A) F ATAGGGATACAGCTATAAATTTTCATGGAGGTTCAGTTGAG 
BalhC (Y34A) R CATGAAAATTTATAGCTGTATCCCTATTAAAAAATGTTAGTCCTTCATC 
BalhC (I35A) F AGGGATACATATGCAAATTTTCATGGAGGTTCAGTTGAGGATATC 
BalhC (I35A) R CCATGAAAATTTGCATATGTATCCCTATTAAAAAATGTTAGTCC 
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Table 2.9 (Continued) 
Mutagenic Primer Oligonucleotide Sequence 
BalhC (H38A) F CATATATAAATTTTGCTGGAGGTTCAGTTGAGGATATCTTTGCT 
BalhC (H38A) R ACTGAACCTCCAGCAAAATTTATATATGTATCCCTATTAAAAAATGT 
BalhC (E66A) F CAGAAAAATTAGCATTACCTATAGAATATATGTGCGACATAAT 
BalhC (E66A) R TCTATAGGTAATGCTAATTTTTCTGCTAATTGTTCTGTACTTAAT 
BalhC (Y71A) F TACCTATAGAAGCTATGTGCGACATAATTAAATTGTTAGACG 
BalhC (Y71A) R ATGTCGCACATAGCTTCTATAGGTAATTCTAATTTTTCTGCT 
BalhC (I75A) F GAATATATGTGCGACGCAATTAAATTGTTAGACGAGAAAAATATTA 
BalhC (I75A) R AACAATTTAATTGCGTCGCACATATATTCTATAGGTAATTCT 
BalhC (L78A) F ACATAATTAAAGCGTTAGACGAGAAAAATATTATAAAAAATTACG 
BalhC (L78A) R TTCTCGTCTAACGCTTTAATTATGTCGCACATATATTCTATAG 
BalhC (K82A) F TGTTAGACGAGGCAAATATTATAAAAAATTACGATTTACAAGAAAAATAT 
BalhC (K82A) R TTATAATATTTGCCTCGTCTAACAATTTAATTATGTCGCAC 
BalhC (R192A) F GTACCGTTTTTAGCAGGAGTAGTACAAGAGCAATATTTTAGTA 
BalhC (R192A) R TGTACTACTCCTGCTAAAAACGGTACTTTGTAACATTTCG 
BalhC (Q196A) F GAGGAGTAGTAGCAGAGCAATATTTTAGTATAGGGCCAATA 
BalhC (Q196A) R TAAAATATTGCTCTGCTACTACTCCTCTTAAAAACGGTACTTTG 
BalhC (Y199A) F TACAAGAGCAAGCTTTTAGTATAGGGCCAATATTC 
BalhC (Y199A) R CTATACTAAAAGCTTGCTCTTGTACTACTCCTCTTAAAAACG 
BalhC (E281A) F TGTATGCCTTGCGAAATAATTGGAAAAGCATTCACTTATAATGTATTTAATTTAAGTT 
BalhC (E281A) R AACTTAAATTAAATACATTATAAGTGAATGCTTTTCCAATTATTTCGCAAGGCATACA 
BalhC (N292A) F AATTTAAGTTCAGCTTTAAATCCTGTATTAAAAGTTCCTGGG  
BalhC (N292A) R TACAGGATTTAAAGCTGAACTTAAATTAAATACATTATAAGTGAATTCTTTTC 
BalhC (N294A) F AATTTAAGTTCAAATTTAGCTCCTGTATTAAAAGTTCCTGG 
BalhC (N294A) R CTTTTAATACAGGAGCTAAATTTGAACTTAAATTAAATACATTATAAGTGAATTC 
CurA (N6S) F CCACACTAATCTCCAAGCTGCCTCCCGCAGTTTCAACTGAT 
CurA (N6S) R GGAGGCAGCTTGGAGATTAGTGTGGACATGGATCCGGATTG 
CurC (D18A) F GGGTATCGCGCGCCGGCAACCAGATCGTTATAGAAGCCGCG 
CurC (D18A) R ATCTGGTTGCCGGCGCGCGATACCCGCAGGTCTGGGTTAAC 
CurC (Q21A) F GCGACGGCAACGCGATCGTTATAGAAGCCGCGTCAAACACA 
CurC (Q21A) R TCTATAACGATCGCGTTGCCGTCGCGCGATACCCGCAGGTC 
CurC (E25A) F AGATCGTTATAGCAGCCGCGTCAAACACATATTGTCTCTCCG 
CurC (E25A) R TTTGACGCGGCTGCTATAACGATCTGGTTGCCGTCGCGCGAT 
CurC (Y31A) F GTCAAACACAGCTTGTCTCTCCGATGAGGCTCTATGGC 
CurC (Y31A) R CGGAGAGACAAGCTGTGTTTGACGCGGCTTCTATAACG 
CurC (E36A) F TCTCTCCGATGCGGCTCTATGGCCTTTCATCTCTGAAGT 
CurC (E36A) R GCCATAGAGCCGCATCGGAGAGACAATATGTGTTTGACG 
CurC (R68A) F GAGACATTGAAGCACTTCAAGCAGCATTTGAAATTCTTTCAGA 
CurC (R68A) R GCTGCTTGAAGTGCTTCAATGTCTCTAGGCTCATACTCGTC 
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Table 2.9 (Continued) 
Mutagenic Primer Oligonucleotide Sequence 
CurC (I75A) F CAGCATTTGAAGCTCTTTCAGAAACTGAAGTTCTTATTCCATCT 
CurC (I75A) R GTTTCTGAAAGAGCTTCAAATGCTGCTTGAAGTCGTTCAATG 
HcaF (D21A) F CCTCCCCGCCTCAAACGGGGGTGTCTATTTTC 
HcaF (D21A) R CCGTTTGAGGCGGGGAGGAAGAAAGTATCTTTATTTAC 
HcaF (F35A) F CGCCAGTTCAGCTCGTATGGACGGTGACGGAATTTAT 
HcaF (F35A) R CGTCCATACGAGCTGAACTGGCGTTATTTCGAAAATAGACAC 
HcaF (D38A) F CATTTCGTATGGCCGGTGACGGAATTTATAACTGGATTGA 
HcaF (D38A) R TCCGTCACCGGCCATACGAAATGAACTGGCGTTATTTC 
HcaF (N72A) F CTCCCCTATCAAGCTCGTGTATTTGAAATTGGAGAGATTTTATATACA 
HcaF (N72A) R TCAAATACACGAGCTTGATAGGGGAGAGGGAGACCATC 
HcaF (R73A) F TCCCCTATCAAAATGCTGTATTTGAAATTGGAGAGATTTTATATACAAATGGGT 
HcaF (R73A) R AATTTCAAATACAGCATTTTGATAGGGGAGAGGGAGACCATC 
HcaF (E76A) F ATCGTGTATTTGCAATTGGAGAGATTTTATATACAAATGGGTTTGT 
HcaF (E76A) R ATCTCTCCAATTGCAAATACACGATTTTGATAGGGGAGAG 
HcaF (E79A) F TGAAATTGGAGCGATTTTATATACAAATGGGTTTGTCCGTG 
HcaF (E79A) R GTATATAAAATCGCTCCAATTTCAAATACACGATTTTGATAG 
HcaF (I80A) F TCGTGTATTTGCAATTGGAGAGATTTTATATACAAATGGGTTTGT 
HcaF (I80A) R CATTTGTATATAAAGCCTCTCCAATTTCAAATACACGATTTTGATAGGGGAG 
TbtF (D19A) F TCCGACCAGTGCTGGCGTTGCTTTCCTGACCCGT 
TbtF (D19A) R GAAAGCAACGCCAGCACTGGTCGGAGCATAACGAACG 
TbtF (L24A) F GCGTTGCTTTCGCGACCCGTGATGGTATTGTGAGTATTACCGGC 
TbtF (L24A) R CATCACGGGTCGCGAAAGCAACGCCATCACTGGTCGG 
TbtF (V30A) F CGTGATGGTATTGCGAGTATTACCGGCGTTTCCATCCACCG 
TbtF (V30A) R CGGTAATACTCGCAATACCATCACGGGTCAGGAAAGCAACG 
TbtF (F68A) F ACGTCGCGCAGCCGTGCTGCGTCTGCTGCAGGCAC 
TbtF (F68A) R ACGCAGCACGGCTGCGCGACGTTCCGGTGCCAG 
TbtF (R71A) F CATTCGTGCTGGCTCTGCTGCAGGCACTGGCAGATC 
TbtF (R71A) R CCTGCAGCAGAGCCAGCACGAATGCGCGACGTTCC 
TbtF (Q74A) F GCGTCTGCTGGCGGCACTGGCAGATCGCGGTCTGATTATCG 
TbtF (Q74A) R CTGCCAGTGCCGCCAGCAGACGCAGCACGAATGCG 
TbtF (R79A) F CACTGGCAGATGCCGGTCTGATTATCGACGCAGCCGG 
TbtF (R79A) R GATAATCAGACCGGCATCTGCCAGTGCCTGCAGCAGACG 
StmE (V12A) F CGTGCAGATCGCTTCCCGGGACGGCGACAACTTC 
StmE (V12A) R GTCCCGGGAAGCGATCTGCACGTTGGGCCGCATC 
StmE (N22A) F CTTCGTCCTCGCCCTGCGCAACGGCGAATACTGGC 
StmE (N22A) R GTTGCGCAGGGCGAGGACGAAGTTGTCGCCGTCCCG 
StmE (Y28A) F CAACGGCGAAGCCTGGCACCTCAACTCGTCGGCG 
StmE (Y28A) R TGAGGTGCCAGGCTTCGCCGTTGCGCAGGTTGAG 
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Table 2.9 (Continued) 
Mutagenic Primer Oligonucleotide Sequence 
StmE (D68A) F  AGACTGTCCGGGCCGACCTCACCGAACTGGTGGACCAGCTC 
StmE (D68A) R TCGGTGAGGTCGGCCCGGACAGTCTGCTCGGGGGCGGA 
StmE (D69A) F CTGTCCGGGACGCCCTCACCGAACTGGTGGACCAGCTCCGC 
StmE (D69A) R AGTTCGGTGAGGGCGTCCCGGACAGTCTGCTCGGGGGCG 
StmE (L73A) F ACCTCACCGAAGCGGTGGACCAGCTCCGCAAGGCCAAGCTGG 
StmE (L73A) R AGCTGGTCCACCGCTTCGGTGAGGTCGTCCCGGACAGTCTGC 
StmE (D75A) F GAACTGGTGGCCCAGCTCCGCAAGGCCAAGCTG  
StmE (D75A) R GCGGAGCTGGGCCACCAGTTCGGTGAGGTCGTC 
StmE (Q76A) F ACTGGTGGACGCGCTCCGCAAGGCCAAGCTGGTC 
StmE (Q76A) R CCTTGCGGAGCGCGTCCACCAGTTCGGTGAGGTCG 
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Chapter 3: Chimeric Leader Peptides for the Generation of Non-Natural Hybrid RiPP Products3 
 
3.1 Introduction 
With the considerable success of natural products as drugs,1-3 great efforts have been invested in using 
synthetic biology to engineer analogs of natural products with desired chemical and biological 
properties.4-6 One popular approach has been to combine enzymes from different biosynthetic pathways to 
generate new products in a process known as combinatorial biosynthesis.7, 8 Most commonly, this 
procedure was applied to polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) 
pathways where different domains or modules were swapped or deleted. This approach enabled alteration 
of the loaded amino acid in non-ribosomal peptides or the loading and/or extender unit and its subsequent 
oxidation state in polyketides.9, 10 Despite these feats, the approach has been largely limited to producing 
new variants of a given pathway rather than building entirely new products or pathways because of the 
incompatibility of interdomain linker regions, module interfaces, as well as other requirements.9, 10 
 Ribosomally synthesized and posttranslationally modified peptides (RiPPs)11 represent another 
group of natural products that provide an attractive starting point for engineering new molecules. The 
potential for engineering RiPPs derives from their leader peptide-guided biosynthetic logic and the 
reduced size of the biosynthetic gene clusters.12 Despite their genetic simplicity, RiPPs are structurally 
and functionally diverse11, 13, 14 and their biosynthesis entails a well-orchestrated modification of a 
ribosomally produced precursor peptide (Figure 3.1a). RiPP biosynthetic proteins bind their respective 
precursor peptide(s) through specific recognition sequences (RS) typically located in the N-terminal 
leader region.12 The majority of prokaryotic RiPP pathways rely on a ~90-residue PqqD-like domain, 
known as the RiPP recognition element (RRE),15 to engage the RS, but some notable examples of leader 
peptide-dependent enzymes lack this domain or do not use it.16-18 Once the leader peptide is bound, the C-
terminal core region of the precursor peptide undergoes posttranslationally modification, sometimes 
extensively, to form azol(in)e heterocycles, lanthionine or sactionine crosslinks, D-amino acids, various 
types of macrocycles, and other modifications.11 The modified core region ultimately becomes the natural 
product as the unmodified leader region is enzymatically removed during biosynthetic maturation. 
Beyond the primary, class-defining modifications installed by leader-dependent enzymes, RiPPs can also 
be endowed with multiple secondary modifications by “tailoring” enzymes. In most cases, these tailoring 
                                                     
3 This chapter is reproduced with permission from Burkhart, B.J.; Kakkar, N.; Hudson, G.A.; van der Donk, W.A.; Mitchell, D.A. 
Chimeric leader peptides for the generation of non-natural hybrid RiPP products. ACS Cent. Sci. 2017, 6, 629-638. Copyright 
2017 American Chemical Society. Experiments were designed by B.J.B., N.K., W.A.v.d.D, and D.A.M. and performed by B.J.B., 
N.K., and G.A.H. B.J.B. wrote this work with contribution from N.K. for section 3.2.3 and 3.2.5. All coauthors reviewed and 
edited this work. 
207 
 
enzymes act on the core region independently of the leader peptide to increase the chemical diversity of 
the core peptide.11 
 The physical separation of leader peptide binding and sites of modification allow RiPP enzymes 
to solve the paradoxical problem of being both specific for a substrate yet promiscuously act upon it.19-25 
Indeed, many natural RiPP pathways have highly variable core regions but retain nearly identical 
biosynthetic enzymes and leader peptides.26-29 RiPPs also increase structural diversity by acquiring new 
enzymes from different pathways to create natural “hybrid” RiPPs,30  sometimes leading to entirely new 
classes as exemplified by the elaboration of linear azol(in)e-containing peptides into the cyanobactin and 
thiopeptide classes (Figure 3.2).11, 31 A few reports have demonstrated artificial combinations of RiPP 
enzymes,32-36 but these examples have not led to combinations of modifications from different RiPP 
classes because they primarily swap enzymes between pathways that produce structurally related 
molecules.32-36 Ideally, more diverse combinations of structural modifications can be harnessed using 
RiPP enzymes, but no general approach has been reported for the production of peptides with 
posttranslational modifications from different RiPP classes. 
In order to address this unmet challenge, we envisioned a “chimeric leader peptide” strategy that 
would enable the rational combination of RiPP modifications. In this method, RSs from two leader 
peptides are concatenated to form a new bifunctional leader peptide within a single precursor peptide 
(Figure 3.1b). With their native RSs present, we hypothesized that two primary modifying enzymes 
would bind to their respective regions on the chimeric leader peptide and sequentially install 
posttranslational modifications, resulting in a hybrid RiPP product. We demonstrate that, after optimizing 
the core sequence and properly designing the co-expression plasmids, this approach successfully 
combines a thiazoline-forming cyclodehydratase (HcaD/F) with primary modifying enzymes from several 
different RiPP classes including sactipeptides (AlbA) and class I and II lanthipeptides (NisB/C and 
ProcM, respectively; Figure 3.1c-e). We also demonstrate how leader-independent tailoring enzymes such 
as MibD and NpnJA (Figure 3.1f) can be included. Thus, this work lays a broad foundation for the 
generation of designer RiPP hybrids. 
 
3.2 Results 
3.2.1 Thiazoline-lanthipeptide (class I) hybrid 
To probe the feasibility of a chimeric leader peptide strategy to mix-and-match disparate RiPP 
biosynthetic pathways (Figure 3.1b), we first sought to combine an azoline-forming cyclodehydratase 
(HcaD/F) with a lanthipeptide synthetase (NisB/C). HcaD/F is a thiazoline-forming cyclodehydratase31 
(Figure 3.1d) and was chosen in part because the RS of the precursor peptide (HcaA) was previously 
defined.37 The other enzyme, NisB/C, originates from the nisin biosynthetic gene cluster and was chosen 
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because of the large body of knowledge pertaining to how the peptide substrate (NisA) is recognized and 
processed (Figure 3.3).38 As a class-defining enzyme, NisB/C forms the characteristic lanthionine (Lan) 
or methyllanthonine (MeLan) residues found in lanthipeptides through a two-step process.38 First, NisB 
catalyzes dehydration of Ser/Thr residues to form the corresponding dehydroalanine (Dha) or 
dehydrobutyrine (Dhb). Next, NisC catalyzes a 1,4-nucleophilic addition of a Cys thiol to the Cβ of the 
dehydro amino acid to form a thioether ring (Figure 3.1e). Being a class I lanthipeptide dehydratase, NisB 
forms Dha/Dhb moieties in a tRNA-dependent manner while other classes of lanthipeptide dehydratases 
employ an ATP-dependent mechanism.38-40 
A chimeric precursor peptide was constructed from the HcaA and NisA precursor peptides to 
serve as a potential substrate for both HcaD/F and NisB/C (Figure 3.4a). The sequence of this hybrid 
peptide (Hyp1.1) was designed to resemble key segments of each parent peptide. HcaD/F and NisB/C 
both have an RRE domain for leader peptide recognition and the RS residues of their substrates are 
known (Figure 3.4). To incorporate both the RS from HcaA and NisA, we replaced the non-essential C-
terminal region of the HcaA leader peptide37 with the essential region of the NisA leader peptide.41, 42 We 
next engineered the core region of the chimeric precursor peptide. Leader-dependent enzymes are known 
to require a certain minimum spacer region between the RS and the core peptide,36, 40, 41 whereas extended 
core sequences are generally accepted.43-46 Therefore, we first introduced a “GGRCG” motif, which  
derives from HcaA, at a position that would be appropriately distanced from the RS of HcaA to facilitate 
HcaD/F processing but too close to the NisA RS to allow for NisB/C processing. This motif was then 
followed by a segment of native NisA core sequence so that it would approximate the natural spacing 
from the NisA RS on the chimeric leader peptide (Figure 3.4a). Only twelve residues of the NisA core 
peptide were used to simplify analysis by mass spectrometry. 
As diagrammed in Figure 3.4, the hybrid was tested by expressing HcaD/F, NisB/C, and His6-
Hyp1.1 in Escherichia coli (see Table 3.1 for plasmids). The modified peptide was affinity purified, 
digested with endoproteinase AspN, and analyzed via matrix-assisted laser desorption ionization time of 
flight mass spectrometry (MALDI-TOF-MS). A mixture of three products was evident. The most 
extensively processed peptide was dubbed Hyp1.1a and contained one thiazoline, two Dhb, one MeLan, 
and one Lan (Figure 3.4). To confirm the structure, we leveraged the fact that thiazolines are readily 
hydrolyzed to Cys under mild acid treatment with a concomitant gain of 18 Da. Treatment with 
iodoacetamide under reducing conditions, which would alkylate free Cys, yielded very little product 
suggesting that the thioether rings were formed in high yield.  
While previous nisin biosynthetic manipulation introduced new tailoring enzymes from related 
pathways32, 33 and hybrids have been synthetically prepared,47, 48 the enzymatic incorporation of a non-
native modification (thiazoline) has not been reported. Our data show the feasibility of combining 
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disparate RiPP pathways to generate new-to-nature hybrids by rationally designing a chimeric leader 
peptide. These results also demonstrate that two RiPP enzymes that compete for modification of the same 
residue (Cys) can still be rendered compatible. In this first example, discrete regions in Hyp1.1 were used 
to mimic the native peptides and a similar approach could be used to append different modified structures 
to the N-terminus of other lanthipeptides. 
 
3.2.2 Thiazoline-sactipeptide hybrid 
Building on these initial results, we next sought to combine HcaD/F with an enzyme from another RiPP 
class that also modifies Cys. For this, the radical S-adenosylmethionine (rSAM) enzyme, AlbA, from 
subtilosin biosynthesis was chosen (Figure 3.5). AlbA is oxygen-sensitive and forms thioether crosslinks 
between Cys thiols and the Cα of an acceptor residue. These linkages are called sactionines and gave rise 
to the RiPP class of sactipeptides (Figure 3.1c, note the difference to Cβ-linked Lan).49, 50 AlbA and 
HcaD/F both harbor RREs,15 and hence this would be a second test of whether structurally similar binding 
domains on two enzymes that both act on Cys could be used to site-selectively modify a peptide substrate. 
Given the short natural leader peptide of SboA, the native substrate for AlbA, a simpler hybrid peptide 
(Hyp2.1) was designed that merely appended the minimal HcaA leader sequence to the N-terminus of 
SboA (Figure 3.6a). A C-terminal Arg was included in the core peptide to enhance MS detection. Because 
the core peptide of SboA has three Cys residues, we expected to see a mixture of modified products, 
which would allow us to assess competition between the two enzymes in the absence of any core peptide 
engineering. 
 The potential thiazoline-sactipeptide hybrid system was first tested by expressing AlbA, HcaD/F, 
and Hyp2.1 in E. coli (Table 3.1). Under high culture aeration (shaking at 250 rpm in baffled flasks), only 
cyclodehydration was observed. Upon reducing the culture aeration (shaking at 100 rpm in non-baffled 
flasks),50 we observed either sactionine-containing (strong signal) or thiazoline-containing (weak signal) 
products. No observable products contained both modifications (Figure 3.7). Although both enzymes 
were active under lower aeration conditions, AlbA appeared to outcompete HcaD/F given the low 
intensity signals for cyclodehydrated products (Figure 3.7). Prior work indicates that both HcaD/F and 
AlbA are highly processive with their native precursor peptides (i.e. substrate processing is faster than 
intermediate release).37, 51 We reasoned that intermediates with Hyp2.1 may also not be released during 
processing, thus preventing formation of a hybrid product. Additionally, if AlbA was acting faster 
because its native core sequence was used in Hyp2.1, thioether formation could preclude subsequent 
azoline formation.  
In order to overcome this challenge, we enhanced the rate of azoline-formation by editing the 
core peptide to include a more native-like “RCGGC” motif resulting in a second hybrid peptide with four 
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Cys (Hyp2.2; Figure 3.6a). Presumably, the “RCGGC” motif would be more efficiently processed by 
HcaD/F while the remaining two Cys native to SboA would remain available for modification by AlbA. 
Upon co-expression of Hyp2.2 with the enzymes (Table 3.1), a mass was detected that was consistent 
with two sactionines and two dehydrations (Figure 3.6c). Mild acid treatment supported the presence of 
two thiazolines, as indicated by a gain of 36 Da. The presence of two sactionines was supported by lack 
of reactivity towards iodoacetamide. Analysis of high-resolution tandem MS spectra localized these 
modifications and corroborated the proposed structure (Figure 3.8). Additional evidence for the structure 
is provided by the following observations: (i) trypsin cuts very slowly at Lys2 near the first crosslink, 
presumably due to steric congestion (for structure, see Figure 3.6c), (ii) Arg12-related tryptic fragments 
were not detected (because the scissile bond was transformed to a thiazoline), and (iii) treatment with 
endoproteinase GluC did not result in digestion at Glu23 (Figure 3.9). Other low intensity signals 
consistent with a tri-thiazoline/mono-sactionine and tetra-thiazoline species were also detected, 
suggesting the hybrid pathway does not necessarily follow a strict processing order (Figure 3.6c). 
Based on the results of Hyp2.1 and 2.2 (Figures 3.6 and 3.7), a change in the sequence context of 
a modifiable residue can change which RiPP enzyme will act at that position. Alteration of surrounding 
residues has been previously shown to enhance or diminish the processing rate of cyclodehydratases.25, 52, 
53 The use of the SboA core sequence initially provided an advantage to AlbA. However, the processing 
efficiency of HcaD/F could be enhanced through insertion of a more native-like RCGGC motif, 
ultimately producing the desired hybrid product.  
Because AlbA and HcaD/F were transplanted from unrelated pathways, we could not use evolved 
biosynthetic controls to ensure that both enzymes act in the desired order to produce a hybrid product. 
Such controls include using protein-protein interactions that channel the substrate from one enzyme to the 
next or tuning biosynthetic enzymes to favor core processing only in a specific order (e.g. LanP and PatG 
proteases preferentially remove recognition sequences after earlier modifications are completed).18, 38 In 
the absence of such controls that are difficult to engineer, a key design feature for controlling hybrid RiPP 
biosynthetic schemes is using the local sequence context to alter the rate of enzymes that compete for the 
same residues or install modifications that block the activity of subsequent enzymes.  
 
3.2.3 Thiazoline-lanthipeptide (class II) hybrid 
Thus far, three different primary RiPP enzymes have been shown to be tolerant toward substrates with 
non-native elements, but it has yet to be determined if a single enzyme pair will be generally able to 
process several different peptide sequences. For convenience, HcaD/F was again chosen for incorporation 
into another hybrid biosynthetic pathway to investigate this question. The class II lanthipeptide synthetase 
ProcM was selected as the second enzyme because it is mechanistically unique compared to the class I 
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NisB/C enzyme and provides another opportunity to test different enzyme types using the hybrid 
approach. ProcM is known to be highly substrate-tolerant, having 30 different native precursor peptides 
(ProcAs) and forming a structurally diverse set of lanthipeptides (Figure 3.10).28, 29, 54-56 Thus, we 
envisioned that it would be well suited for producing structurally diverse hybrid RiPPs.  Furthermore, use 
of ProcM would extend the scope of the method because it does not contain an RRE;16 in fact, the site of 
leader peptide binding on ProcM is currently not known. 
A chimeric leader peptide for ProcM and HcaD/F was designed analogously to the previous 
hybrids. The minimal HcaA leader peptide was joined with the C-terminal portion of ProcA2.8 because 
the majority of the ProcA N-terminus is dispensable for processing.28 Accordingly, the final 19 residues 
of the ProcA2.8 leader peptide were placed after the first 25 residues of the HcaA leader region (Figure 
3.11a). As first trial, the native core sequence of ProcA2.8 was used to create Hyp3.1, which contained 
two Cys. Co-expression of Hyp3.1, HcaD/F, and ProcM (Table 3.1) produced a peptide with two Lan; no 
thiazolines were detected (Figure 3.12). Thus, as with the sactipeptide hybrid Hyp2.1, use of a native 
ProcA core peptide in the chimeric peptide resulted in ProcM outcompeting HcaD/F. Rather than 
improving HcaD/F catalysis by altering the local sequence of the core peptide, we decided to investigate a 
different control mechanism. We placed the gene for Hyp3.1 on the same plasmid as that for HcaD/F and 
lowered the copy number of the plasmid encoding ProcM to tune the activity in the desired direction 
(Table 3.1). This arrangement afforded a hybrid product with one thiazoline, as indicated by mild acid 
treatment, and one Lan (Figure 3.12). Analysis of MS/MS fragmentation indicated that the thiazoline was 
located at the N-terminal Cys while the Lan was at the C-terminus (Figure 3.13). It appeared, however, 
that the thiazoline at core position 3 (residue 13 of the AspN-digested peptide) inhibited dehydration at 
Ser9, indicating that thiazolines may occasionally interfere with downstream hybrid processing.  A low 
intensity ion consistent with a peptide containing two Lan was also observed, indicating the hybrid was 
not formed in quantitative yield. Substitution of the acceptor Ser9 to Ala in Hyp3.2 eliminated this side 
product (Figures 3.14 and 3.15). These data demonstrate how modest sequence alterations readily lead to 
the production of a single hybrid product without resorting to insertion of longer motifs.  
The general tolerability of HcaD/F and ProcM encouraged us to design a new hybrid based on a 
peptide with a completely different core sequence, ProcA3.3 (Figure 3.10). Like Hyp3.1, this hybrid 
(Hyp4.1) appended the HcaA minimal leader sequence to the C-terminal portion of the ProcA3.3 leader 
peptide (Figure 3.11a). The native ProcA3.3 core sequence contains two Cys that normally form a dual 
MeLan “ring-within-a-ring” topology in prochlorosin 3.3 (Figure 3.10). Co-expression of Hyp4.1, ProcM, 
and HcaD/F resulted in two major products: Hyp4.1a and Hyp4.1b (Figure 3.16). Hyp4.1a contained one 
Dhb, one thiazoline, and a non-natural MeLan between Thr18 and Cys21 (Figure 3.17). Hyp4.1b 
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displayed modifications similar to native prochlorosin 3.3, suggesting that ProcM had processed the 
substrate before HcaD/F.  
With HcaD/F and ProcM both able to act upon two different core peptides derived from native 
ProcA sequences, we next designed additional hybrids to direct enzymatic processing with greater 
precision. In the product of Hyp4.1, Cys21 forms a MeLan with Thr18, which places the thiazoline at 
Cys14 outside the MeLan macrocycle (Figure 3.17). We then wondered if we could create a hybrid in 
which a thiazoline would be within a (Me)Lan macrocycle. A Thr18Ala mutation was introduced 
(Hyp4.2; Figure 3.11a) to prevent Cys21 from generating a MeLan with Thr18 with the intention that it 
would then form a larger thioether ring with Thr11. After co-expression, Hyp4.2 was converted into a 
mixture of modified products (two thiazolines, thiazoline and Lan, or two Lan), indicating that each Cys 
could be modified by either enzyme (Figure 3.16). Although diversity generating systems can be 
advantageous, a mixture of products was not our desired outcome, and thus, we aimed to again tune the 
hybrid pathway to produce a single RiPP product. Accordingly, we designed Hyp4.3 in which we placed 
Asp before Cys21 to decrease the efficiency of HcaD/F processing at this position (i.e. Met20Asp 
substitution to Hyp4.2; Figure 3.11a). Expression of Hyp4.3 with HcaD/F and ProcM yielded primarily 
one product (Hyp4.3a) that contained one Dhb, one thiazoline, and one MeLan based on mild acid 
hydrolysis and iodoacetamide labeling (Figure 3.11c). MS/MS indicated that Cys21 was converted to 
MeLan, supporting our prediction that HcaF/D is less efficient in processing Cys with a preceding Asp 
residue (Figure 3.18; Figure 3.11c). The thiazoline was verified to be within the macrocycle through 
linearization by thermolysin digestion and subsequent MS/MS analysis (Figure 3.19). The 
stereochemistry of the MeLan was confirmed to be the native DL configuration by chiral GC/MS (Figure 
3.20), providing support that this ring was likely still formed enzymatically.38 The other low intensity ions 
observed from co-expression with Hyp4.3 appeared to be a mixture of isobaric species (Figure 3.21). 
The previous example demonstrates that a thiazoline can be installed within a large, 11-residue 
MeLan macrocycle. We next investigated whether a thiazoline could be placed within a smaller (Me)Lan 
macrocycle. For this purpose, we generated another variant of the ProcA2.8 core (Hyp3.3; Figure 3.11a). 
We introduced an additional Arg-Cys motif that we envisioned would become a thiazoline within a 7-
residue Lan macrocycle. Upon co-expression, the modified peptide had three dehydrations (-54 Da), two 
of which were susceptible to mild acid treatment, indicating the presence of two thiazolines and one Lan 
(Figure 3.11d). Lack of iodoacetamide labeling further indicated that all Cys were modified, and MS/MS 
fragmentation data support the proposed modified Hyp3.3 structure (Figure 3.22).  
Overall, these experiments with HcaD/F and ProcM suggest that the chimeric leader peptide 
strategy will be amenable to creating libraries of modified peptides. After plasmid design optimization, 
ProcM and HcaD/F processed several peptides with altered core sequences and produced different 
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modified structures with different arrangements of thiazoline heterocycles and (Me)Lan rings. The ability 
to further tune hybrid biosynthesis toward a single desired product through simple core sequence changes 
was also demonstrated. HcaD/F-dependent azoline-formation can apparently be inhibited by employing a 
C-terminal Cys or by using an “Asp-Cys” motif, which reduces residue competition. Conversely, a simple 
“Arg-Cys” motif was robustly cyclodehydrated in Hyp3.3. This is notable as the earlier examples relied 
on larger motifs to introduce thiazolines. With the use of minimalistic motifs to tune enzyme activity, and 
the usage of enzymes with diverse sequence preferences, we anticipate a wide diversity of new-to-nature 
RiPPs will be accessible through the chimeric leader peptide engineering approach.  
 
3.2.4 Hybrids with secondary tailoring enzymes 
Although our chimeric leader peptide strategy was designed for combining leader-dependent “primary” 
RiPP biosynthesis enzymes, the method should also allow interfacing with secondary tailoring enzymes. 
Many RiPP pathways have tailoring enzymes that install functional groups critical for bioactivity.11 We 
chose to combine the D-Ala-forming Dha reductase NpnJA from Nostoc punctiforme PCC 73102 (Figure 
3.1f) with the HcaD/F and ProcM hybrid system.57 NpnJA appears to prefer hydrophobic flanking 
residues, so a D2V/T3S double substitution was introduced into the Hyp4.2 peptide to create Hyp4.4 
(Figure 3.23a).57 Co-expression of Hyp4.4, HcaD/F, and ProcM initially produced three detectable species 
(Figure 3.23). The most intense ion (labeled as Hyp4.4a) was a hybrid containing one thiazoline, one 
MeLan, and one Dha (from dehydration of the newly introduced Ser3). Upon treating Hyp4.4a with 
NpnJA and NADPH in vitro, a new +2 Da product resulted (Hyp4.4b; Figure 3.23d), indicative of D-Ala 
formation. We also successfully combined HcaD/F with MibD, a flavin-dependent enyzme from 
Microbispora sp. 107891,58 to produce a C-terminally decarboxylated, linear azoline-containing peptide 
(Figure 3.24). 
These results indicate that our approach for creating hybrid RiPPs can be extended to leader-
independent modifications, provided the proper modifiable sequence is present. Even though tailoring 
enzymes tend to bind directly to the core peptide, inserting short motifs into the core in conjunction with a 
chimeric leader peptide led here to three distinct posttranslational modifications from unrelated pathways.  
 
3.3 Discussion 
Rational design of biosynthetic pathways to produce custom molecules has long been a goal of 
combinatorial biosynthesis and natural product synthetic biology. Despite progress in understanding 
natural pathways, the chemical space that can be explored by current engineering techniques is limited 
compared to what is theoretically possible.9, 10 In this work, we demonstrate how a chimeric leader 
peptide has the potential to unlock the vast chemical space afforded by RiPPs. This concept was inspired 
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by how natural pathways can combine different enzymes (Figure 3.2) and represents a major step forward 
in RiPP engineering. Although prior work has demonstrated enzyme swapping within related pathways, 
such as for nisin and the cyanobactins,27, 30, 32-36 this study is to our knowledge the first demonstration of 
leveraging the recognition sequences and programmability of RiPP enzymes to mix-and-match the 
primary, class-defining structural features from unrelated classes. In total, four mechanistically unique 
enzymes were shown to be tolerant to manipulation of their leader peptides and insertion of non-native 
sequences. 
The primary difficulty we encountered was ensuring that the enzymes acted at the desired 
locations and in the correct order. Being from unrelated pathways, there were no natural biosynthetic 
checkpoints to guide processing toward a single hybrid product, meaning the enzymes could compete for 
the same residue or act in a fashion that blocked the other enzyme. However, modest editing of the core 
sequence was sufficient to exploit the innate selectivity of an enzyme to yield the desired product. Future 
work with other enzymes that exhibit different substrate preferences may lead to a toolbox of enzymes for 
use in specific applications. Optimizing expression levels of each enzyme through plasmid design also 
adds another layer of control. Despite the successful use of these design principles in this work, there are 
likely some RiPP modifications that are inherently incompatible or too difficult to generally combine 
given their different structural requirements or limited promiscuity of their enzymes. Nonetheless, based 
on the enzymes combined here, we predict that many other hybrid RiPP combinations will be feasible.   
In summary, chimeric leader peptides appear to be a broadly applicable and effective platform for 
creating hybrid RiPPs. In the cases shown here, the method afforded significant product yields (~1 mg/L 
of culture for the core peptide without any optimization) and employed a standard co-expression plasmid 
system. Moreover, RiPP enzymes can be chosen even if the enzymes act on the same residue. Our 
approach was successful regardless of native leader peptide length (8 vs. 60+), its binding affinity (~5 µM 
for ProcA/ProcM vs. ~50 nM for HcaA/HcaF),37, 55 how it was bound (RRE or non-RRE binding site), or 
whether the binding site was previously known. Further, our approach is amenable to the inclusion of 
leader-independent enzymes. Accordingly, the chimeric leader peptide strategy holds much potential for 
combinatorial RiPP biosynthesis and opens the door for the generation of additional hybrid RiPP 
compounds. 
 
3.4 Methods 
3.4.1 General methods 
Materials were purchased from Fisher Scientific, Gold Biotechnology, or Sigma-Aldrich unless otherwise 
noted. Tryptone and yeast extract were purchased from Dot Scientific. Restriction enzymes (REs), AspN 
endoprotease, Q5 polymerase, T4 DNA ligase, and deoxynucleotides (dNTPs) were purchased from New 
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England Biolabs (NEB). Oligonucleotide primers were synthesized by Integrated DNA Technologies (IDT) 
and are listed in Table 3.2. DNA spin columns were purchased from Epoch Life Sciences, and DNA 
sequencing was performed by the Roy J. Carver Biotechnology Center (UIUC). All polymerase chain 
reactions (PCRs) were conducted on an S1000 thermal cycler (Bio-Rad). 
 
3.4.2 Cloning 
Plasmids were constructed using REs and DNA ligase or by Gibson assembly (GA). For RE cloning, the 
target gene was amplified with Q5 polymerase, and after PCR cleanup using the QIAquick PCR Purification 
Kit Protocol, the amplicon was digested with restriction enzymes for ligation into a similarly digested and 
purified vector. For amplifications which gave more than one product, a gel extraction was performed. 
Ligations were performed with T4 DNA ligase at 23 °C for 1 h (100 ng vector and 3-fold excess insert). 
For GA, the standard protocol was followed with guidance from the NEBuilder Assembly tool 
(nebuilder.neb.com). Inserts were generated using Q5 polymerase and purified as above. Vector backbones 
were linearized using PCR or restriction enzymes and similarly purified.  
Genes for the cyclodehydratase (HcaF and HcaD),37 lanthipeptide synthetase (ProcM and 
NisB/C),59 dehydroalanine reductase (NpnJ),57 and flavoenzyme decarboxylase (MibD)60 were cloned 
previously from their native organisms. All new plasmids used in this study are listed in Table 3.1 and were 
constructed using primers listed in Table 3.2. The subtilosin radical SAM gene (AlbA) and its precursor 
peptide (SboA) were cloned from Bacillus subtilis strain 168 genomic DNA.  
The hybrid peptides were built from HcaA, SboA, or ProcA precursor peptides through overlap 
extension PCR and initially cloned into a modified pET28 vector with an N-terminal maltose-binding 
protein (MBP) affinity tag (pET28-MBP). This intermediate was then used to clone MBP-tagged hybrid 
peptides into duet vectors or to express the peptide for in vitro activity assays. The NisA-derived hybrid 
peptide was synthesized as a gblock (IDT) for subsequent cloning and was cloned directly into a duet vector 
in frame with a His6 tag.  Duet vectors pACYCDuet, pCDFDuet, pETDuet, and pRSFDuet were used for 
co-expression in E. coli (see Table 3.1), as has been well established,61 and genes were sequentially cloned 
into each multiple cloning site. To insert the cyclodehydratase HcaF and HcaD genes into a single multiple 
cloning site, the genes were taken together as a single amplicon from pETDuet-HcaF-HcaD. 
 
3.4.3 Site-directed mutagenesis 
Changes to the sequence of hybrid peptides were made with cloned PFU or KOD polymerase (a 
proofreading DNA polymerase isolated from Thermococcus kodakaraensis) and the site-directed 
mutagenesis (SDM) primers in Table 3.2 following the Agilent QuikChange protocol. 
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3.4.4 In vivo production of modified hybrid peptides 
BL21(RIPL-DE3) chemically competent cells were co-transformed with pairs of duet vectors (Table 3.2) 
and selected with 100 µg/mL ampicillin for pETDuet, 50 µg/mL kanamycin for pRSFDuet or pET28, and 
34 µg/mL chloramphenicol for pACYCDuet. Initial cultures were started from single colonies and grown 
in 10 mL of Luria−Bertani (LB) broth in 18 mm glass culture tubes at 37 °C supplemented with appropriate 
antibiotics for several hours, and then used to inoculate 0.5 or 1 L of the same media. Cells were grown to 
~0.8 OD600, put on ice for 10 min, and induced with 0.6 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) 
at 22 °C except for co-expressions containing AlbA, which were shaken at 100 rpm in non-baffled flasks 
to reduce aeration (see Figure 3.5).62 After 18 h induction, cells were harvested at 4000  g for 15 min at 4 
°C, washed with TBS (Tris-buffered saline: 25 mM Tris pH 8.0, 150 mM NaCl), and centrifuged again at 
4000  g for 10 min at 4 °C. Cell pellets were stored for up to 1 week at -20 °C. 
 
3.4.5 Protein expression and purification 
BL21(DE3-RIPL) cells were transformed with plasmids containing the tagged proteins and selected using 
appropriate antibiotics. Starter cultures were grown in 10 mL LB with antibiotics and used to inoculate 1 L 
of similarly prepared media. After reaching an OD600 of ~0.8, cells were induced overnight with IPTG. 
Next, cells were harvested by centrifugation at 4000  g for 15 min at 4 °C, washed with TBS, and then 
subjected to centrifugation at 4000  g for 10 min at 4 °C. Cell pellets were stored for up to 1 week at -20 
°C. Proteins used for in vitro assays were purified using affinity chromatography via the MBP or His6 tag.  
MBP-tagged proteins were purified from E. coli cells using amylose resin (NEB). The resin was 
pre-equilibrated with 5 bed volumes of Buffer A [50 mM Tris pH 7.5, 500 mM NaCl, 2.5% (v/v) glycerol, 
0.1% (v/v) Triton X-100]. Cell pellets were suspended in Buffer A and sonicated 3 times for 30 seconds at 
10-13 W using a Misonix MICROSON XL2000 Cell Disruptor with 10 min incubations at 4 °C between 
each 30 second sonication period to prevent sample heating. The lysate was clarified by centrifugation at 
34000  g for 1 h on a Sorvall RC 6 plus centrifuge, applied to the equilibrated resin, and washed with 10 
bed volumes of Buffer B [50 mM Tris pH 7.5, 400 mM NaCl, 2.5% (v/v) glycerol]. Protein was then eluted 
using Elution Buffer [50 mM Tris pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol, 10 mM maltose] and 
collected into Amicon Ultra 15 mL Filter centrifugal filters [30kDa NMWL (Nominal Molecular Weight 
Limit)]. The eluted protein was concentrated and a 10-fold buffer exchange was performed into Storage 
Buffer [50 mM HEPES, 300 mM NaCl, 2.5% (v/v) glycerol] through centrifugation at 4000  g. The final 
protein concentration was calculated from the absorbance at 280 nm (NanoDrop 2000 UV-Vis 
Spectrophotometer) with the predicted protein extinction coefficient (http://web.expasy.org/protparam/) 
and the Bradford assay (Pierce™ Coomassie Protein Assay Kit). All proteins were stored at -80 °C. Note 
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that after initial column loading, all wash and storage buffers were supplemented with 1 mM tris-(2-
carboxylethyl)-phosphine (TCEP). 
His6-tagged proteins were purified identically to the above protocol except the buffer composition 
differed as follows: Buffer A [50 mM Tris pH 7.5, 500 mM NaCl, 2.5% (v/v) glycerol, 15 mM imidazole], 
Buffer B [50 mM Tris pH 7.5, 400 mM NaCl, 2.5% (v/v) glycerol, 30 mM imidazole], and Elution Buffer 
[50 mM Tris pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol, 250 mM imidazole]. 
 
3.4.6 Purification of modified hybrid peptides 
All hybrid peptides except Hyp1.1 were MBP-tagged and purified as described above. Typically, >20 mg 
of MBP-tagged peptide (corresponding to >1 mg of core peptide after affinity tag removal) was obtained 
from 1 L of culture. Hyp1.1 was expressed as a His6-tagged peptide and purified by the following procedure. 
The harvested cells were resuspended in 25 mL of LanA Buffer 1 [6 M guanidine hydrochloride, 20 mM 
NaH2PO4, pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole], and lysed by sonication (50% amplitude, 
1.0 s pulse, 2.0 s pause, 5 min). The sample was subjected to centrifugation (23,700 × g for 30 min at 4 °C) 
and the supernatant containing the His6-tagged peptide was retained for further purification. The His6-
tagged peptide was then purified by immobilized metal affinity chromatography (IMAC) using 2-4 mL of 
His60 Ni Superflow Resin (Clontech). The supernatant was applied to the column and the column was 
washed with 2 column volumes of LanA Buffer 1 followed by 2 column volumes of LanA Buffer 2 [4 M 
guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 300 mM NaCl, 30 mM imidazole], and then 
eluted with 3 column volumes of LanA Elution Buffer [4 M guanidine hydrochloride, 20 mM Tris, pH 7.5 
at 25 °C, 100 mM NaCl, 1 M imidazole]. The elution fractions containing the peptide were desalted by 
Vydac C4 SPE column and lyophilized and stored at -80 °C.  
 
3.4.7 In vitro modification assays 
In vitro assays were performed with purified proteins and peptides as described previously.37, 56, 57, 63 In 
general, peptides were supplied at 50 µM. Proteins were present at 5 to 20 µM and allowed to react for 16 
h. Reactions were carried out in synthetase buffer [50 mM Tris pH 7.5, 125 mM NaCl, 20 mM MgCl2, 1 
mM TCEP]. However, assays with the dehydroalanine reductase (NpnJA) were performed in 50 mM 
HEPES pH 7.4 with 1.5 mM NADPH. 
 
3.4.8 MALDI-TOF-MS 
Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) was used 
to analyze posttranslational modifications based on their characteristic mass changes and reactivity towards 
mild acid or iodoacetamide treatment.64 Upon in vitro or in vivo modification, peptides were digested with 
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a commercial protease (AspN, ArgC, proteomics grade trypsin, GluC, or thermolysin) following the 
manufacturer’s protocol. Hydrochloric acid (200 mM) or iodoacetamide (20 mM at 8 pH) were individually 
added to an aliquot of the digestion and allowed to react for 1 h in the dark at 22 °C. Next, the samples were 
desalted with a ZipTip (Millipore) according to the manufacturer’s instructions and eluted into 3.5 µL of 
70 % MeCN. Then, 0.5 µL was applied to a MALDI target plate with 1 µL of matrix and subsequently 
mixed until crystallized. For the Hyp2.1 and Hyp2.2 peptides, the ideal matrix solution was 20 mg/mL 
sinapinic acid (SA) with 10 mg/mL 2,5-dihydroxybenzoic acid (DHB) in 70 % MeCN. All other peptides 
were applied with a matrix solution of 20 mg/mL of α-cyano-4-hydroxycinnamic acid (CHCA) and 10 
mg/mL DHB in 60% MeCN. The samples were analyzed using a Bruker Daltonics UltrafleXtreme MALDI-
TOF mass spectrometer in reflector/positive mode using the default RP900_4500_Da.par method. 
 
3.4.9 High performance liquid chromatography (HPLC) purification of modified hybrid peptides 
A subset of peptides were desalted and purified (>75%) for MS/MS characterization. Hyp3.2 was purified 
for determination of the stereochemistry of its MeLan (see below). The separations were performed on an 
Agilent 1200 series HPLC fitted with a 10  250 mm Betasil C18 column (Fisher Scientific). A gradient 
elution was used with Buffer A (10 mM ammonium bicarbonate) and Buffer B (10 mM ammonium 
bicarbonate in 90% MeCN) according to the following linear gradient combinations: at t=0 min, 6% B; 
t=3.0 min, 6% B; t=6.0 min, 15% B; t=21.0 min, 40% B; t=24.0 min, 100% B; t=33.0 min, 100% B; t=37.0 
min, 6% B; t=47.0 min, 6% B. Hyp3.x peptides eluted around 11 min whereas Hyp4.x eluted around 16 
min. Hyp2.2 was purified using a different linear gradient combination: at t=0 min, 6% B; t=3.0 min, 6% 
B; t=7.0 min, 23% B; t=23.0 min, 52% B; t=26.0 min, 100% B; t=32.0 min, 100% B; t=37.0 min, 6% B; 
t=45.0 min, 6% B. Hyp2.2 eluted at 20 min. After elution from the column, the MeCN portion of the solvent 
was removed in a vacufuge (Eppendorf), and the remaining liquid was lyophilized using a FreeZone 4.5 L 
benchtop freeze dry system (Labconco). 
 
3.4.10 HRMS and MS/MS analysis 
HPLC-purified peptides or peptides desalted using a ZipTip were diluted 1:1 using ESI mix (80% MeCN, 
19% water, 1% formic acid). Samples were directly infused into a ThermoFisher Scientific Orbitrap Fusion 
ESI-MS using an Advion TriVersa Nanomate 100. The MS was calibrated and tuned with Pierce LTQ 
Velos ESI Positive Ion Calibration Solution (ThermoFisher). The MS was operated using the following 
parameters: resolution, 100,000; isolation width (MS/MS), 2 m/z; normalized collision energy (MS/MS), 
35; activation q value (MS/MS), 0.4; activation time (MS/MS), 30 ms. Fragmentation was performing using 
collision-induced dissociation (CID) at 35%. Data analysis was conducted using the Qualbrowser 
application of Xcalibur software (Thermo-Fisher Scientific). 
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3.4.11 Determination of methyllanthionine stereochemistry 
The stereochemistry of the MeLan in Hyp4.3a was determined according to previously reported methods,65 
with slight modification. Briefly, after HPLC, the peptide sample was dissolved in 3 mL of 6 M DCl in 
D2O (used to distinguish non-enzymatic epimerization products upon GC-MS analysis) and placed in a 
sealed glass pressure tube. This mixture was heated to 110 °C for 24 h without stirring.  After being allowed 
to cool, the solvent was removed in vacuo. In a separate round bottom flask, acetyl chloride (1.5 mL) was 
added dropwise to MeOH (5 mL) at 0 °C with stirring.  This solution (4 mL) was then added to the 
hydrolysate, which was again heated to 110 °C for 1 h.  After cooling, the solvent was removed, and the 
residue was taken up in 3 mL of CH2Cl2. The suspension was then cooled to 0 °C and pentafluoropropionic 
acid (1 mL) was added dropwise. Next, the sample was heated to 110 °C for 30 min and allowed to cool.  
The solvent was again removed before suspending the derivatized product in MeOH (200 L) prior to 
GCMS analysis. 
The derivatized samples were analyzed by GC-MS (Agilent HP 6890N) using an Agilent CP-
Chirasil-L-Val column (25 m  0.25 mm  0.12 m), with co-injection of previously prepared DL-MeLan 
and LL-MeLan standards for stereochemical verification.66  Samples were applied to the column via split 
injection and run according to the following temperature method: 150 °C injection for 3 min, then raised to 
200 °C by 3 °C /min and held (21.6 min total runtime). The MS was operated using selected ion monitoring 
at 379 Da for the detection of MeLan isomers.  
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3.6 Figures 
 
 
Figure 3.1 Overview of RiPP biosynthesis. (a) A generic RiPP gene cluster and the key maturation steps. 
(b) Chimeric leader peptide strategy for combining modifying enzymes from unrelated pathways. 
Examples of primary RiPP modification enzymes combined in this work include: (c) Cα-crosslinked 
sactipeptides, (d) azoline-containing RiPPs and (e) Cβ-crosslinked lanthipeptides. (f) Examples of 
secondary RiPP modification enzymes used in this work to install D-Ala residues and decarboxylate C-
terminal Cys residues. 
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Figure 3.2 Natural “hybrid” RiPP biosynthetic gene clusters. (a) For linear azol(in)e-containing peptides, 
such as plantazolicin, the cyclodehydratase is the class-defining modifying enzyme. A tailoring enzyme 
also di-methylates the N-terminus upon leader peptide proteolysis. (b) Cyanobactins are defined by the 
presence of a PatG-like protease which recognizes a C-terminal motif to cyclize peptides after removal of 
the N-terminal leader region (by a PatA-like N-terminal protease). However, most cyanobactin gene 
clusters have acquired a cyclodehydratase and thus install two primary modifications (azolines and N-to-C 
macrocyclization). (c) Thiopeptides have three major modifications: azol(in)es, dehydrated amino acids, 
and a 6-membered nitrogen-containing heterocycle (here, pyridine). Because the cyclodehydratase and 
dehydratase can be found in other RiPP classes, the cycloaddition enzyme is the class-defining feature of  
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Figure 3.2 (Continued) 
thiopeptides. In contrast to RRE-containing and leader peptide-dependent lanthipeptide (LanB) 
dehydratases,67 the related thiopeptide dehydratases, which also contain an RRE, are leader-independent 
(red “x” in figure).68  
It is notable that RiPP pathways employ multiple enzymes that are dependent on certain recognition 
motifs and that these motifs tend to occupy distinct parts of the peptide (see panel b and c).24, 27, 68 Leader 
proteases could also be considered leader-dependent and similarly tend to bind a part of the leader not used 
by other enzymes.24, 27 Nature might have evolved these physically separate binding sites to improve 
biosynthetic efficiency. Regardless, it appears that the recognition sequences are “plug and play” and 
simply need to be inserted into an existing peptide for a new enzyme to act on it.  
 
 
 
 
 
 
Figure 3.3 Structure and precursor peptide of nisin. (a) The structure of nisin A is shown with a red arrow 
indicating where Hyp1.1 was truncated to simplify MS/MS analysis of the modified core peptide. (b) The 
NisA precursor peptide sequence is shown with marked leader and core regions. The C-terminal region of 
the leader peptide is not required for binding or processing.41, 42 
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Figure 3.4 Production of a thiazoline-lanthipeptide (class I) hybrid. (a) Design of the Hyp1.1 sequence 
from HcaA and NisA precursor peptides. Portions of the leader peptides that were combined are colored. 
The recognition sequences (RSs) bound by the RREs of the cognate enzymes are indicated with a pink 
box. The orange underlined regions were combined to generate the chimeric core region. (b) Overview of 
experimental procedure. (c) Structure of thiazoline-lanthipeptide (class I) hybrid Hyp1.1a upon AspN 
digestion. Thiazolines are blue while dehydrations and (Me)Lan are red. Numbering is based on the core 
position, not peptide length after digestion. (d) The mass of Hyp1.1a (MALDI-TOF-MS) is consistent 
with one thiazoline, two dehydrations, and two (Me)Lan. These modifications are supported by acid 
hydrolysis (blue arrow, +18 Da) and by lack of labeling by iodoacetamide (green arrow, +57 Da). 
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Figure 3.5 Structure and precursor peptide of subtilosin A. (a) The structure of subtilosin A is shown with 
colored posttranslational modifications. The native peptide is macrocyclized (light brown), but the enzyme 
responsible for this modification has not been studied. (b) The precursor peptide, SboA, is marked with 
leader and core regions. Little is known about how sactipeptide leader peptide-binding occurs and many 
have unusually short leader peptides.15, 67 Nonetheless, the leader peptide of SboA is required for 
modification by AlbA.46, 47 
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Figure 3.6 Production of a thiazoline-sactipeptide hybrid. (a) Design of hybrid peptides. Orange 
underlining indicates edited sequences. (b) Overview of the experimental procedure for combination of 
HcaD/F and AlbA. (c) Structure of thiazoline-sactipeptide hybrid (modified Hyp2.2). Numbering is based 
on the core position, not peptide length after digestion. (d) The mass of the modified peptide is consistent 
with two thiazolines and two sactionine linkages. The two sets of peaks correspond to protease digestion 
at different sites (gray font). The structure is supported by acid hydrolysis, lack of labeling by 
iodoacetamide, and resistance to proteolytic digestion (see also Figure S6). Arrows and triangles represent 
+18 and −2 Da, respectively. Red coloring indicates positions resistant to trypsin digestion. 
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Figure 3.7 Hyp2.1 co-expression with HcaD/F and AlbA at high and low aeration. (a) Overview of 
experimental procedure. Hyp2.1 was expressed in E. coli with HcaD/F (pET-2.1-FD) and AlbA (pACYC-
AlbA) at high or low aeration.50, 62 (b) Under high aeration (250 rpm, baffled flasks), only thiazoline-
containing products were detected. The primary product contained 3 thiazolines with a minor 2 thiazoline-
containing species also detected based on acid hydrolysis and iodoacetamide labeling. (c) With low aeration 
(100 rpm, non-baffled flask), the predominant signal (4023 Da) corresponds to the peptide with three C-
S crosslinks based on lack of iodoacetamide labeling, but a low intensity thiazoline-containing species was 
observed at lower mass range because trypsin cuts more readily at Lys2 in the non-crosslinked products. 
227 
 
 
Figure 3.8 MS/MS of thiazoline-modified sactipeptide Hyp2.2. (a) Structure of modified Hyp2.2. (b) Even 
at low collision energies, thioether crosslinks (thioamidals) are known to undergo elimination to form the 
corresponding dehydroamino acid.50 This enables localization of the crosslinked residues by the 
characteristic -2 Da at the acceptor amino acid. Fragments identified in panel are mapped onto the structure. 
(c) MS/MS fragmentation spectrum for Hyp2.2 annotated with identified ions. (d) Table of predicted and 
observed m/z values for ions observed in panel c (next page). 
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d 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppm) 
b7+ 754.4458 754.4453 0.6 
b162+ 759.3762 759.3739 3.1 
b222+ 1007.9575 1007.9572 0.4 
b242+ 1113.0262 1113.0250 1.1 
b24-y26+ 836.3654 836.3649 0.6 
b353+ 1098.8557 1098.8551 0.5 
y4+ 531.3038 531.3035 0.5 
y5+ 676.3566 676.3562 0.6 
y7+ 846.4621 846.4615 0.7 
y8+ 945.4941 945.4935 0.7 
y9+ 1016.5312 1016.5304 0.8 
y10+ 1073.5527 1073.5522 0.5 
y11+ 1144.5898 1144.5888 0.9 
y14+ 1533.7849 1533.7836 0.8 
y162+ 873.4359 873.4353 0.7 
y262+ 1291.1150 1291.1135 1.1 
 
Figure 3.8 (Continued) 
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Figure 3.9 GluC digestion of thiazoline-modified and thioether-crosslinked Hyp 2.2. (a) Experimental 
overview. Hyp2.2 was expressed with HcaD/F (pET-2.2-HcaD/F) and AlbA (pACYC-AlbA) in E. coli. (b) 
Deduced structure of modified Hyp2.2 after treatment with GluC. (c) MALDI-TOF-MS analysis of 
modified peptide after GluC treatment and chemical derivatization. No digestion occurred at the internal 
Glu residue of the crosslinked peptide, supporting the proposed topology.  
 
230 
 
 
 
Figure 3.10 Structures and precursor peptides of two prochlorosins. (a) Structure of prochlorosin 2.8 and 
3.3 with posttranslational modifications catalyzed by ProcM colored orange. (b) ProcM has over 30 
different precursor peptides.29 The sequence of the ProcA2.8 and ProcA3.3 precursor peptides are displayed 
with their leader and core regions. Only the C-terminal portion of these peptides are required for processing 
by ProcM,28 and in general LanM enzymes appear to bind the region of the leader peptide closest to the 
core peptide.69 
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Figure 3.11 Production of hybrid thiazoline-lanthionine (class II) hybrids. (a) Design of hybrid peptides. 
Orange underlining indicates edited positions of the core peptide. The dashed line indicates the leader 
peptide of the ProcA2.8 and Proc3.3. (b) Experimental overview for combination of HcaD/F and ProcM. 
(c) Deduced structure and MALDI-TOF-MS support of posttranslational modifications for Hyp4.3. 
Numbering is based on the core position, not peptide length after digestion. (d) Same as in panel c but for 
Hyp3.3. 
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Figure 3.12 Optimization of HcaD/F-ProcM co-expression and plasmid design. (a) Experimental overview. 
(b) Expression of Hyp3.1 and ProcM on the same plasmid (pRSF-3.1-M) with HcaD/F (pET-F-D) resulted 
in only lanthionine formation as assessed by MALDI-TOF-MS. (c) Placing ProcM on a lower copy number 
plasmid (pACYC) and moving HcaD/F to the same plasmid as Hyp3.1 gave primarily a thiazoline-
lanthionine product; however, a minor two lanthionine product was also detected (species at -36 Da that 
remains after acid treatment). (d) Legend and design of plasmids constructed for this experiment (Table 
3.1). CmR, AmpR, and KanR are chloramphenicol, ampicillin, and kanamycin resistance markers. 
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Figure 3.13 MS/MS fragmentation of thiazoline/lanthionine in modified Hyp3.1. (a) Structure of the 
thiazoline-lanthionine modified Hyp3.1 product. Although Ser9 is normally dehydrated by ProcM, 
thiazoline formation may inhibit dehydration at this site. Dashed lines indicate identified fragments in the 
mass spectrum. (b) MS/MS fragmentation spectrum for modified Hyp3.1 annotated with identified ions. 
(c) Table of predicted and observed m/z values for ions observed in panel b (next page). 
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c 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppm) 
b4+ 473.1878 473.1911 6.8 
b5+ 602.2304 602.2346 7.0 
b6+ 659.2519 659.2566 7.1 
b7+ 758.3203 758.3256 7.0 
b8+ 829.3574 829.3631 6.8 
b9+ 886.3789 886.3848 6.7 
b192+ 907.3816 907.3879 6.9 
y8+ 952.3505 952.3570 6.8 
y9+ 1049.4033 1049.4106 6.9 
y10+ 1180.4438 1180.4515 6.5 
y12+ 1364.5286 1364.5373 6.4 
y13+ 1435.5657 1435.5758 7.0 
 
Figure 3.13 (Continued) 
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Figure 3.14 MALDI-TOF-MS analysis of thiazoline/lanthionine modified Hyp3.2. Compared to Hyp3.1, 
Hyp3.2 carries a Ser9Ala substitution. (a) Experimental overview. Hyp3.2 was co-expressed with HcaD/F 
(pET-3.2-FD) and ProcM (pACYC-M) in E. coli. (b) Deduced structure of modified Hyp3.2. (c) MALDI-
TOF-MS analysis confirms the presence of a thiazoline based on the +18 Da shift upon mild acid 
treatment (blue arrow). The lack of iodoacetamide labeling indicates that the other Cys formed a 
lanthionine (orange arrow). All ions here are sodiated. The lack of GluC digestion at the two Glu near the 
C-terminus and the MS/MS data in Figure 3.15 support the proposed structure. 
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Figure 3.15 MS/MS fragmentation of thiazoline/lanthionine in modified Hyp3.2 digested with AspN. 
(Previous page) (a) Structure of the thiazoline-lanthionine modified Hyp3.2 product. Dashed lines indicate 
identified fragments in the mass spectrum. (b) MS/MS fragmentation spectrum for modified Hyp3.2 
annotated with identified ions. (c) Table of predicted and observed m/z values found for ions observed in 
panel b (next page). 
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c 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppm) 
b3+ 358.1609 358.1629 5.6 
b4+ 487.2035 487.2062 5.7 
b5+ 544.2249 544.2280 5.7 
b6+ 643.2934 643.2970 5.7 
b7+ 714.3305 714.3345 5.7 
b8+ 771.3519 771.3563 5.7 
b162+ 757.8257 757.8298 5.4 
b182+ 841.8706 841.8752 5.5 
b192+ 907.3909 907.3961 5.7 
y9+ 1049.4033 1049.4089 5.3 
y10+ 1180.4438 1180.4502 5.4 
y12+ 1348.5337 1348.5415 5.8 
y13+ 1419.5708 1419.5781 5.2 
y202+ 1046.4166 1046.4223 5.5 
y212+ 1074.9273 1074.9330 5.3 
y222+ 1110.4459 1110.4517 5.3 
y232+ 1159.9800 1159.9862 5.3 
y242+ 1188.4908 1188.4972 5.4 
y252+ 1253.0121 1253.0194 5.8 
 
Figure 3.15 (Continued) 
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Figure 3.16 Thiazoline and lanthionine product mixtures produced with Hyp4.1 and Hyp4.2. (a) 
Experimental overview.  (b) When Hyp4.1 was co-expressed with HcaD/F (pET-4.1-FD) and ProcM 
(pACYC-M), two main products were detected. Hyp4.1a has one thiazoline and lanthionine (see Figure 
3.19 for MS/MS), but the lack of mild acid hydrolysis and lack of iodoacetamide labeling suggested that 
Hyp4.1b displayed modifications akin to native prochlorosin 3.3. (c) With the Thr18Ala substitution in 
Hyp4.2 (underlined, panel a), co-expression of Hyp4.2 with HcaD/F (pET-4.2-FD) and ProcM (pACYC-
M) produced multiple products indicating there was little preference for the modification order. Hyp4.2a 
contained two thiazolines, Hyp4.2b contained one thiazoline, while the other products were not susceptible 
to mild acid hydrolysis. Hyp4.2c likely contains two lanthionines while Hyp4.2d displayed a free Cys based 
on iodoacetamide labeling. Blue/brown arrows indicate acid hydrolysis (+18 Da). Orange arrows indicate 
Dhb/MeLan formation (-18 Da). Green arrow indicates carbamidomethylation upon reaction with 
iodoacetamide (+57 Da).  
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Figure 3.17 MS/MS fragmentation of modified Hyp4.1a. (a) Modified structure of the Dhb, thiazoline, and 
lanthionine modified Hyp4.1a. Dashed lines indicate identified fragments in the mass spectrum. (b) MS/MS 
fragmentation spectrum for modified Hyp4.1a annotated with identified ions. (c) Table of predicted and 
observed m/z values for ions in panel b (next page). 
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c 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppm) 
b3+ 256.0928 256.0940 4.6 
b4+ 369.1769 369.1785 4.4 
b6+ 568.2726 568.2741 4.3 
b8+ 780.4250 780.4285 4.4 
b9+ 917.4839 917.4879 4.4 
b10+ 1000.5255 1000.5211 4.4 
b11+ 1071.5582 1071.5628 4.3 
y11+ 1110.4642 1110.4692 4.5 
y112+ 555.7357 555.7383 4.6 
y12+ 1181.5013 1181.5063 4.3 
y122+ 591.2543 591.2570 4.7 
y13+ 1264.5384 1264.5439 4.3 
y132+ 632.7728 632.7758 4.7 
y14+ 1401.5973 1401.6038 4.6 
y142+ 701.3023 701.3056 4.7 
y15+ 1514.6814 1514.6889 5.0 
y152+ 757.8443 757.8479 4.7 
y162+ 807.3785 807.3821 4.5 
y172+ 842.8971 842.9009 4.5 
y182+ 906.9264 906.9303 4.4 
[y18-H2O]2+ 897.9211 897.9251 4.5 
y192+ 963.4684 963.4727 4.5 
y202+ 991.9791 991.9836 4.5 
y203+ 661.6552 661.6584 4.8 
 
Figure 3.17 (Continued) 
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Figure 3.18 MS/MS fragmentation of modified Hyp4.3a. (a) Structure of the Dhb, thiazoline, and 
lanthionine modified Hyp4.3. Dashed lines indicate identified fragments in the mass spectrum. (b) MS/MS 
fragmentation spectrum for modified Hyp4.3 annotated with identified ions. (c) Table of predicted and 
observed m/z values for ions in panel b (next page). 
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c 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppb) 
b3+ 256.0928 256.0927 312.4 
b4+ 369.1769 369.1767 541.7 
b5+ 497.2354 497.2353 281.6 
b6+ 568.2726 568.2725 176.0 
b7+ 667.3410 667.3408 269.7 
b9+ 917.4839 917.4834 566.8 
b10+ 1000.5211 1000.5206 479.8 
b11+ 1071.5582 1071.5576 559.9 
y4+ 462.1952 462.1950 454.4 
y5+ 590.2901 590.2900 288.0 
y8+ 775.3702 775.3698 451.4 
y11+ 1080.4536 1080.4530 536.8 
y112+ 540.7304 540.7304 147.9 
y12+ 1151.4907 1151.4899 677.4 
y122+ 576.2490 576.2488 329.7 
y13+ 1234.5278 1234.5279 48.6 
y132+ 617.7676 617.7675 161.9 
y14+ 1371.5867 1371.5861 444.7 
y142+ 686.2970 686.2968 320.6 
y15+ 1484.6708 1484.6703 107.8 
y152+ 742.8390 742.8389 175.0 
y162+ 792.3732 792.3730 290.3 
y172+ 827.8918 827.8915 374.4 
y182+ 891.9211 891.9206 583.0 
y192+ 948.4631 948.4626 601.0 
y202+ 976.9739 976.9736 245.7 
y203+ 651.6517 651.6516 168.8 
 
Figure 3.18 (Continued) 
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Figure 3.19 MS/MS fragmentation of modified Hyp4.3a after thermolysin digestion. (a) Structure of the 
lanthionine ring fragment of Hyp4.3 after digestion by thermolysin. Dashed lines indicate identified 
fragments in the mass spectrum. (b) MS/MS fragmentation spectrum for lanthionine ring of Hyp4.3 after 
digestion and HPLC-purification annotated with identified ions. (c) Table of predicted and observed m/z 
values of ions seen in panel b (next page). 
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c 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppm) 
b2+ 251.1503 251.1516 5.4 
b42+ 534.2744 534.2773 5.4 
b72+ 605.2844 605.2876 5.2 
[b7+H2O]2+ 614.2897 614.2929 5.2 
b9+ 200.1394 200.1405 5.7 
b10+ 315.1663 315.1679 5.1 
b122+ 651.2975 651.3010 5.3 
y32+ 538.7419 538.7448 5.4 
y42+ 596.2553 596.2586 5.4 
y9+ 324.1013 324.1028 4.9 
y10+ 395.1384 395.1403 5.0 
y112+ 570.7499 570.7528 5.1 
y122+ 639.2793 639.2827 5.3 
y123+ 426.5220 426.5242 5.1 
 
Figure 3.19 (Continued) 
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Figure 3.20 GC-MS analysis of Hyp3.3 MeLan. After hydrolysis and derivatization, the MeLan of Hyp3.3 
co-eluted when spiked with authentic DL-MeLan but not with LL-MeLan, indicating that the 
stereochemistry of the lanthionine in Hyp3.3 is DL as in the native prochlorosins.65 
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Figure 3.21 MS/MS fragmentation of Hyp4.3 minor products. (a) Structure of two minor products (azoline 
or Dhb) after expression of Hyp4.3 with HcaD/F (pET-4.3-FD) and ProcM (pACYC-M). A third product, 
a species containing two lanthionines, also formed (from a Michael-like addition within in the Dhb product) 
based on MALDI-TOF-MS analysis (Figure 3.6c), but did not undergo fragmentation, likely owing to the 
lanthionines. Dashed lines indicate identified fragments. (b) Annotated MS/MS spectrum for minor 
products. (c) Table of predicted and observed m/z values for ions from panel b. Red (azoline) and blue 
(Dhb) colors indicate the two species (next page) 
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c 
Azoline species 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppm) 
b3+ 274.1034 274.1045 4.3 
b4+ 387.1874 387.1890 4.0 
b5+ 515.2460 515.2483 4.4 
b6+ 586.2831 586.2856 4.2 
b7+ 685.3515 685.3543 4.0 
b8+ 798.4356 798.4389 4.1 
b9+ 935.4945 935.4983 4.1 
y132+ 618.7661 618.7687 4.3 
y142+ 687.2955 687.2984 4.1 
y152+ 743.8376 743.8407 4.2 
y162+ 793.3718 793.3749 4.0 
y172+ 828.8903 828.8936 4.0 
y182+ 892.9196 892.9230 3.8 
y202+ 977.9724 977.9762 3.9 
y213+ 685.9999 686.0027 4.1 
 
Dhb species 
Ion Theoretical mass (Da) Observed mass (Da) Error (ppm) 
b3+ 256.0928 256.0939 4.1 
b4+ 369.1769 369.1784 4.2 
b5+ 497.2354 497.2374 3.9 
b6+ 568.2726 568.2748 4.0 
b7+ 667.3410 667.3437 4.1 
b8+ 780.4250 780.4283 4.2 
b9+ 917.4839 917.4877 4.1 
y132+ 627.7713 627.7740 4.2 
y142+ 696.3008 696.3041 4.7 
y152+ 752.8428 752.8457 3.8 
y162+ 802.3770 802.3799 3.6 
y172+ 837.8956 837.8989 4.0 
y182+ 901.9249 901.9284 3.9 
y202+ 986.9776 986.9814 3.8 
y213+ 685.9999 686.0027 4.1 
 
Figure 3.21 (Continued) 
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Figure 3.22 MS/MS fragmentation of thiazoline/lanthionine modified Hyp3.3. (a) Structure of the modified 
Hyp3.3 product containing two thiazolines and one lanthionine. Dashed lines indicate identified fragments 
in the mass spectrum. (b) MS/MS fragmentation spectrum for modified Hyp3.3 annotated with identified 
ions. (c) Table of predicted and observed m/z values for ions observed in panel b (next page). 
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c 
Ion Theoretical mass(Da) Observed mass (Da) Error (ppm) 
b162+ 757.8257 757.8303 6.0 
y9+ 975.3811 975.3856 4.6 
y10+ 1106.4216 1106.4267 4.6 
y12+ 1274.5115 1274.5176 4.8 
y13+ 1345.5486 1345.5554 5.0 
y14+ 1482.6075 1482.6150 5.1 
y202+ 1009.4055 1009.4103 4.8 
y212+ 1037.9162 1037.9214 5.0 
y222+ 1073.4348 1073.4398 4.7 
y242+ 1151.4797 1151.4851 4.7 
y252+ 1216.0010 1216.0067 4.7 
 
Figure 3.22 (Continued) 
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Figure 3.23 Combination of two primary and one secondary RiPP modifications. (a) Design of hybrid 
peptide. Orange underlining highlights changed residues. (b) Experimental overview for combining 
HcaF/D, ProcM, and NpnJA. (c) Deduced structure of Hyp4.4b. (d) MALDI-TOF-MS analysis of Hyp4.4 
products. The initially formed hybrid has a Dha, thiazoline (arrow indicates hydrolysis) and MeLan. The 
formation of D-Ala from Dha is indicated by the +2 Da shift (triangle) of the Hyp4.4a species upon 
addition of NpnJA. The weak ion labeled as -72 Da is likely a peptide that underwent two 
cyclodehydrations and two dehydrations. 
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Figure 3.24 Design and production of decarboxylated linear azol(in)e-containing peptide. (a) A hybrid 
peptide was designed to enable modification by HcaD/F and the leader-independent tailoring enzyme MibD 
from Microbispora sp. 107891. MibD is a LanD enzyme and carries out oxidative decarboxylation of C-
terminal Cys to the corresponding aminoenethiolate, and its preferred core sequence is S-(F/W/N)-(N/C)-
S-(F/Y/W/N)-C-C.63 This motif was mimicked by changing the C-terminus of the peptide to SAFAC to 
create Hyp3.4. Although the ProcM leader region was present, ProcM was not used in this experiment. (b) 
Anticipated hybrid biosynthesis. As both thiazoline and decarboxylation are smaller modifications 
occurring on different ends of the core peptide, the enzymes can presumably act in any order. (c) Overview 
of experiment. Hyp3.4 was co-expressed with HcaD/F (pET-3.4-FD) and MibD in pCDFDuet (see plasmid 
list in Table 3.1). The peptide was purified, digested with AspN, and analyzed by MALDI-TOF-MS. (d) 
The mass spectrum shows a several ions, but the most intense peak (labeled Hyp3.4a) corresponded to the 
desired hybrid product. (e) Deduced structure of the hybrid Hyp3.4a product after AspN digestion. 
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3.7 Tables 
Table 3.1 New plasmids generated for this study and their use in combinations. Hybrid peptides (Hyp) are 
listed in Figure 3.4, 3.6, 3.11, 3.23 and 3.24. HcaF-HcaD comprise a two-component, thiazoline-forming 
cyclodehydratase, NisB and NisC form a class I lanthipeptide synthetase, while ProcM is a class II 
lanthipeptide synthetase. Constructs for the tailoring enzymes MibD and NpnJA are reported elsewhere.57, 
63 The combinations of plasmids used for co-expression and the figure where the results are presented are 
also listed. Abbreviations: No., number; MCS, multiple cloning site; MBP, maltose-binding protein.  
 
No. Name Plasmid backbone (copy number70) 
Gene(s) 
MCS1; MCS2 
Co-expression of plasmids; 
Figure for result 
1 pACYC-B-C pACYCDuet (10-12) NisB; NisC 1+2+3; Fig. 3.4 
2 pRSF-F-D pRSFDuet (>100) HcaF; HcaD 1+2+3; Fig. 3.4 
3 pCDF-1.1 pCDFDuet (20-40) His6-Hyp1.1; (empty) 1+2+3; Fig. 3.4 
4 pACYC-AlbA pACYCDuet (10-12) (empty); AlbA See below 
5 pET-2.1-FD pETDuet (~40) MBP-Hyp2.1; HcaF-HcaD 5+4; Fig. 3.7 
6 pET-2.2-FD pETDuet (~40) MBP-Hyp2.2; HcaF-HcaD 6+4; Fig. 3.6 
7 pET-3.1-FD pETDuet (~40) MBP-Hyp3.1; HcaF-HcaD 7+16; Fig. 3.7 
8 pET-3.2-FD pETDuet (~40) MBP-Hyp3.2; HcaF-HcaD 8+16; Fig. 3.14 
9 pET-3.3-FD pETDuet (~40) MBP-Hyp3.3; HcaF-HcaD 9+16; Fig. 3.11 
10 pET-3.4-FD pETDuet (~40) MBP-Hyp3.4; HcaF-HcaD 10+11; Fig. 3.24 
11 pCDF-MibD pCDFDuet (20-40) MibD; (empty) 10+11; Fig. 3.24 
12 pET-4.1-FD pETDuet (~40) MBP-Hyp4.1; HcaF-HcaD 12+16; Fig. 3.16 
13 pET-4.2-FD pETDuet (~40) MBP-Hyp4.2; HcaF-HcaD 13+16; Fig. S12 
14 pET-4.3-FD pETDuet (~40) MBP-Hyp4.3; HcaF-HcaD 14+16; Fig. 4 
15 pET-4.4-FD pETDuet (~40) MBP-Hyp4.4; HcaF-HcaD 15+16; Fig 5 
16 pACYC-M pETDuet (~40) (empty); ProcM See above 
17 pRSF-3.1-M pRSFDuet (>100) MBP-Hyp3.1; ProcM 17+18; Fig. S8 
18 pET-F-D pETDuet (~40) HcaF; HcaD 17+18; Fig. S8 
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Table 3.2 Nucleotide sequences. Restriction enzyme sites are underlined. F, forward; R, reverse. SDM, 
site-directed mutagenesis. 
Primer 
Name Primer sequence (5’ to 3’) Purpose 
AlbA F AAAAGATATCAATGTTTATAGAGCAGATGTTTCCATTTATTAATGAAAG RE cloning of pACYC-AlbA (EcoRV) 
AlbA R AAAGACGTCCTAAATAAGCTGGACCACGTCTTCT RE cloning of pACYC-AlbA (AatII) 
HcaD F AAAAGATCTAATGACTCAAAATATATTACTTATAGGGGATGGC RE cloning of pET-F-D (BglII) 
HcaD R AAAAGGTACCCTATGGAAACGGGTGCGGATG RE cloning of pET-F-D (KpnI) 
HcaF F AAAGGATCCAATGAGTAACCTTCCAGCACATGC RE cloning of pET-F-D (BamHI) 
HcaF R AAAGCGGCCGCTCATAGACCGTCCTCCTTTGC RE cloning of pET-F-D (NotI) 
MBP-Hyp3.1 
(pRSF) F ATCACCACAGCCAGGATCCGAATTCAATGAAAATCGAAGAAGGTAAACTGG 
Gibson assembly of 
pRSF-3.1-ProcM (EcoRI) 
MBP-Hyp3.1 
(pRSF) R GTTCGACTTAAGCATTATGCGGCCGCTTAGCACTCACCCTCCCAAT 
Gibson assembly of 
pRSF-3.1-ProcM (NotI) 
MBP-Hyp3.1 
(pET) F CATCACCACAGCCAGGATCCGAAAATCGAAGAAGGTAAACTGGTAATC 
Gibson assembly of pET-
3.1-FD (BamHI) 
MBP-Hyp3.1 
(pET) R CGACTTAAGCATTATGCGGCCGCTTAGCACTCACCCTCCCAATAG 
Gibson assembly of pET-
3.1-FD (NotI) 
HcaF-HcaD F CATATGGCAGATCTCAATTGGATATCAATGAGTAACCTTCCAGCACATG Gibson assembly of pET-Hyp-FD (EcoRV) 
HcaF-HcaD R CCAGACTCGAGGGTACCGACGTCTATGGAAACGGGTGCGG Gibson assembly of pET-Hyp-FD (AatII) 
MBP-Hyp4.1 F CATCACCACAGCCAGGATCCGAAAATCGAAGAAGGTAAACTGGTAATC Gibson assembly of pET-4.1-FD (BamHI) 
MBP-Hyp4.1 R TTAAGCATTATGCGGCCGCAAGCTTCTATGCGCGGCACATTTTG Gibson assembly of pET-4.1-FD (HindIII) 
MBP-Hyp2.1 F ACCATCATCACCACAGCCAGGATCCTAAAATCGAAGAAGGTAAACTGGTAATC Gibson assembly of pET-2.1-FD (BamHI) 
MBP-Hyp2.1 R CGACTTAAGCATTATGCGGCCGCTTAACGCCATAGACCGAATAGACC Gibson assembly of pET-2.1-FD (NotI) 
HcaA leader F AAAGGATCCATGAATCAGTTTCAACAAGAACTAC RE cloning of MBP-tagged Hyp3.1 (BamHI) 
HcaA leader 
(3.1) R GCGATGAGAGTTTAGATCCCAATACACAACATTACCAGT overlaps ProcA2.8 
ProcA2.8 F GTTGTGTATTGGGATCTAAACTCTCATCGCCAAAATCTG overlaps HcaA leader 
ProcA2.8 R AAAAAGCTTTTAGCACTCACCCTCCCAATAGG RE cloning of MBP-tagged Hyp3.1 (HindIII) 
HcaA leader F AAAGGATCCATGAATCAGTTTCAACAAGAACTAC RE cloning of MBP-tagged Hyp4.1 (BamHI) 
HcaA leader 
(4.1) R AGCGGCAGCATTAAGATCCCAATACACAACATTACCAGT overlaps ProcA3.3 
ProcA3.3 F GTTGTGTATTGGGATCTTAATGCTGCCGCTTCTG overlaps HcaA leader 
ProcA3.3 R AAAAAGCTTCTATGCGCGGCACATTTTGG RE cloning of MBP-tagged Hyp4.1 (HindIII) 
HcaA leader F AAAGGATCCATGAATCAGTTTCAACAAGAACTAC RE cloning of MBP-tagged Hyp2.1 (BamHI) 
HcaA leader 
(2.1) R GACAGCTTTTTTCATATCCCAATACACAACATTACCAG overlaps SboA 
SboA F GTTGTGTATTGGGATATGAAAAAAGCTGTCATTGTAGAAAAC overlaps HcaA leader 
SboA R AAAGCGGCCGCTTACCCCCATAGACCGAATAGACCTGTTGC RE cloning of MBP-tagged Hyp2.1 (NotI) 
SboA BamHI F AAAGGATCCATGAAAAAAGCTGTCATTGTAGAAAACAAAGG RE cloning 
SboA NotI R AAAGCGGCCGCTTACCCCCATAGACCGAATAGACCTGTTGC RE cloning 
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Table 3.2 (Continued) 
Hyp2.1 F ATTCGGTCTATGGCGTTAAGCGGCCGCACTCGAGCAC SDM 
Hyp2.1 R CGGCCGCTTAACGCCATAGACCGAATAGACCTGTTGC SDM 
Hyp2.2 F ACATGCTCGATCGGAGCCCGTTGCGGTGGATGTGGTCCTATCCCTGATTTTGAAATTGC SDM 
Hyp2.2 R ATTTCAAAATCAGGGATAGGACCACATCCACCGCAACGGGCTCCGATCGAGCATGTTGC SDM 
Hyp3.2 F AACCATGCTCCAGCTATGCCTCCATCCTATTGGGA SDM 
Hyp3.2 R GGAGGCATAGCTGGAGCATGGTTATGACAGGCCG SDM 
Hyp 3.3 F GCCTCCATCCTATCGTTGTGGTGAGTGCTAAGCGGCCGCATAATGC SDM 
Hyp 3.3 R GCTTAGCACTCACCACAACGATAGGATGGAGGCATAGCTGGAGCATGG SDM 
Hyp4.2 F ACGGCGGGGCCAAAATGTGCCGCGCATAG SDM 
Hyp4.2 R CACATTTTGGCCCCGCCGTAACATCCAGCCG SDM 
Hyp4.3 F GCGGGGCCAAAGACTGCCGCGCATAGAAGCTTGCGGCCGCAT SDM 
Hyp4.3 R TATGCGCGGCAGTCTTTGGCCCCGCCGTAACATCCAGCCGTG SDM 
Hyp4.4 F CGGCGGAGGCGTTTCCGGCATCCAAGCGGTGCTGCAC SDM 
Hyp4.4 R CTTGGATGCCGGAAACGCCTCCGCCGCTAGCGGCTTCC SDM 
Hyp1.1 Trunc F GTATTTCGCTATGTACACCCGGTTGTAAAGCGTAAGGAGCTCTGTAAGGTTGTAACATGA SDM 
Hyp1.1 Trunc R TCATGTTACAACCTTACAGAGCTCCTTACGCTTTACAACCGGGTGTACATAGCGAAATAC SDM 
Hyp1.1 F GATTTGGTATCTGTTTCGAAGAAAGATTCACGTTGCGGTCCACGCATTACAAGTATTTC SDM 
Hyp1.1 R GAAATACTTGTAATGCGTGGACCGCAACGTGAATCTTTCTTCGAAACAGATACCAAATC SDM 
Hyp4.5 F AGCGCGTTTGCGTGCTAAGCGGCCGCATAATGCTTAAGTCGAACAGAAAGTAATC SDM 
Hyp4.5 R GCCTGTCATAACCATGCTCCATCTATGCCTCCATCCTATAGCGCGTTTGCGTGC SDM 
 
3.8 References 
(1) Newman, D. J.; Cragg, G. M. Natural Products as Sources of New Drugs from 1981 to 2014. J. 
Nat. Prod. 2016, 79 (3), 629-661. 
(2) Ganesan, A. The Impact of Natural Products Upon Modern Drug Discovery. Curr. Opin. Chem. 
Biol. 2008, 12 (3), 306-317. 
(3) Katz, L.; Baltz, R. H. Natural Product Discovery: Past, Present, and Future. J. Ind. Microbiol. 
Biotechnol. 2016, 43 (2-3), 155-176. 
(4) Breitling, R.; Takano, E. Synthetic Biology of Natural Products. Cold Spring Harb. Perspect. 
Biol. 2016, 8 (10). 
(5) King, J. R.; Edgar, S.; Qiao, K.; Stephanopoulos, G. Accessing Nature's Diversity through 
Metabolic Engineering and Synthetic Biology. F1000Res. 2016, 5. 
255 
 
(6) Smanski, M. J.; Zhou, H.; Claesen, J.; Shen, B.; Fischbach, M. A.; Voigt, C. A. Synthetic Biology 
to Access and Expand Nature's Chemical Diversity. Nat. Rev. Microbiol. 2016, 14 (3), 135-149. 
(7) Leadlay, P. F. Combinatorial Approaches to Polyketide Biosynthesis. Curr. Opin. Chem. Biol. 
1997, 1 (2), 162-168. 
(8) Weissman, K. J.; Leadlay, P. F. Combinatorial Biosynthesis of Reduced Polyketides. Nat. Rev. 
Microbiol. 2005, 3 (12), 925-936. 
(9) Weissman, K. J. Genetic Engineering of Modular PKSs: From Combinatorial Biosynthesis to 
Synthetic Biology. Nat. Prod. Rep. 2016, 33 (2), 203-230. 
(10) Winn, M.; Fyans, J. K.; Zhuo, Y.; Micklefield, J. Recent Advances in Engineering Nonribosomal 
Peptide Assembly Lines. Nat. Prod. Rep. 2016, 33 (2), 317-347. 
(11) Arnison, P. G.; Bibb, M. J.; Bierbaum, G.; Bowers, A. A.; Bugni, T. S.; Bulaj, G.; Camarero, J. 
A.; Campopiano, D. J.; Challis, G. L.; Clardy, J., et al. Ribosomally Synthesized and Post-
Translationally Modified Peptide Natural Products: Overview and Recommendations for a 
Universal Nomenclature. Nat. Prod. Rep. 2013, 30 (1), 108-160. 
(12) Oman, T. J.; van der Donk, W. A. Follow the Leader: The Use of Leader Peptides to Guide 
Natural Product Biosynthesis. Nat. Chem. Biol. 2010, 6 (1), 9-18. 
(13) Walsh, C. T. Blurring the Lines between Ribosomal and Nonribosomal Peptide Scaffolds. ACS 
Chem. Biol. 2014, 9 (8), 1653-1661. 
(14) McIntosh, J. A.; Donia, M. S.; Schmidt, E. W. Ribosomal Peptide Natural Products: Bridging the 
Ribosomal and Nonribosomal Worlds. Nat. Prod. Rep. 2009, 26 (4), 537-559. 
(15) Burkhart, B. J.; Hudson, G. A.; Dunbar, K. L.; Mitchell, D. A. A Prevalent Peptide-Binding 
Domain Guides Ribosomal Natural Product Biosynthesis. Nat. Chem. Biol. 2015, 11 (8), 564-
570. 
(16) Dong, S. H.; Tang, W.; Lukk, T.; Yu, Y.; Nair, S. K.; van der Donk, W. A. The Enterococcal 
Cytolysin Synthetase Has an Unanticipated Lipid Kinase Fold. eLife 2015, 4. 
(17) Li, K.; Condurso, H. L.; Li, G.; Ding, Y.; Bruner, S. D. Structural Basis for Precursor Protein-
Directed Ribosomal Peptide Macrocyclization. Nat. Chem. Biol. 2016, 12 (11), 973-979. 
(18) Koehnke, J.; Bent, A.; Houssen, W. E.; Zollman, D.; Morawitz, F.; Shirran, S.; Vendome, J.; 
Nneoyiegbe, A. F.; Trembleau, L.; Botting, C. H., et al. The Mechanism of Patellamide 
Macrocyclization Revealed by the Characterization of the Patg Macrocyclase Domain. Nat. 
Struct. Mol. Biol. 2012, 19 (8), 767-772. 
(19) Islam, M. R.; Shioya, K.; Nagao, J.; Nishie, M.; Jikuya, H.; Zendo, T.; Nakayama, J.; Sonomoto, 
K. Evaluation of Essential and Variable Residues of Nukacin Isk-1 by NNK Scanning. Mol. 
Microbiol. 2009, 72 (6), 1438-1447. 
256 
 
(20) Pavlova, O.; Mukhopadhyay, J.; Sineva, E.; Ebright, R. H.; Severinov, K. Systematic Structure-
Activity Analysis of Microcin J25. J. Biol. Chem. 2008, 283 (37), 25589-25595. 
(21) Just-Baringo, X.; Albericio, F.; Álvarez, M. Thiopeptide Engineering: A Multidisciplinary Effort 
Towards Future Drugs. Angew. Chem., Int. Ed. 2014, 53 (26), 6602-6616. 
(22) Maksimov, M. O.; Pan, S. J.; James Link, A. Lasso Peptides: Structure, Function, Biosynthesis, 
and Engineering. Nat. Prod. Rep. 2012, 29 (9), 996-1006. 
(23) Field, D.; Cotter, P. D.; Ross, R. P.; Hill, C. Bioengineering of the Model Lantibiotic Nisin. 
Bioengineered 2015, 6 (4), 187-192. 
(24) Yang, X.; van der Donk, W. A. Ribosomally Synthesized and Post-Translationally Modified 
Peptide Natural Products: New Insights into the Role of Leader and Core Peptides During 
Biosynthesis. Chem. Eur. J. 2013, 19 (24), 7662-7677. 
(25) Ruffner, D. E.; Schmidt, E. W.; Heemstra, J. R. Assessing the Combinatorial Potential of the 
Ripp Cyanobactin Tru Pathway. ACS Synth. Biol. 2015, 4 (4), 482-492. 
(26) Donia, M. S.; Hathaway, B. J.; Sudek, S.; Haygood, M. G.; Rosovitz, M. J.; Ravel, J.; Schmidt, E. 
W. Natural Combinatorial Peptide Libraries in Cyanobacterial Symbionts of Marine Ascidians. 
Nat. Chem. Biol. 2006, 2 (12), 729-735. 
(27) Sardar, D.; Pierce, E.; McIntosh, J. A.; Schmidt, E. W. Recognition Sequences and Substrate 
Evolution in Cyanobactin Biosynthesis. ACS Synth. Biol. 2015, 4 (2), 167-176. 
(28) Zhang, Q.; Yang, X.; Wang, H.; van der Donk, W. A. High Divergence of the Precursor Peptides 
in Combinatorial Lanthipeptide Biosynthesis. ACS Chem. Biol. 2014, 9 (11), 2686-2694. 
(29) Li, B.; Sher, D.; Kelly, L.; Shi, Y.; Huang, K.; Knerr, P. J.; Joewono, I.; Rusch, D.; Chisholm, S. 
W.; van der Donk, W. A. Catalytic Promiscuity in the Biosynthesis of Cyclic Peptide Secondary 
Metabolites in Planktonic Marine Cyanobacteria. Proc. Natl. Acad. Sci. USA 2010, 107 (23), 
10430-10435. 
(30) Sardar, D.; Schmidt, E. W. Combinatorial Biosynthesis of Ripps: Docking with Marine Life. 
Curr. Opin. Chem. Biol. 2016, 31, 15-21. 
(31) Burkhart, B. J.; Schwalen, C. J.; Mann, G.; Naismith, J. H.; Mitchell, D. A. YcaO-Dependent 
Posttranslational Amide Activation: Biosynthesis, Structure, and Function. Chem. Rev. 2017, 117 
(8), 5389-5456. 
(32) van Heel, A. J.; Mu, D.; Montalban-Lopez, M.; Hendriks, D.; Kuipers, O. P. Designing and 
Producing Modified, New-to-Nature Peptides with Antimicrobial Activity by Use of a 
Combination of Various Lantibiotic Modification Enzymes. ACS Synth. Biol. 2013, 2 (7), 397-
404. 
257 
 
(33) Zhang, Q.; van der Donk, W. A. Catalytic Promiscuity of a Bacterial Α-N-Methyltransferase. 
FEBS Lett. 2012, 586 (19), 3391-3397. 
(34) Sardar, D.; Lin, Z.; Schmidt, E. W. Modularity of Ripp Enzymes Enables Designed Synthesis of 
Decorated Peptides. Chem. Biol. 2015, 22 (7), 907-916. 
(35) Zhao, X.; Kuipers, O. P. Identification and Classification of Known and Putative Antimicrobial 
Compounds Produced by a Wide Variety of Bacillales Species. BMC genomics 2016, 17, 882. 
(36) Hao, Y.; Pierce, E.; Roe, D.; Morita, M.; McIntosh, J. A.; Agarwal, V.; Cheatham, T. E., 3rd; 
Schmidt, E. W.; Nair, S. K. Molecular Basis for the Broad Substrate Selectivity of a Peptide 
Prenyltransferase. Proc. Natl. Acad. Sci. USA 2016, 113 (49), 14037-14042. 
(37) Dunbar, K. L.; Tietz, J. I.; Cox, C. L.; Burkhart, B. J.; Mitchell, D. A. Identification of an 
Auxiliary Leader Peptide-Binding Protein Required for Azoline Formation in Ribosomal Natural 
Products. J. Am. Chem. Soc. 2015, 137 (24), 7672-7677. 
(38) Repka, L. M.; Chekan, J. R.; Nair, S. K.; van der Donk, W. A. Mechanistic Understanding of 
Lanthipeptide Biosynthetic Enzymes. Chem. Rev. 2017, 117 (8), 5457–5520. 
(39) Garg, N.; Salazar-Ocampo, L. M.; van der Donk, W. A. In Vitro Activity of the Nisin 
Dehydratase NisB. Proc. Natl. Acad. Sci. USA 2013, 110 (18), 7258-7263. 
(40) Ortega, M. A.; Hao, Y.; Zhang, Q.; Walker, M. C.; van der Donk, W. A.; Nair, S. K. Structure 
and Mechanism of the Trna-Dependent Lantibiotic Dehydratase NisB. Nature 2015, 517 (7535), 
509-512. 
(41) Khusainov, R.; Moll, G. N.; Kuipers, O. P. Identification of Distinct Nisin Leader Peptide 
Regions That Determine Interactions with the Modification Enzymes NisB and NisC. FEBS open 
bio 2013, 3, 237-242. 
(42) Plat, A.; Kluskens, L. D.; Kuipers, A.; Rink, R.; Moll, G. N. Requirements of the Engineered 
Leader Peptide of Nisin for Inducing Modification, Export, and Cleavage. Appl. Environ. 
Microbiol. 2011, 77 (2), 604-611. 
(43) Chatterjee, C.; Patton, G. C.; Cooper, L.; Paul, M.; van der Donk, W. A. Engineering Dehydro 
Amino Acids and Thioethers into Peptides Using Lacticin 481 Synthetase. Chem. Biol. 2006, 13 
(10), 1109-1117. 
(44) Goto, Y.; Ito, Y.; Kato, Y.; Tsunoda, S.; Suga, H. One-Pot Synthesis of Azoline-Containing 
Peptides in a Cell-Free Translation System Integrated with a Posttranslational Cyclodehydratase. 
Chem. Biol. 2014, 21 (6), 766-774. 
(45) Rink, R.; Wierenga, J.; Kuipers, A.; Kluskens, L. D.; Driessen, A. J. M.; Kuipers, O. P.; Moll, G. 
N. Production of Dehydroamino Acid-Containing Peptides by Lactococcus Lactis. Appl. Environ. 
Microbiol. 2007, 73 (6), 1792-1796. 
258 
 
(46) Lubelski, J.; Overkamp, W.; Kluskens, L. D.; Moll, G. N.; Kuipers, O. P. Influence of Shifting 
Positions of Ser, Thr, and Cys Residues in Prenisin on the Efficiency of Modification Reactions 
and on the Antimicrobial Activities of the Modified Prepeptides. Appl. Environ. Microbiol. 2008, 
74 (15), 4680-4685. 
(47) McKinnie, S. M. K.; Ross, A. C.; Little, M. J.; Vederas, J. C. The Solid Phase Supported Peptide 
Synthesis of Analogues of the Lantibiotic Lactocin S. MedChemComm 2012, 3 (8), 971-975. 
(48) Zhang, F.; Kelly, W. L. Saturation Mutagenesis of Tsra Ala4 Unveils a Highly Mutable Residue 
of Thiostrepton A. ACS Chem. Biol. 2015, 10 (4), 998-1009. 
(49) Fluhe, L.; Knappe, T. A.; Gattner, M. J.; Schafer, A.; Burghaus, O.; Linne, U.; Marahiel, M. A. 
The Radical SAM Enzyme AlbA Catalyzes Thioether Bond Formation in Subtilosin A. Nat. 
Chem. Biol. 2012, 8 (4), 350-357. 
(50) Himes, P. M.; Allen, S. E.; Hwang, S.; Bowers, A. A. Production of sactipeptides in Escherichia 
Coli: Probing the Substrate Promiscuity of Subtilosin A Biosynthesis. ACS Chem. Biol. 2016, 11 
(6), 1737-1744. 
(51) Fluhe, L.; Marahiel, M. A. Radical S-Adenosylmethionine Enzyme Catalyzed Thioether Bond 
Formation in Sactipeptide Biosynthesis. Curr. Opin. Chem. Biol. 2013, 17 (4), 605-12. 
(52) Melby, J. O.; Dunbar, K. L.; Trinh, N. Q.; Mitchell, D. A. Selectivity, Directionality, and 
Promiscuity in Peptide Processing from a Bacillus Sp. Al Hakam Cyclodehydratase. J. Am. 
Chem. Soc. 2012, 134 (11), 5309-5316. 
(53) Tang, W.; Jimenez-Oses, G.; Houk, K. N.; van der Donk, W. A. Substrate Control in 
Stereoselective Lanthionine Biosynthesis. Nat. Chem. 2015, 7 (1), 57-64. 
(54) Yu, Y.; Mukherjee, S.; van der Donk, W. A. Product Formation by the Promiscuous 
Lanthipeptide Synthetase Procm Is under Kinetic Control. J. Am. Chem. Soc. 2015, 137 (15), 
5140-5148. 
(55) Thibodeaux, C. J.; Ha, T.; van der Donk, W. A. A Price to Pay for Relaxed Substrate Specificity: 
A Comparative Kinetic Analysis of the Class II Lanthipeptide Synthetases ProcM and HalM2. J. 
Am. Chem. Soc. 2014, 136 (50), 17513-17529. 
(56) Mukherjee, S.; van der Donk, W. A. Mechanistic Studies on the Substrate-Tolerant Lanthipeptide 
Synthetase ProcM. J. Am. Chem. Soc. 2014, 136 (29), 10450-10459. 
(57) Yang, X.; van der Donk, W. A. Post-Translational Introduction of D-Alanine into Ribosomally 
Synthesized Peptides by the Dehydroalanine Reductase Npnj. J. Am. Chem. Soc. 2015, 137 (39), 
12426-12429. 
259 
 
(58) Ortega, M. A.; Hao, Y.; Walker, M. C.; Donadio, S.; Sosio, M.; Nair, S. K.; van der Donk, W. A. 
Structure and Trna Specificity of MibB, a Lantibiotic Dehydratase from Actinobacteria Involved 
in NAI-107 Biosynthesis. Cell Chem. Biol. 2016, 23 (3), 370-80. 
(59) Shi, Y.; Yang, X.; Garg, N.; van der Donk, W. A. Production of Lantipeptides in Escherichia 
Coli. J. Am. Chem. Soc. 2011, 133 (8), 2338-2341. 
(60) Ortega, M. A.; Cogan, D. P.; Mukherjee, S.; Garg, N.; Li, B.; Thibodeaux, G. N.; Maffioli, S. I.; 
Donadio, S.; Sosio, M.; Escano, J., et al. Two Flavoenzymes Catalyze the Post-Translational 
Generation of 5-Chlorotryptophan and 2-Aminovinyl-Cysteine During NAI-107 Biosynthesis. 
ACS Chem Biol 2017, 12 (2), 548-557. 
(61) Tolia, N. H.; Joshua-Tor, L. Strategies for Protein Coexpression in Escherichia Coli. Nat. 
Methods 2006, 3 (1), 55-64. 
(62) McDaniel, L. E.; Bailey, E. G. Effect of Shaking Speed and Type of Closure on Shake Flask 
Cultures. Appl. Microbiol. 1969, 17 (2), 286-290. 
(63) Ortega, M. A.; Cogan, D. P.; Mukherjee, S.; Garg, N.; Li, B.; Thibodeaux, G. N.; Maffioli, S. I.; 
Donadio, S.; Sosio, M.; Escano, J., et al. Two Flavoenzymes Catalyze the Post-Translational 
Generation of 5-Chlorotryptophan and 2-Aminovinyl-Cysteine During NAI-107 Biosynthesis. 
ACS Chem. Biol. 2017, 12 (2), 548–557. 
(64) Dunbar, K. L.; Mitchell, D. A. Insights into the Mechanism of Peptide Cyclodehydrations 
Achieved through the Chemoenzymatic Generation of Amide Derivatives. J. Am. Chem. Soc. 
2013, 135 (23), 8692-8701. 
(65) Tang, W.; van der Donk, W. A. Structural Characterization of Four Prochlorosins: A Novel Class 
of Lantipeptides Produced by Planktonic Marine Cyanobacteria. Biochemistry 2012, 51 (21), 
4271-4279. 
(66) Liu, W.; Chan, A. S.; Liu, H.; Cochrane, S. A.; Vederas, J. C. Solid Supported Chemical 
Syntheses of Both Components of the Lantibiotic Lacticin 3147. J. Am. Chem. Soc. 2011, 133 
(36), 14216-14219. 
(67) Wieckowski, B. M.; Hegemann, J. D.; Mielcarek, A.; Boss, L.; Burghaus, O.; Marahiel, M. A. 
The Pqqd Homologous Domain of the Radical Sam Enzyme Thnb Is Required for Thioether 
Bond Formation During Thurincin H Maturation. FEBS Lett. 2015, 589 (15), 1802-1806. 
(68) Zhang, Z.; Hudson, G. A.; Mahanta, N.; Tietz, J. I.; van der Donk, W. A.; Mitchell, D. A. 
Biosynthetic Timing and Substrate Specificity for the Thiopeptide Thiomuracin. J. Am. Chem. 
Soc. 2016, 138 (48), 15511-15514. 
260 
 
(69) Xie, L.; Miller, L. M.; Chatterjee, C.; Averin, O.; Kelleher, N. L.; van der Donk, W. A. Lacticin 
481: In Vitro Reconstitution of Lantibiotic Synthetase Activity. Science 2004, 303 (5658), 679-
681. 
(70) Held, D.; Yaeger, K.; Novy, R. New Coexpression Vectors for Expanded Compatibilities in E. 
Coli. InNovations 2003, 18, 4-6. 
  
261 
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A.1 Structural and functional insight into an unexpectedly selective N-methyltransferase involved 
in plantazolicin biosynthesis 
Reproduced with permission from Lee, J.; Hao, Y.; Blair, P.M.; Melby, J.O.; Agarwal, V.; Burkhart, B.J.; 
Nair, S.K.; Mitchell, D.A.  Structural and functional insight into an unexpectedly selective N-
methyltransferase involved in plantazolicin biosynthesis. Proc. Natl. Acad. Sci. USA 2013, 110, 12954-
12959. PMCID: PMC3740862. Copyright 2013 National Academy of Sciences. 
 
I used PyMOL to analyze the structure of two methyltransferases, BamL and BpumL, and to model 
peptide substrates. This analysis revealed potential constraints for substrate recognition and provided 
insight into the narrow substrate scope of these two enzymes. I created Figure S5 and generated mutant 
proteins (BamL T38A, T38F, L132A, L132F, L162A, and L162F). 
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A.2 Discovery of a new ATP-binding motif involved in peptidic azoline biosynthesis 
Reproduced with permission from Dunbar, K.L.; Chekan, J.R.; Cox, C.L.; Burkhart, B.J.; Nair, S.K.; 
Mitchell, D.A. Discovery of a new ATP-binding motif involved in peptidic azoline biosynthesis. Nat. 
Chem. Biol. 2014, 10, 823-829. PMCID: PMC4167974. Copyright 2014 Nature Publishing Group. 
 
I discovered that BalhC was necessary and sufficient for leader peptide binding whereas BalhD did not 
significantly interact with the leader peptide. I generated Figure 4c. 
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A.3 Identification of an auxiliary leader peptide-binding protein required for azoline formation in 
ribosomal natural products 
Reproduced with permission from Dunbar, K.L.; Tietz, J.I.; Cox, C.L.; Burkhart, B.J. & Mitchell, D.A. 
Identification of an auxiliary leader peptide-binding protein required for azoline formation in ribosomal 
natural products. J. Am. Chem. Soc. 2015, 137, 7672-7677. PMCID: PMC4481143. Copyright 2015 
American Chemical Society. 
 
I demonstrated the role of HcaF in leader peptide binding, showed that HcaD does not interact with the 
leader peptide, and performed binding studies with leader peptide mutants to reveal the contribution of 
different residues to binding and the minimal peptide length. I produced Table 1 and Figure 3 and S15. 
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A.4 In vitro biosynthesis and substrate tolerance of the plantazolicin family of natural products 
Reproduced with permission from Deane, C.D.; Burkhart, B.J.; Blair, P.M.; Tietz, J.I.; Lin, A.; Mitchell, 
D.A. In vitro biosynthesis and substrate tolerance of the plantazolicin family of natural products. ACS 
Chem. Biol. 2016, 11, 2232-2243. PMCID: PMC4992447. Copyright 2016 American Chemical Society. 
 
I performed experiments to investigate leader peptide recognition by the PZN synthetase and homologous 
proteins from the Bpum, Cms, and Blin biosynthetic gene clusters. From these results, I authored a 
section of this paper entitled “Leader Peptide Recognition and Binding by the PZN Synthetase.” I also 
assisted in the overall editing and writing of the paper and generated Table S1 and S2 and Figure S3, 5, 
S6, S40, and S41. 
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